var title_f36_13_37072="Breast MRI of multifocal breast cancer";
var content_f36_13_37072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Breast MRI of multifocal breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be useful for determining disease extent in newly diagnosed cancer patients. These images show the MRI of a patient with a palpable retroareolar mass.",
"    <br>",
"     (A) T2-weighted imaging demonstrates an intermediate signal irregular mass just beneath the nipple as well as a T2-hypointense area posteriorly.",
"     <br>",
"      (B) Post contrast T1-weighted sagittal image demonstrates a suspiciously enhancing lesion in the inferior subareolar breast as well as an ill-defined area of non-mass enhancement posteriorly within the same ductal unit.",
"      <br>",
"       (C) Subtraction of pre and post contrast images confirm the two separate lesions with the posterior lesion being occult to both mammography and ultrasound. Biopsy of both areas was performed revealing invasive ductal carcinoma anteriorly and ductal carcinoma in situ posteriorly.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37072=[""].join("\n");
var outline_f36_13_37072=null;
var title_f36_13_37073="Acute sinusitis (sinus infection)";
var content_f36_13_37073=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/13/37073/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37073/contributors\" id=\"au1922\">",
"       Peter H Hwang, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37073/contributors\" id=\"au1924\">",
"       Anne Getz, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/13/37073/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37073/contributors\" id=\"se6334\">",
"       Mark D Aronson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/13/37073/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37073/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/13/37073?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ACUTE SINUSITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Rhinosinusitis, or more commonly sinusitis, is the medical term for inflammation (swelling) of the lining of the sinuses and nose. The sinuses are the hollow areas within the facial bones that are connected to the nasal openings (",
"     <a class=\"graphic graphic_figure graphicRef75045 \" href=\"mobipreview.htm?9/62/10210\">",
"      figure 1",
"     </a>",
"     ). The sinuses are lined with mucous membranes, similar to the inside of the nose.",
"    </p>",
"    <p>",
"     There are two main types of sinusitis: acute and chronic. Acute sinusitis is inflammation that lasts for less than four weeks while chronic sinusitis lasts for more than 12 weeks. Acute sinusitis is common, affecting approximately one million people per year in the United States.",
"    </p>",
"    <p>",
"     This article will discuss the causes, symptoms, and treatment of acute sinusitis in adults. Information about the common cold is also available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      \"Patient information: The common cold in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ACUTE SINUSITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The most common cause of acute sinusitis is a viral infection associated with the common cold. Bacterial sinusitis occurs much less commonly, in only 0.5 to 2 percent of cases, usually as a complication of viral sinusitis.",
"    </p>",
"    <p>",
"     Because antibiotics are effective only against bacterial, and not viral, infections, most people do not need antibiotics for acute sinusitis. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"      \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ACUTE SINUSITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of acute sinusitis include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Nasal congestion or blockage",
"      </li>",
"      <li>",
"       Thick, yellow to green discharge from the nose",
"      </li>",
"      <li>",
"       Pain in the teeth",
"      </li>",
"      <li>",
"       Pain or pressure in the face that is worse when bending forwards",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other acute sinusitis symptoms can include fever (temperature greater than 100.4&ordm;F or 38&ordm;C), fatigue, cough, difficulty or inability to smell, ear pressure or fullness, headache, and bad breath.",
"    </p>",
"    <p>",
"     In most cases, these symptoms develop over the course of one day and begin to improve within seven to 10 days.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      DO I NEED TO BE EXAMINED?",
"     </span>",
"    </p>",
"    <p>",
"     It is difficult to know if you have a viral or bacterial sinus infection initially. However, most people with a viral infection improve without treatment within seven to 10 days after symptoms begin. Bacterial sinusitis also sometimes improves without treatment, although it can also worsen and require treatment.",
"    </p>",
"    <p>",
"     If one or more of the following bothersome symptoms last",
"     <strong>",
"      more",
"     </strong>",
"     than seven days, an examination by a healthcare provider is recommended:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Thick, yellow to green discharge from the nose",
"      </li>",
"      <li>",
"       Face or tooth pain, especially if it is only on one side",
"      </li>",
"      <li>",
"       Tenderness over the maxillary sinuses (located on the left and right side of the nose, inside the cheekbones)",
"      </li>",
"      <li>",
"       Symptoms that initially improve and then worsen",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      When to seek immediate help",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have one or more of the following symptoms, you should seek medical attention immediately (even if symptoms have been present for less than seven days):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       High fever (&gt;102.5&ordm; F or 39.2&ordm; C)",
"      </li>",
"      <li>",
"       Sudden, severe pain in the face or head",
"      </li>",
"      <li>",
"       Double vision or difficulty seeing",
"      </li>",
"      <li>",
"       Confusion or difficulty thinking clearly",
"      </li>",
"      <li>",
"       Swelling or redness around one or both eyes",
"      </li>",
"      <li>",
"       Stiff neck, shortness of breath",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ACUTE SINUSITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Initial treatment of a sinus infection aims to relieve symptoms since almost everyone will improve within the first 7 to 10 days. Experts recommend avoiding antibiotics during this time unless there is clear evidence of a severe bacterial infection. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Moderate or severe symptoms'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Initial treatment",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-prescription pain medications, such as acetaminophen (eg, Tylenol&reg;) or ibuprofen (eg, Motrin&reg;, Advil&reg;) are recommended for pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Nasal irrigation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Flushing the nose and sinuses with a saline solution several times per day can help to decrease pain caused by congestion. Instructions for nasal irrigation are provided in the table (",
"     <a class=\"graphic graphic_table graphicRef71059 \" href=\"mobipreview.htm?42/33/43548\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Nasal decongestants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal decongestant sprays, including oxymetazoline (Afrin&reg;) and phenylephrine (Neo-synephrine&reg;) can be used to temporarily treat congestion. However, these sprays should not be used for more than two to three days due to the risk of rebound congestion (when the nose is congested constantly unless the medication is used repeatedly).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Other treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other treatments for congestion, such as oral antihistamines (such as",
"     <span class=\"nowrap\">",
"      diphenhydramine/Benadryl&reg;)",
"     </span>",
"     or zinc supplements are not proven to improve symptoms of sinusitis and can have unwanted side effects. Medications to thin secretions (such as guaifenesin) may help to clear mucus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H49567905\">",
"     <span class=\"h2\">",
"      Second-line treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If symptoms have not improved in seven to ten days, you should arrange for medical evaluation. You may need further treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H49567866\">",
"     <span class=\"h3\">",
"      Nasal steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal steroids (steroids delivered by a nasal spray) can help to reduce swelling inside the nose, usually within two to three days. These drugs have few side effects and dramatically relieve symptoms in most people.",
"    </p>",
"    <p>",
"     There are a number of nasal steroids available by prescription. These drugs are all effective, but differ in how frequently they must be used and how much they cost.",
"    </p>",
"    <p>",
"     You may need to use a nasal decongestant for a few days before starting a nasal steroid to reduce nasal swelling; this will allow the nasal steroid to reach more areas of the nasal passages. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Nasal decongestants'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Do I need an antibiotic?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If bothersome symptoms of sinusitis persist for 10 or more days, it is possible that you have bacterial sinusitis. The need for antibiotics depends upon the severity of your symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h4\">",
"      Mild symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two possible treatment options if you have",
"     <strong>",
"      mild",
"     </strong>",
"     sinusitis symptoms: treat with antibiotics or continue to watch and wait for one week.",
"    </p>",
"    <p>",
"     Watching and waiting is a reasonable option because up to 75 percent of people with bacterial sinusitis improve within one month without antibiotics. During the watch and wait period, treatments to improve symptoms are recommended. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Initial treatment'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     If symptoms worsen or do not improve after watching and waiting, treatment with an antibiotic is usually recommended. Treatments to relieve symptoms are recommended while using antibiotics. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Initial treatment'",
"     </a>",
"     above and",
"     <a class=\"local\" href=\"#H49567866\">",
"      'Nasal steroids'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h4\">",
"      Moderate or severe symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most healthcare providers will prescribe an antibiotic for moderate to severe symptoms (temperature &gt;38.3&ordm; C or 101&ordm; F",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     severe pain that interferes with usual activities).",
"    </p>",
"    <p>",
"     Treatments to relieve symptoms are also recommended during antibiotic treatment. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Initial treatment'",
"     </a>",
"     above and",
"     <a class=\"local\" href=\"#H11\">",
"      'Nasal decongestants'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     One of the least expensive and most effective antibiotics for sinusitis is amoxicillin. An alternate antibiotic will be prescribed if you are allergic to penicillin. Regardless of which antibiotic is prescribed, it is important to follow the dosing instructions carefully and to finish the entire course of treatment. Taking the medication less often than prescribed or stopping the medication early can lead to complications, such as a recurrent infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      What if I do not improve with treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you do not improve or worsen after a course of antibiotics, you should be re-examined. Further testing may be recommended, such as x-ray or CT scan imaging, or an exam of the inside of the sinuses. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"      \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=see_link\">",
"      \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In some cases, symptoms of sinusitis improve but then recur. This is usually because the infection was not completely eliminated by the antibiotic. An alternate antibiotic, extended antibiotic treatment,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     further testing may be recommended, depending upon your individual situation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498681513\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027505\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/53/17234?source=see_link\">",
"      Patient information: Sinusitis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/37/14930?source=see_link\">",
"      Patient information: Chronic sinusitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/18/16674?source=see_link\">",
"      Patient information: Rinsing out your nose with salt water (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027522\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=see_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=see_link\">",
"      Microbiology and antibiotic management of chronic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=see_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/sinusitis/\">",
"        www3.niaid.nih.gov/topics/sinusitis/",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/13/37073/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 9, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/13/37073?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37073/abstract/1\">",
"      Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007; 137:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37073/abstract/2\">",
"      Piccirillo JF. Clinical practice. Acute bacterial sinusitis. N Engl J Med 2004; 351:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37073/abstract/3\">",
"      Ah-See KW, Evans AS. Sinusitis and its management. BMJ 2007; 334:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37073/abstract/4\">",
"      Tan T, Little P, Stokes T, Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 2008; 337:a437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_13_37073=[""].join("\n");
var outline_f36_13_37073=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ACUTE SINUSITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ACUTE SINUSITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ACUTE SINUSITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           DO I NEED TO BE EXAMINED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ACUTE SINUSITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/62/10210\" title=\"figure 1\">",
"           Facial sinus PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43548\" title=\"table 1\">",
"           Nasal irrigation instruct",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_13_37074="Types of endoleak after endovascular repair";
var content_f36_13_37074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of endoleak after endovascular repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four types of endoleaks are seen after an endovascular repair of an abdominal aortic aneurysm. Type I is due to an incompetent seal at the proximal (or distal) attachment site. Type II results from flow into and out of the aneurysm sac from a patent branch vessel (lumbar). Type III endoleak results from dissociation of modular components. Type IV is due to leaks though the porous graft material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37074=[""].join("\n");
var outline_f36_13_37074=null;
var title_f36_13_37075="Sickle endothelial interactions";
var content_f36_13_37075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Model of sickle cell-endothelial cell adhesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sickle red cells (RBCs) are shown here as red biconcave ovals and the vascular endothelium as a layer of gray elongated flat cells. Three steps of adhesion are shown: (A) Initial contact, (B) Rolling adhesion, and (C) Firm adhesion. Initial contact of sickle RBCs with endothelium is through binding of an erythroid P-selectin ligand with endothelial cell P-selectin. The interaction of E-selectin with a sialylated carbohydrate RBC ligand also participates in initial adhesion. These same molecules that initially slow flowing sickle cells also mediate their rolling along the vascular wall. Several ligand-receptor cognate pairs are involved in firm adhesion, which creates an adhesive nidus behind which rigid, sickled RBCs become trapped. Some of these are shown in this diagram. CD36 on the sickle RBC binds to alphaVbeta3 integrin on the endothelial cell by using plasma thrombospondin (TSP) as a bridging molecule. The RBC integrin alpha4beta1 binds directly to vascular cell adhesion molecule-1 (VCAM-1). Activated endothelial cells express alpha5beta1 and additional alphaVbeta3 to which sickle cells stick. Gaps are created between activated endothelial cells, which expose adhesive subendothelial matrix proteins (laminin, TSP, von Willebrand Factor) that also bind sickle cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37075=[""].join("\n");
var outline_f36_13_37075=null;
var title_f36_13_37076="Mitral annular calcium PA";
var content_f36_13_37076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral annular calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This frontal radiograph of the chest demonstrates extensive, coarse, semi-lunar calcifications within the annulus of the mitral valve (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37076=[""].join("\n");
var outline_f36_13_37076=null;
var title_f36_13_37077="AIP infiltrate Light LP";
var content_f36_13_37077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a pancreas biopsy in a patient with autoimmune pancreatitis. The acinar parenchyma is atrophic and fibrotic and contains a lymphoplasmacytic infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37077=[""].join("\n");
var outline_f36_13_37077=null;
var title_f36_13_37078="Medication-induced esophagitis";
var content_f36_13_37078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medication-induced esophagitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     Donald O Castell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37078/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/13/37078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications can induce esophageal abnormalities via both systemic and local actions. Examples of systemic effects include gastroesophageal reflux promoted by smooth muscle relaxants, and medication-induced compromise of the immune system, resulting in infectious complications. This topic review will discuss only drugs that cause direct esophageal mucosal injury.",
"   </p>",
"   <p>",
"    Documentation of esophageal mucosal injury induced by the local caustic effect of medication was first described in a patient who ingested",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    tablets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/1\">",
"     1",
"    </a>",
"    ]. It is likely that similar injuries had occurred prior to that time, but were underdiagnosed because of the relative lack of flexible fiberoptic endoscopy. Since the initial report, the frequency of pill-induced esophageal injury has continued to grow.",
"   </p>",
"   <p>",
"    The types of medication causing direct esophageal injury can be roughly divided into antibiotics, antiinflammatory agents, and others.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetracyclines are the most common antibiotics to induce esophagitis, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Essentially all of the antiinflammatory agents can damage the esophagus; the highest number of reported cases has been with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The major offenders in the \"other\" category include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      preparations, and iron compounds in the United States; emepronium, alprenolol, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/17/41234?source=see_link\">",
"       pinaverium",
"      </a>",
"      are common etiologies in other countries. In addition, the bisphosphonate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      can cause esophagitis (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Bisphosphonate-induced esophageal injury'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury is believed to be due to prolonged contact of the caustic contents of the medication with the esophageal mucosa. This theory is supported by animal studies in which lesions identical to those found in patients were induced by direct mucosal placement of the same medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Clinically, this hypothesis is supported by the typical esophageal lesion showing a small punched out ulcer in a limited area that was conceivably in contact with a high concentration of medication released from a dissolving pill. In addition, the site of injury is frequently found in areas in which the esophageal lumen is compromised by the aortic arch, the esophagogastric junction, or an enlarged left atrium. Thus, medication-induced injury requires that the pill or capsule remain in the esophagus for a prolonged interval, and that its contents be inherently caustic to the esophageal mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Esophageal retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of esophageal retention of pills or capsules occurs in normal individuals. However, the following situations enhance pill retention, thereby increasing the likelihood of esophageal injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both a lack of an adequate liquid bolus and a long period in the recumbent position are believed to play a major role in pill retention.",
"     </li>",
"     <li>",
"      Ingestion of a pill immediately prior to sleep favors prolonged retention since salivation and swallowing frequency are markedly reduced during sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study demonstrated that age greater than 70 years and decreased peristaltic amplitudes were associated with a greater likelihood of pill retention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with cardiac disease, particularly following thoracotomy, also appear to be at increased risk. Although this may be due to anatomical changes in the mediastinum, these patients are often more elderly and likely to be taking commonly implicated drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      or potassium compounds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, pill-induced esophageal injury has not been commonly reported in patients with known esophageal motility disorders. These patients are often more attentive to swallowing function, which may provide protection when pills are ingested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Caustic potential of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed mechanisms of caustic injury induced by various pills include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A local acid burn may be caused by medications such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      , ascorbic acid,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      , and emepronium. Each of these compounds has a pH less than 3 when dissolved in distilled water or saliva [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/6\">",
"       6",
"      </a>",
"      ]. However, other equally caustic medications such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      do not alter pH.",
"     </li>",
"     <li>",
"      Local hyperosmolality from high concentrations of dissolving medication may be capable of tissue destruction and vascular injury, a mechanism suggested for potassium-induced lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical patient with medication-induced esophagitis does not have a history of prior esophageal disease. Patients will often present with the sudden onset of odynophagia and retrosternal pain; the pain may be so severe that swallowing saliva is difficult. Patients often relate (after careful questioning) the onset of symptoms to the swallowing of a pill without water, commonly at bedtime. Typical scenarios include the teenage patient with acne who takes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    at bedtime without water, and the elderly patient in a nursing care facility given a number of medications with a small amount of water while recumbent prior to sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication-induced esophagitis is often suspected when typical symptoms appear abruptly after improper ingestion of a pill known to cause esophageal injury. In these cases, a clinical diagnosis may be made without the requirement for confirmatory endoscopy or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography.",
"   </p>",
"   <p>",
"    However, diagnostic confirmation becomes more important in patients with particularly severe or atypical symptoms, or if an alternate diagnosis is likely. Flexible upper endoscopy is the most sensitive procedure; findings are abnormal in virtually 100 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/8\">",
"     8",
"    </a>",
"    ]. Endoscopy is also helpful to rule out alternate diagnoses such as reflux esophagitis, infectious esophagitis, or malignancy.",
"   </p>",
"   <p>",
"    The typical endoscopic appearance of pill-induced esophageal injury is a discrete ulcer with relatively normal surrounding mucosa (",
"    <a class=\"graphic graphic_picture graphicRef60089 \" href=\"mobipreview.htm?0/40/640\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76438 graphicRef55447 \" href=\"mobipreview.htm?34/42/35489\">",
"     picture 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/8\">",
"     8",
"    </a>",
"    ]. The ulcers may range in size from 1 or 2 mm to several centimeters long. They may be single or multiple and may be surrounded by mild local inflammatory changes. Although the typical ulcer involves only the mucosa, deeper degrees of penetration can occur and localized perforation has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Remnants of the offending pill may occasionally be identified at the site of injury. As noted above, the most common sites of injury are the proximal esophagus near the compression from the aortic arch, and the distal esophagus in patients with left atrial enlargement.",
"   </p>",
"   <p>",
"    The lesion rarely may be characterized by a profuse exudate with nodularity suggestive of a polypoid neoplasm; this finding is particularly true with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    -induced injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/11\">",
"     11",
"    </a>",
"    ]. Esophageal stricture is also relatively rare; when it occurs, antiinflammatory drugs are typical causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal biopsies are rarely helpful, typically showing only acute inflammatory changes. However, biopsy does help to exclude malignancy and infection if they are suspected clinically.",
"   </p>",
"   <p>",
"    Even with an air contrast technique, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    esophagogram is not as sensitive as endoscopy for the typical pill-induced ulceration. It can, however, help to exclude complications or malignancy and it is more likely to provide additional information regarding possible extrinsic esophageal compression that might predispose to repetition of the process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATE-INDUCED ESOPHAGEAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates inhibit bone turnover by decreasing the resorption of bone through inhibition of the recruitment and function of osteoclasts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    .) They have been shown to be particularly effective in women with postmenopausal osteoporosis, and may also be useful in patients with hypercalcemic complications of malignancy, and to delay skeletal complications in women with bone metastases from cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .) These potentially beneficial effects have led to rapid spread of their use worldwide.",
"   </p>",
"   <p>",
"    Severe esophageal injury reported in three patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    as treatment for postmenopausal osteoporosis raised some concern about possible risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/13\">",
"     13",
"    </a>",
"    ]. This same review analyzed postmarketing surveillance data from the manufacturer. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic findings in the patients with esophageal injury generally suggested a chemical esophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the esophageal wall. Bleeding was rare.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       Alendronate",
"      </a>",
"      had been prescribed to an estimated 475,000 patients worldwide. Adverse effects related to the esophagus had been reported in 199 patients; 51 (26 percent) were considered to have serious or severe effects, while 32 required hospitalization.",
"     </li>",
"     <li>",
"      In most of the patients for whom adequate information was available, esophageal complications occurred during the first month of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      In those patients for whom adequate information was available on water intake and posture, it is thought that more than 50 percent either took the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      without an adequate quantity of water (less than 180 to 240 mL [6 to 8 oz]) or failed to remain upright for 30 minutes or more after taking the tablet.",
"     </li>",
"     <li>",
"      Esophagitis was more common in patients with preexisting esophageal disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This survey did not provide useful information on the true frequency of symptomatic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    -induced esophageal injury. A major clinical trial of 994 patients who received alendronate for three years as treatment for postmenopausal osteoporosis found that the incidence of adverse upper gastrointestinal effects was similar to that in patients treated with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/14\">",
"     14",
"    </a>",
"    ]. This low incidence has been confirmed by other investigators for both daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/15\">",
"     15",
"    </a>",
"    ], and weekly administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/16\">",
"     16",
"    </a>",
"    ]. It is possible that the apparent low incidence of adverse effects in these studies is related to the frequent follow-up visits and regular reminders to patients regarding proper use of the medication.",
"   </p>",
"   <p>",
"    Thus, on the basis of the currently available reports, the actual incidence of severe or serious esophageal effects in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or other bisphosphonate for postmenopausal osteoporosis appears to be quite low, well under 1 percent. It would also appear that the incidence of such complications can be further reduced by using the following precautions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These medications should be used with caution in patients with preexisting esophageal disorders and patients with other types of upper gastrointestinal disease.",
"     </li>",
"     <li>",
"      These medications should be discontinued in patients who develop symptoms of esophagitis. The esophageal lesion appears to improve when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      is discontinued, as is typical of other reports of medication induced esophagitis.",
"     </li>",
"     <li>",
"      These medications should be taken with at least 240 mL (8 oz) of water to minimize the risk of the tablet getting stuck in the esophagus and causing local erosions.",
"     </li>",
"     <li>",
"      Patients should stand or sit upright for at least 30 minutes, and should eat a meal afterwards.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One interesting aspect of the report on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    -induced esophagitis is that the lesions described included severe ulcerative esophagitis involving 10 cm or more of the esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/13\">",
"     13",
"    </a>",
"    ]. These lesions are somewhat unusual compared with those occurring in the typical case of pill-induced esophagitis, with the extent of involvement raising some interesting questions that require further study: Do bisphosphonates have a greater potential to cause esophageal injury than other medications? Are these medications distributed more widely within the esophagus? Does the medication initially enter the stomach and subsequently reflux back into the esophagus, producing the extensive injury reported? The availability of an effective weekly or monthly formulation of alendronate will probably decrease the incidence of esophageal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another bisphosphonate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , which is available for both prevention and treatment of osteoporosis, appears to have minimal gastrointestinal toxicity. In a large clinical trial, the incidence of gastrointestinal side effects was not different from placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/19\">",
"     19",
"    </a>",
"    ]. In a pooled analysis of nine clinical trials that included 10,068 patients randomly assigned to risedronate (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for up to three years, upper gastrointestinal tract adverse events were no different between the two groups (29.8 and 29.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/20\">",
"     20",
"    </a>",
"    ]. Unlike clinical trials with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , patients with active gastrointestinal disease were not excluded from the study.",
"   </p>",
"   <p>",
"    In an endoscopic study of 515 postmenopausal women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (5 mg per day) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (10 mg per day) for two weeks, significantly fewer gastric ulcers were seen in the risedronate group (4.1 percent versus 13.2 percent for alendronate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/21\">",
"     21",
"    </a>",
"    ]. However, it is not known if risedronate is superior to alendronate when given long-term for prevention and treatment of osteoporosis.",
"   </p>",
"   <p>",
"    Cyclical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    is one of the earlier available, but less potent bisphosphonates that has been studied in the treatment of postmenopausal osteoporosis and Paget disease. Etidronate does not appear to be associated with adverse gastrointestinal events, even in patients who concomitantly use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , corticosteroids, or nonsteroidal antiinflammatory drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of medication-induced esophageal injury heal without intervention within a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37078/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, the most important aspect of therapy is to make the correct diagnosis and then to avoid reinjury with the drug. When possible, potentially caustic oral medications should be discontinued. If their use is unavoidable, a liquid preparation may be substituted. In the patient without an apparent predisposition to esophageal injury (eg, a large left atrium), the potentially injurious medication may be resumed after the injury resolves (with careful instructions on how to take the medication in the case of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is not clear whether specific therapy is required, or even effective, in treating the acute lesion. Antacids, histamine (H2) receptor blockers, proton pump inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , and even local anesthetic agents are often prescribed, but their value is unsubstantiated. Even potent acid suppressing drugs seem unlikely to offer any real advantage, unless gastroesophageal reflux is believed to be exacerbating or perpetuating the injury. Theoretically, the most effective approach might be frequent ingestion of a slurry or suspension of sucralfate to provide a protective coat on the esophageal mucosa and promote healing.",
"   </p>",
"   <p>",
"    For the patient who is unable to eat or drink because of the severe odynophagia, a temporary period of parenteral hydration or alimentation may be required. Dilation may be needed if stricturing has occurred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of potentially injurious medications should be avoided in patients with a large left atrium or following cardiac surgery. Slight lubrication of the esophagus with a preliminary sip of water prior to ingesting the actual medication may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160410701\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The types of medication causing direct esophageal injury can be roughly divided into antibiotics, antiinflammatory agents, and others. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tetracyclines are the most common antibiotics to induce esophagitis, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Essentially all of the antiinflammatory agents can damage the esophagus; the highest number of reported cases has been with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Other medications associated with esophagitis include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      preparations, and iron compounds in the United States; emepronium, alprenolol, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/17/41234?source=see_link\">",
"       pinaverium",
"      </a>",
"      are common etiologies in other countries. In addition, the bisphosphonate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      can cause esophagitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanism of injury is believed to be due to prolonged contact of the caustic contents of the medication with the esophageal mucosa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following situations enhance pill retention, thereby increasing the likelihood of esophageal injury (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Esophageal retention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lack of an adequate liquid bolus and a long period in the recumbent position",
"     </li>",
"     <li>",
"      Ingestion of a pill immediately prior to sleep",
"     </li>",
"     <li>",
"      Age greater than 70 years and decreased peristaltic amplitudes",
"     </li>",
"     <li>",
"      Patients with cardiac disease, particularly following thoracotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients will often present with the sudden onset of odynophagia and retrosternal pain; the pain may be so severe that swallowing saliva is difficult. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medication-induced esophagitis is often suspected when typical symptoms appear abruptly after improper ingestion of a pill known to cause esophageal injury. In these cases, a clinical diagnosis may be made without the requirement for confirmatory endoscopy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      radiography. However, diagnostic confirmation becomes more important in patients with particularly severe or atypical symptoms, or if an alternate diagnosis is likely. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of medication-induced esophageal injury heal without intervention within a few days and it is not clear whether specific therapy is required, or even effective, in treating the acute lesion. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/1\">",
"      Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br Heart J 1970; 32:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/2\">",
"      Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers. a clinical and experimental study. Laryngoscope 1983; 93:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/3\">",
"      Olovson SG, Bj&ouml;rkman JA, Ek L, Havu N. The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model. Acta Pharmacol Toxicol (Copenh) 1983; 53:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/4\">",
"      SCHNEYER LH, PIGMAN W, HANAHAN L, GILMORE RW. Rate of flow of human parotid, sublingual, and submaxillary secretions during sleep. J Dent Res 1956; 35:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/5\">",
"      Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/6\">",
"      Carlborg B, Densert O. Esophageal lesions caused by orally administered drugs. An experimental study in the cat. Eur Surg Res 1980; 12:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/7\">",
"      BOLEY SJ, ALLEN AC, SCHULTZ L, SCHWARTZ S. POTASSIUM-INDUCED LESIONS OF THE SMALL BOWEL. I. CLINICAL ASPECTS. JAMA 1965; 193:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/8\">",
"      Kikendall JW, Friedman AC, Oyewole MA, et al. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci 1983; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/9\">",
"      Henry JG, Shinner JJ, Martino JH, Cimino LE. Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride. Pediatr Cardiol 1983; 4:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/10\">",
"      Singh NP, Rizk JG. Oesophageal perforation following ingestion of over-the-counter ibuprofen capsules. J Laryngol Otol 2008; 122:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/11\">",
"      Wong RK, Kikendall JW, Dachman AH. Quinaglute-induced esophagitis mimicking an esophageal mass. Ann Intern Med 1986; 105:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/12\">",
"      Bonavina L, DeMeester TR, McChesney L, et al. Drug-induced esophageal strictures. Ann Surg 1987; 206:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/13\">",
"      de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/14\">",
"      Liberman UA, Weiss SR, Br&ouml;ll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/15\">",
"      Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/16\">",
"      Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/17\">",
"      Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/18\">",
"      Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/19\">",
"      Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/20\">",
"      Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/21\">",
"      Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/22\">",
"      van Staa T, Abenhaim L, Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997; 103:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37078/abstract/23\">",
"      Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37:740.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2255 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-4874105216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37078=[""].join("\n");
var outline_f36_13_37078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H160410701\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Esophageal retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Caustic potential of medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BISPHOSPHONATE-INDUCED ESOPHAGEAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H160410701\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2255|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/40/640\" title=\"picture 1\">",
"      Medication esophagitis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/0/12303\" title=\"picture 2A\">",
"      Pill esophagitis CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/2/37934\" title=\"picture 2B\">",
"      Pill esophagitis II CPC Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_13_37079="Tension-type headache in adults: Acute treatment";
var content_f36_13_37079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tension-type headache in adults: Acute treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     Frederick R Taylor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37079/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/13/37079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache (TTH) is the most ubiquitous headache in the general population, and is one of the most common reasons why over-the-counter analgesics are purchased. Despite the high frequency of TTH and the total disability society bears due to this primary headache, treatment has been driven more by anecdote and word-of-mouth consensus than by therapeutic trials. This situation is perhaps due to the typically mild nature of TTH, such that patients with this type of headache usually self-diagnose and self-treat unless they have concurrent migraine or develop chronic TTH.",
"   </p>",
"   <p>",
"    Understanding the pathophysiology of TTH is likely the key to formulating a mechanistically sound, optimum treatment plan. Unfortunately, the scientific understanding of TTH lags that of migraine, and the postulated TTH mechanisms have produced limited treatment leads. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link&amp;anchor=H3#H3\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the acute treatment of TTH in adults. Preventive treatment of TTH is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of TTH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute or abortive (symptomatic) therapy of TTH ranges from nonpharmacologic therapies to simple and combination analgesic medications. Some general principles are relevant to the pharmacologic therapy of TTH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abortive therapy is more effective when given early after headache onset in patients with migraine. By analogy, it is presumed that the earlier the treatment is given for TTH, the better, although no valid data exist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute treatment of migraine in adults\", section on 'Approach to treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Starting with the maximum initial medication dose in acute therapy is customary, with the goal of limiting later repetitive doses. However, there is no definitive evidence to support this principle, even though a dose ranging curve likely exists with simple analgesics. Ideally, treatment should be individualized. Some patients may obtain good relief with low analgesic doses. In such cases, a higher dose trial can be employed if recurrences are frequent, although it is not a foregone conclusion that higher doses will prevent recurrence.",
"     </li>",
"     <li>",
"      The effectiveness of analgesics tends to decrease with increasing headache frequency.",
"     </li>",
"     <li>",
"      Chronic TTH is often associated with comorbid stress, anxiety, and depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/1\">",
"       1",
"      </a>",
"      ]. In this setting, simple analgesics are usually of little or no benefit.",
"     </li>",
"     <li>",
"      Avoiding medication overuse headache (MOH) is an important goal of therapy. Therefore, management of TTH ideally requires limitation of acute therapy. The use of triptans (for migraine) or over-the-counter combination analgesics should be limited to nine or fewer days a month on average, butalbital-containing analgesics to three or fewer days a month, and nonsteroidal anti-inflammatory drugs (NSAIDs) to 15 or fewer days a month to prevent medication overuse headache. The more restrictive limits on butalbital-containing analgesics are due to their high potential for MOH. In general, it is best to avoid the use of opioids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      butalbital for the regular management of primary headaches. These issues are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=see_link&amp;anchor=H8#H8\">",
"       \"Medication overuse headache: Etiology, clinical features, and diagnosis\", section on 'Causal medications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=see_link&amp;anchor=H18#H18\">",
"       \"Medication overuse headache: Treatment and prognosis\", section on 'Follow-up and relapse prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preventive treatment is recommended for patients with TTH who exhibit any increase in headache frequency or disability, or for patients who have long-duration headaches. \"Preemptive\" prophylaxis (ie, employing prophylactic techniques before the headaches become chronic) should be considered and discussed with the patient whenever acute medication requests increase even a little, or when stress or muscle or emotional factors worsen, or are anticipated to worsen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"       \"Tension-type headache in adults: Preventive treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Judging the success of acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Validated criteria for judging the effectiveness of acute TTH therapy in clinical practice are not yet available, but such criteria do exist for acute migraine treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of specific TTH measures, the migraine criteria can be used by practitioners to judge the success of acute TTH treatment and to identify patients who may benefit from a change in therapy.",
"   </p>",
"   <p>",
"    Reasonable goals for an acute headache treatment regimen include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the patient pain-free and functioning normally in two to four hours (at most) after the treatment?",
"     </li>",
"     <li>",
"      Does the treatment work consistently without routine headache recurrence? (ie, is the treatment successful in &ge;75 percent of treatments?)",
"     </li>",
"     <li>",
"      Is the patient able to plan his or her day? (ie, is disability limited?)",
"     </li>",
"     <li>",
"      Is the patient comfortable with the medication side effects? (ie, is it tolerable?)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment should be considered ineffective if two or more of these criteria are consistently not met.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIMPLE ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence from clinical trials supports the use of simple analgesic agents, including nonsteroidal anti-inflammatory drugs (NSAIDs), in the treatment of TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, 2010 guidelines from the European Federation of Neurological Societies concluded that simple analgesics and NSAIDs are recommended for the treatment of episodic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4\">",
"     4",
"    </a>",
"    ]. Although some evidence is conflicting, there are two or more trials of acute TTH treatment that generally suggest benefit for each of the following agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"       Ketoprofen",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available data suggest that NSAIDs are more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, although simple analgesics and NSAIDS are useful for episodic TTH, their effectiveness is modest at best, with pain-free rates at two hours ranging from 16 to 37 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal anti-inflammatory drugs (NSAIDs) are mainstays of acute TTH therapy. They are effective and are also less likely to lead to medication overuse headache than other commonly used analgesics, such as butalbital,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/6\">",
"     6",
"    </a>",
"    ]. NSAIDs appear to have similar effectiveness for TTH when compared with each other in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. In addition, NSAIDs were more effective for TTH than acetaminophen in some trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/12-16\">",
"     12-16",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following randomized controlled trials illustrate the range of observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trials evaluating the treatment of episodic TTH,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      200 mg was superior to 500 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/20\">",
"       20",
"      </a>",
"      ], while comparable to low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (275 mg) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      (12.5 and 25 mg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, conventional ibuprofen 400 mg was comparable to low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (12.5 and 25 mg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/11\">",
"       11",
"      </a>",
"      ], while conventional or solubilized ibuprofen 400 mg was superior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      1000 mg or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial that enrolled 963 patients with moderate to severe TTH, single doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      1000 mg and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      375 mg were significantly superior to placebo but not significantly different from each other [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single-center trial involving 703 subjects with TTH, one dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      25 mg (but not 12.5 mg) was significantly better than placebo as assessed by the primary outcome measure, the four-hour sum of pain relief intensity differences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      1000 mg was nonsignificantly more effective than placebo on some outcome measures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/14\">",
"       14",
"      </a>",
"      ]. In a smaller single-center randomized controlled trial, ketoprofen 50 mg was significantly better than placebo, paracetamol 500 and paracetamol 1000 mg, while neither of the paracetamol groups differed from the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/15\">",
"       15",
"      </a>",
"      ]. Ketoprofen 25 mg was nonsignificantly more effective than placebo.",
"     </li>",
"     <li>",
"      In a multicenter trial that evaluated 330 attacks of episodic TTH, rates of \"worthwhile effect\" or total relief for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      25 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      1000 mg, and placebo were 70, 61, and 36 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/19\">",
"       19",
"      </a>",
"      ]. Both ketoprofen and acetaminophen were statistically superior to placebo, while the difference between ketoprofen and acetaminophen treatment was not significant.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       Diclofenac",
"      </a>",
"      (12.5 mg and 25 mg) was effective for episodic TTH compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/11\">",
"       11",
"      </a>",
"      ], but no trials have evaluated diclofenac for TTH at the higher doses of 50 to 100 mg that were effective in migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4,11\">",
"       4,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      may be effective for moderate to severe acute TTH. In a trial involving 41 patients randomly assigned to treatment with either intramuscular ketorolac 60 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      50 mg plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      25 mg, or normal saline, ketorolac treatment was significantly more effective than placebo at 0.5 hours and one hour, and more effective than meperidine plus promethazine at two hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/21\">",
"       21",
"      </a>",
"      ]. Meperidine plus promethazine was no more effective than placebo at any time point.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H482161361\">",
"    <span class=\"h2\">",
"     Acetaminophen and aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen (paracetamol)",
"    </a>",
"    has been studied and compared in more TTH trials than any other, and is recommended by some experts as first-line therapy for TTH.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    1000 mg was significantly more effective than placebo in most trials while smaller doses were not superior to placebo. As an example, one trial evaluated 638 subjects from the United Kingdom aged 16 to 65 years with episodic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    1000 mg, paracetamol 1000 mg, and aspirin 500 mg (response rates 75.7, 71.2, and 70.3 percent), but not paracetamol 500 mg (response rate 63.8 percent), were statistically more effective than placebo, despite a high placebo response rate (54.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has consistently been reported more effective than placebo in doses of 500-1000 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. One study demonstrated a significant dose&ndash;response relationship of aspirin with 1000 mg being superior to 500, and 500 mg being superior to 250 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, an early trial found that nearly 650 mg of either solid or effervescent aspirin was more effective than placebo for the treatment of TTH with no difference in efficacy between the two forms of aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available data, we recommend treatment with simple analgesics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and NSAIDs for patients with episodic TTH, and we suggest use of an oral NSAID for initial therapy rather than acetaminophen alone.",
"   </p>",
"   <p>",
"    Reasonable choices for acute TTH include a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (200 or 400 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (375 or 550 mg).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     Ketoprofen",
"    </a>",
"    25 or 50 mg is effective, but this product is no longer generally available over-the-counter. For patients who cannot tolerate NSAIDs, a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    1000 mg can be used instead.",
"   </p>",
"   <p>",
"    For in-office or inpatient treatment of moderate to severe TTH, we suggest treatment with intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    60 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER ACUTE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various combination agents, triptans, muscle relaxants, and nonpharmacologic treatments have been employed to treat TTH. Of these, combination analgesics containing caffeine are the most useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination analgesics containing caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of caffeine (64 to 200 mg) with simple analgesics is more effective for the treatment of episodic TTH than simple analgesics alone, but at the cost of an increased frequency of side effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early clinical trial reported that the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      1000 mg and caffeine 64 mg was more effective for relief of TTH than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      1000 mg alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/24\">",
"       24",
"      </a>",
"      ]. In a later multicenter randomized controlled trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      400 mg combined with caffeine 200 mg was statistically superior to ibuprofen 400 mg alone, caffeine 200 mg alone, and placebo treatment in one or more outcome variables [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/25\">",
"       25",
"      </a>",
"      ]. In the first 90 minutes, caffeine alone was as effective as ibuprofen alone or the combination agent.",
"     </li>",
"     <li>",
"      In a number of clinical trials, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      500 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      500 mg, and caffeine 130 mg was more effective for the treatment of episodic TTH than acetaminophen 1000 mg alone or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/26\">",
"       26",
"      </a>",
"      ]. In addition, several trials found that the combination of acetaminophen 1000 mg and caffeine 130 mg was superior to acetaminophen alone or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/26\">",
"       26",
"      </a>",
"      ]. Combination agents had more side effects (mainly gastrointestinal discomfort and dizziness) than acetaminophen alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 1743 patients who were used to treating their episodic TTH or migraine attacks with non-prescription analgesics, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (500 mg) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (400 mg) plus caffeine (100 mg) was superior to the combination without caffeine and to monotherapy with aspirin, acetaminophen, caffeine, and placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another randomized trial found that the fixed combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      , and caffeine was more effective than the oral NSAID nimesulide for pain-free relief at two hours and a variety of other outcome measures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the use of caffeine combined with simple analgesics for patients who fail monotherapy with simple analgesics such as a NSAID or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . A reasonable choice is a single dose of two tablets of combined acetaminophen 250 mg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    250 mg, and caffeine 65 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combination analgesics containing butalbital and codeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although we do not recommend them for TTH, combination agents containing butalbital and opioids are widely used, and even recommended by some experts, for TTH of moderate severity and for probable migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/29\">",
"     29",
"    </a>",
"    ]. There are no comparative studies examining the efficacy of combination analgesics with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, drugs with psychotropic effects such as opioids and barbiturates are known to increase propensity for overuse, which can cause or contribute to the transformation of episodic TTH to chronic TTH. Furthermore, these agents have the potential for the development of tolerance, dependency, and toxicity. Therefore, opioids and barbiturates should be not used in TTH when better options (eg, simple analgesics and combination analgesics containing caffeine) are available.",
"   </p>",
"   <p>",
"    However, the use of butalbital and opioids for patients with TTH may be considered in situations where NSAIDs or simple analgesics with caffeine are ineffective or contraindicated (eg, the third trimester of pregnancy). Combination agents of butalbital or opioids with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be used when other analgesics are contraindicated due to ulcers or severe renal failure. Butalbital with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may be used in hepatic failure.",
"   </p>",
"   <p>",
"    When practitioners encounter patients who are using opioids and barbiturates inappropriately for TTH, a \"stop or brake\" policy should be instituted and firmly maintained. The use of these medications is either stopped, or the frequency of use is braked by limiting them to no more than two days per week and an absolute maximum of 18 tablets per month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Triptans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found that TTH occurring in a migraineur responds to a triptan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The benefit of triptans in this situation is probably due to similar mechanisms of TTH and migraine in a migraineur. In these patients, mechanistically, TTH is a mild form of migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited and conflicting regarding the value of triptans for pure TTH. A small trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    2 mg and 4 mg given subcutaneously had a modest but significant beneficial effect in patients reported to have pure chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/32\">",
"     32",
"    </a>",
"    ]. However, another study found that sumatriptan 100 mg tablet was no better than placebo for the treatment of pure episodic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/33\">",
"     33",
"    </a>",
"    ]. European guidelines for TTH published in 2010 concluded that triptans most likely do not have a clinically relevant effect in patients with TTH and cannot be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle relaxants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no adequate controlled trials evaluating muscle relaxants for the treatment of TTH. These agents are not considered effective, have a risk of habituation, and are not recommended in acute treatment of TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37079/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonpharmacologic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions for TTH include heat, ice, massage, rest, and biofeedback. However, no therapeutic trials have been performed to support one form over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who fail acute treatment of TTH, several important possible causes should be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of TTH is inaccurate. In such cases, the most likely diagnosis is migraine without aura; the inaccurate diagnosis often results from underreporting of migraine symptoms or disability by the patient, or from failure of the practitioner to recognize migraine. Less likely, the diagnosis of TTH is correct but the patient has chronic TTH, which is less responsive to acute therapies than episodic TTH. Least likely, but a critical consideration nevertheless, is that the headache description is consistent with TTH, but the pathophysiologic mechanism is due to a secondary headache etiology, such as a brain tumor.",
"     </li>",
"     <li>",
"      The diagnosis of headache type is correct but the acute treatment fails due to the wrong medication choice, inadequate dosage of otherwise effective medication, delayed treatment, severity of the headaches, or a very rapid progression of disability. (These factors are also typical of failure of acute migraine therapy).",
"     </li>",
"     <li>",
"      The diagnosis of headache type is correct and acute therapy is utilized optimally, but the patient has or develops medication overuse headache (due to excessive regular use of analgesics, typically more often than nine days a month, with headache greater than 15 days per month).",
"     </li>",
"     <li>",
"      The patient has unrealistic expectations of therapy (eg, an expectation of freedom from pain within 10 minutes of using an analgesic medication), or the patient has depression,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anxiety disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with pure episodic tension-type headache (TTH) of mild to moderate severity, we recommend treatment with simple analgesics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and NSAIDs (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest initial therapy with NSAIDs rather than acetaminophen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Reasonable choices include a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      200 or 400 mg, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      375 mg or 550 mg. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Simple analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with definite or probable TTH of moderate to severe intensity who are evaluated in a medical facility, we suggest treatment with intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      60 mg (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Simple analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of caffeine with the simple analgesics",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      is more effective for the treatment of TTH than simple analgesic monotherapy, although side effects are likely to be more frequent with combination therapy. The role of caffeine combined with NSAIDs other than ibuprofen has not been adequately examined. For patients with TTH that is unresponsive or poorly responsive to monotherapy with simple analgesics, we suggest the use of caffeine combined with simple analgesics (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). A reasonable choice is a single dose of two tablets of combined acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Combination analgesics containing caffeine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using combination therapies containing either butalbital or opioids for initial treatment of TTH (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). These medications are associated with multiple risks, including tolerance, dependency, toxicity, and the development of medication overuse headache. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Combination analgesics containing butalbital and codeine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoiding medication overuse headache is a major goal of therapy for TTH. This ideally requires limitation of acute therapy to nine days per month on average, and typically a maximum of two doses per treatment day. We suggest a \"preemptive\" prophylaxis approach to avoid the development of medication overuse headache in patients who exhibit an increase in headache frequency or disability, and for those who have long-duration headaches. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive treatment of TTH is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"       \"Tension-type headache in adults: Preventive treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/1\">",
"      Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/2\">",
"      Dowson AJ, Tepper SJ, Baos V, et al. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 2004; 20:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/3\">",
"      Jensen R. Tension-type Headache. Curr Treat Options Neurol 2001; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/4\">",
"      Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/5\">",
"      Ashina S, Ashina M. Current and potential future drug therapies for tension-type headache. Curr Pain Headache Rep 2003; 7:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/6\">",
"      Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia 2004; 24:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/7\">",
"      Mart&iacute;nez-Mart&iacute;n P, Raffaelli E Jr, Titus F, et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 2001; 21:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/8\">",
"      Lange R, Lentz R. Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Drugs Exp Clin Res 1995; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/9\">",
"      Diamond S. Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. Headache 1983; 23:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/10\">",
"      van Gerven JM, Schoemaker RC, Jacobs LD, et al. Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. Br J Clin Pharmacol 1996; 42:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/11\">",
"      Kubitzek F, Ziegler G, Gold MS, et al. Low-dose diclofenac potassium in the treatment of episodic tension-type headache. Eur J Pain 2003; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/12\">",
"      Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J Clin Pharmacol 1996; 36:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/13\">",
"      Packman B, Packman E, Doyle G, et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 2000; 40:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/14\">",
"      Mehlisch DR, Weaver M, Fladung B. Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache 1998; 38:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/15\">",
"      Dahl&ouml;f CG, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia 1996; 16:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/16\">",
"      Miller DS, Talbot CA, Simpson W, Korey A. A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache 1987; 27:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/17\">",
"      Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 2003; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/18\">",
"      Prior MJ, Cooper KM, May LG, Bowen DL. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 2002; 22:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/19\">",
"      Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia 1998; 18:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/20\">",
"      Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/21\">",
"      Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. Neurology 1998; 50:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/22\">",
"      von Graffenried B, N&uuml;esch E. Non-migrainous headache for the evaluation of oral analgesics. Br J Clin Pharmacol 1980; 10 Suppl 2:225S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/23\">",
"      Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study. Headache 1987; 27:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/24\">",
"      Schachtel BP, Thoden WR, Konerman JP, et al. Headache pain model for assessing and comparing the efficacy of over-the-counter analgesic agents. Clin Pharmacol Ther 1991; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/25\">",
"      Diamond S, Freitag FG. The use of ibuprofen plus caffeine to treat tension-type headache. Curr Pain Headache Rep 2001; 5:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/26\">",
"      Migliardi JR, Armellino JJ, Friedman M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/27\">",
"      Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/28\">",
"      Cerbo R, Centonze V, Grazioli I, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol 2005; 12:759.",
"     </a>",
"    </li>",
"    <li>",
"     Lenaerts ME, Newman LC. Tension-type headache. In: Wolff's headache and other head pain, Silberstein SD, Lipton RB, Dodick DW (Eds), Oxford University Press, New York 2008. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/30\">",
"      Cady RK, Gutterman D, Saiers JA, Beach ME. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 1997; 17:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/31\">",
"      Lipton RB, Cady RK, Stewart WF, et al. Diagnostic lessons from the spectrum study. Neurology 2002; 58:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/32\">",
"      Brennum J, Kjeldsen M, Olesen J. The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache. Cephalalgia 1992; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37079/abstract/33\">",
"      Brennum J, Brinck T, Schriver L. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996; 3:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3358 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37079=[""].join("\n");
var outline_f36_13_37079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Judging the success of acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIMPLE ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonsteroidal anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H482161361\">",
"      Acetaminophen and aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER ACUTE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination analgesics containing caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combination analgesics containing butalbital and codeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Triptans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle relaxants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonpharmacologic treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT FAILURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_13_37080="Lymphomatoid papulosis histology";
var content_f36_13_37080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Histopathology of lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 341px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFVAfkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6O8UeIF0BNOA06+1K4v7r7JBb2ZiDlxFJKSTK6KAFifv6Vm/8JZqn/Qi+JP8Av/p//wAlUnjlgmu+BmYhQNZkJJOMf8S+8rEt3vNa1HxfeyeL9U0zS9JvRAiWcVo0aRLZwSuxMkDsTukc9emMCobleyHbS5uf8Jbqn/QjeJP+/wDp/wD8lVT1Dx9c6dHvvPBniKJScAGbTyT9ALrJrk/hlq9v8TNKvLvQ/G/jOAWkwiliuYNOjkGVyrfJbn5Tzjn+E8VteBLaPVvBfh3VtV23F9d6fb3M88xLMzvErMR2AJJOAMc0czj8RdOMZPUenxVWR9kXg3xVI/8AdRLRj+lxV1fiDcldx8E+J0H/AE0axT+dyK0xBHJERbQxRxnqzrwfw71XuY4oYXaZWlwOqxMwx7L0/M0c99kaunT6XIF8e3LKCvg7XyD/ANPOnf8AyVRJ47uo03yeDfEKpnG43GnAZ+v2qltrrS4InntrbMg43iMM/wCAxn8qktr62vLoSQ6bK06LxLPHgpnsCen4UOUuwvZIYPHF6RkeCvEePXztPx/6VVHL4/uYmAfwZ4jBPT97Yf8AyVWxK74LXF1FEuMkBulY63WjPe7vPE1wmcFj0+nPFTGcn0uCopk0fjXUJEDp4H8TFT0PmWHP/k1T28Y6kq7m8DeJQPUzaf8A/JVVr3XLK1JMjxIvT5LhyT+A4/OsuXxNYEH7RtEZIAaS7XJ49O1Ne1eqX9feNYe5ur4y1FxlPBHiNgfSfTv/AJKpx8XaoOvgbxL/AN/tP/8AkquKvNVtIo1NjPKjsf3cQulAbnsAc4qymtwSNG95YTpLGcrMsry4PrlXJH4ircZ2v/X5jeGfQ6v/AIS/Usc+BvEn/f7T/wD5KqvJ47vI3CP4I8TBz0XfYZP4faaxYPEyySFRrtqmBjZNHJuz/vbgMfhVpNYkOWn1PR54dvSWUJ+pX+dQ/aLcX1fuacXji8mBMXgvxC+OuLjT8j6/6VxUdz4+urXH2jwZ4jjB6FpbDH5/aqqx6nbybXNnYTbejW86vj6belVr3VLNJ0muIb1EGPkhV2GfUllwD9DQnNvYFQuaMXxAnlIEfg7xCSeR+/0//wCSqnfxrqCAE+BvExyMjbJYN/K6qCC90/VbdWikkOeV81Q2Pz/nTYbW8hvnhtpJI4pBvVpJzsz7Kc59xgD37VLqNb6A6KW45/iBdRnD+CPFCn3NiP8A25pv/Cw5uM+DfEYz6y2H/wAlVpCHUkTMskLjHJBP8sVz+pWmt3CusJt/LcllLDJHtxThU5t2hxowl1NaDxvez/6nwX4ic+guNPz/AOlVTf8ACXap/wBCN4k/7/af/wDJVc9YRyRT7bm2uoLlQMSRjKt6Y/8A1V0enajP9qWKVhJGwGD3zgdfzonOS2CeHt8LuJ/wluqf9CL4k/7/AGn/APyVR/wluqf9CN4k/wC/2n//ACVW8HBcrkFgMkZpcj1FYPESMOVGB/wluqf9CL4k/wC/2n//ACVR/wAJbqn/AEIviT/v/p//AMlVvO4Vc/y5pdw6EjP1o+sSDlRgf8Jbqn/Qi+JP+/8Ap/8A8lUf8Jbqn/Qi+JP+/wBp/wD8lV0GaKPrEg5Uc/8A8Jbqn/QjeJP+/wBp/wD8lVYg8YWj+CNQ8TzWd9b2tgl29xbSCMzqbZ5EkX5XKE5ibGGweOa2K82uv+SDePPp4i/9KrutaVVzeomrFx/ixEkqxt4Q8Th26f8AHnj8/tGKkm+Kawrul8IeJVX1Jssf+lNcnpp/4SzxxZaRa6ld6XAthdXkr2SQMzusluqAmWNxjEj9AO1c3otzoHiW60aJtX+IFvbaxcy2lnczx6YIpJY/vLtjjZ1+pUCuxqEXZ3N5wpU5csr/AIHqFr8U0upTHB4R8SO6jJG6yHH43NRH4tWwvpLP/hFvEBuo+XiEliWX6j7TXmeqS3vgvU/EdjZzXGoQafexW8VxdhN4VraGUqfLVQfmkbHHcVnaR4ckk8YDWYrnaswMskTA7lYjkfTNbww8JR5m9DSOGjOzjex69/wtiLzmiPhDxOHXqCLMfr9oph+LtsGx/wAIr4jJzghWsjj64ueK4PW4b3VLuO0065WO4hfLZ4BXvk1Q8JQaXaapqEEOppd3chB2KcgY64PfrQsPFxvct4WCdm2eo3HxUS32+b4R8SDd02tZN/K5psXxXilJEfhLxKxHUA2X/wAk1kXph1PToreUFJIz1XjIrD/tD7HrttY28DObg7N+PwqFRTEsLC3U6aL416dLffY08L+JTc7tuzFoOfr9oxWz/wALFl27j4N8SAdeZLAf+3Ncd4hs7HR9WiudpFy6ZYAZAx3qeXUZJYV2sXUjCk+9DpRdnESwsXqmdPF8SmlXdH4P8Rkf9dLH/wCSaq3HxZgtrqO2m8J+I0nk4VN1kc/+TNc/qEn/AAj2hR6pqZmaJnCqsfJYnv7VktYJq91aazC7NEoEkZBxkHjn6GhUY7vYFhoN6M67WfjNY6LLHHqfhfxHA8n3RmzbP5XBqFvjfpS3sFo3hvxELicZjX/Q/mH1+0YH415l45nk1jxZYWBhGP48DJbFWvE3hq3S60W4urgWckWAdx689K1WGp2XM3dlPCRS3PXYfiNLPuEXg3xIxAycSWPT/wACaoXPxdtLWfybjwv4gSTrtMlj/wDJNYNhqKRa1bWrSCOOYhRIPfivOfijp13a+J3ntD59qrBfl+8p7g1NLDRnLlbsS8NFO2p65pXxq07VpJksPDPiOV4Ttcf6GuD+NwPStM/Eth18HeJf++rH/wCSa838CrbQNqF+1pJllUvt/h464qUeOLG5imhkBhvFfavGVcetKWHV2o3H9ViehP8AE7ZE0jeD/EoRQWPzWPT6faaw7D486Nf3gtbTw14mluCcbBHag/rPXMzeJbPdHALhJw5wWjOQrfWtrTtPtVLTW0MYuSuS4ABJ9aPYxiveuL6rHe51H/CzW2sw8G+J2C9dpsjj8rmsO8+PWiWd01tceHfEazKcFQto2PxFxisax0jVNMkvotQZmt7lsq+7rn0FefePNNs9GuI7yXzJGYgGMHGcVdLD05Ss2DwsLXue+QfEWWe0W5h8G+JGhZdwIksMkfT7TmqifFWKQOU8JeJCEOG+ax4/8ma8k0XXdX8SW9rLpCTItrKE8sEADoR9RxXpmui307Q57i5gQ3TIJCsZHzPjkCs54dQdmyVh4t2FT416c8jRr4W8TGReq7bTP5faKk1P4yWemQW0994U8TwxXHETFbQ7vyuOPxrA8LxNrWnDVvsDRRxk5J6naOgrL8XXE2o6KzWUAElqpYRtyAv+NNUYc3KaLCQfU6+/+NWn2Fkl3deFvEy27dHC2jD8cXBxUw+MNmbI3f8Awi/iJbcANvZrIDB6dbmvPfhxp+oa3otwdRCAPJthEgwGHp9K6nxL4Lln8G3cdtJGbiJg2wfdyP4R+FEqNOMuVsTw9JdWbKfGOxfZs8M+IG3jK7XsTkf+BNB+MVoJCn/CKeJdw6jFn/8AJFeTeBbSUT7JYws0RwA3bnnNegWFnBqNzidP3inGT0anOhCDtcbwtNK+p6D4P8ZQ+Jr2/s10rUtNuLOGC4ZL3yfnSUyBCpikcdYmyDg9K6ivOfAFrJafELxMkrbidL00jHYebej+lejVyNWehwzSUmkcJ8UbY3d54LgVdxfWm4zj/lxuzXJX/hjWdd8I/EXw54duLO1u7zV4beSa4dwixGxszJjAYkkZHPqea7jx5/yG/A/JH/E5k6df+QfeVT8Q+FvCd1cSX+r+H9Fu764IQzXNlFLI7YCjLMpJwMfgKyc2pWKjdx5TG8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzVz4VXNv/wrTwu6rIfK0i0DyOMKp8leBmsh/CXhG+cQ6P4P8PtChw0v9mwE8dTuKkfz/CtTVNa07w9YxWdn9lluYYxFDbRAbIVAwAAMKoA9uMVTi5vlS1NadGVzYj1J7xpJltnNtG37vcNqtj+Ik9fYD+dYuv3N1MA+qPY2djuBAutzufT5Bz+eK4PWfFOuSXKpFb3d2zAEnzBDFHnnA4JbHToPaq99oeqarFBLfajDbQMN5hslw3Xuzkk/jXTDDKOsml+J2RwzW50uo/ErR7aWKyi1HUZ5m4VbO3ESKB2wcmpbLxCskc8tp55PVvPBLfjnj8q5qw0wabFdXKyXF420PLM2AFUdgAAAvU4ArdkgWOzsmeLMswaQrnHA/n9Kp0qcdIo3hRhFalTUX1e6uciZ4mOFJfHf0Az6+orMmsTIuJNTnYqxBGBs3Z9BnP481rXl5fsLRYbGKLSNskkt4Wy6MudoC9T0HAHeprG8tbWGz+0ae8O/d5zyfNIhAHUHGM5BwPWru0rpFKSWyMy20+C2VZHePzGODN5PzH6d6fPbRXG6R2eSIEANNIWyT6f4dqmn06fUd+o28rpZyy7U8wZVeedvtVDULiwstajtYblXLBWG5VDjORnpk8+npQnd76ml77CX/gDTdUheV4FVzjEoLKfwxx/OsceGta0kpDYalHDbITtaSESvt/ukMdpHA5wK6CTVrtIHt7hvLjX5mbnOR/DxVdr9Wjy0odSgYs7kD7xHHcng1cZVNm7olwu7sri38zSmkudE0hr3IQSo0iR49kVhj6Cruj3Etq3k30DNZSDIFrO5UDpykxYflUc93E+lISep2M0jfdOfyxzUMF3aR7Yrq8SMvIViDtgO2R8owOOvA+nNJptA4JKx1KPbabbh7SWQxAExxzW27bnsCnI/CqcnxC0yESQXU6BhwRiVVPsSw5pdMu/IuBCpXLvsIY/NnnirT6kRJJbyxK8CvtLsM/hnsK5+SN9Vf5/8AzlS12M608TafcTNNLFbtBnBeBtpH5cdMdqvS6jYXflrpd5cRszfcufuA+zjP8jUesWWiX1viSOJyxPIUZH0PUda4y48MWqTs8OrfY1b7nlptBP91hnHJ/z2q4whPXVD9nF6nsmj6nqsJEd61tOo4DBufp6VsWwaa5mBeSNThkC7cD15wa8GstR1DSnEclwklsW2MzuQV7Aqc9OnHavVfD+rO2nxT795Tlstk/ifQ1y18M46o5q2H5dUbOqGe0t5XmuC0GQjPj5kyQA34ZrBeW50m8D3Uqtl8hsY+XOecexrpYrpdRtnaRR9juVZPUjjH5nrVIot/p8VrdfZJUZQjtKo3HHHAycn8K5ovlXvIxhPl3RnXHiWSeSW6sLRhEQsK3G0sXOflH91Rkk85OD0p/8AZGtXZSTUJbhs/eCXpTHOQAqqB19/8KkurKG0uYlj1W4t5gmIYgVSMY4zhwQMZ/hAPsau3M2n2cSHUtVcKv3gJWTcfzJ/AED2q+ayXIvwZLstIr8CGKw1G23fZpLyNyckGVXB/BmOPyrM1N9RaQCXXNTsJBkKPsqxoxPbdsYH8K3IbvTYYT9nhv3ibnf5MjA/i1Nl1CCSIJELmN5PljPllA7em77v4H8jSUpKV2vwFbo1+AyHxWluxi1G3dGUDDRHzCRjqRhSPwBrVtte02427LpAW6BwU/nWZYedaKfttlNb4/5amRSj/goAB98CtL7PHcxlHWKRSOjqCD+FZ1FC+34g4xeqNNZFYAqQQemO/wBK84uv+SDeO/p4i/8ASm7rY/smbTtQZrbzreKU5jMM2UDf3fLOOOvrWFhx+z742EjFnEfiHcxXGT9pu88dq0oxSejuY1IpbM574O2IsfiZZR/aUuHGh3asVzwRPaVF4N+DGvaPJ4cWVPD9hPpmqtqFxq9hNI13dxFifs5BhT5CCAcuw46dqdrdjoZ0eO48SWOm3H2fK77i3SXbnGcZBx0HT0rivGNj4BsvDltKumWsr35+R7OziQxAHnnb+nevTlRlVnfudOIp80nNs7/XGdfHnjNUjd/M1KFcYyv/AB42v606OJLC6LPcKr7fnUjGPrWR4BtNL0XwtGmjjfZ3ebks8QjKsfl5A7/L+lSzob61k2TKzMu0Ox4qlHl907KEbU9Rbe4sp7+53yxq91E0ZKNyc8ZFUvC3gSLwtqz61e3iSWKL+6Ucs5PHPpXJW2jXmjaxYzRK935Um1jGCQcnJx7VY1jxHqC+MXguIsQll3QtwAD3FdXJLVQejREkpNXNbxDLrlpPcXVrJ5mms+9SCMhf51v+HfEdrb2kN7di1gmD/JLOwXJ9iTWtd6kbPwq6WNnHNdSKQquPlYehryZ9NuPiNcGQ+RpTWACSoVbYcnqo9eOlRFKcfeVkiZza0SO++IHiezn1S1W8ZUkkTcskQyCp6c96k8MXGyMMqrcwbgc9hVa60jQx4ctNHu2d1t0Ecd2VAkDZJz9OelWvDFnpnhqwktp7/e0z7w0p28dsVL5eSyHG6Vmg8Y39zqniK30wh30RvlaPZwTjgg+uazdV1C58P3unaVY28yW2MHOTnJrq7+/tdNgS8nu4zbxfvM4zgCoIvGWj+LNOuZrSFvtEGFYMuCAehpRbsvd0QtE0kZGmzW02tlxhpLch2JHTLc896b8cfCuo6rJZ3mnsrInHl7sZ9xVlltbJ5p9gEsvyH8a1fC/jaCXxA+jXsBliihZRK+CAQO/8qScoy54LYusm9Tk7PS77+xtO+2ttu1bblTnAzSeI9M1dBqlxaSuZpmXeEHIHcisXxN47vdK8VxWSwIbWJlLo65LZOcg/SvV0it5XuZSxUyxjHoTirlKULSfUnnUtOx5X8Op9Y0u4mjuFlNrOnz/aBkZz05+tbuo+GNMk1CW+uzHaxIhLlTtXPbFcx4tt/EFt4nF3aW9wbRAMbTlDgdT6V1h0uLxV4cgl1Sc2LufmVTjkfWtJvVTva/YE7XSPPvBPhO5vmu5pLyOztonCxtK2BI2eMfhXteiRpYWUDalcpFPGoyM8SDsQe9cN4n+HN5f6XYDwteQXAtlKvbNLtYnP3hWvF4fmg8Gw6XqN9C2oxxszx+aGZf8AZxU1ZRqWdzOLt7p017qX9rTqbedJreHlWjIOCeuaxvE+i2WryKl1C0quoC8Hp9exrlPg9HYWev3Vre6taPDJlViEmCWB469/pXrcGqabe6vJbpIsTxI0ZVjwp9axqJ0pWj0KU7aWOK0e0sNBtjbwhYIh6sASf8ax/FFnrF9qME2kyGSBAMxk4x3yK57x54U1y41+5uY9txaMSFlR8qg9677wnJBZaBbwSb55II9jy44B9M1q0oJTTu2Xe70Rt+DtQ1GLTfJ1F40cHOwY6e9cBrK+Ibnx3BceH2eS0eYBxDjYBnDBwe2M10rarYJcIt1Phs8BR0NU9H0o+HZNV1+XU/KtmVysXd88ioh7rcrbilFJMx/H/iJo9ZttGsibfypQ/mIcBjn+le1aNcQXlvZiSdPmUFiB8sjYrwXThF4hhuZ7uNVmUkxtt+YE9/rVLwX4l1zSVayV7iWXzzgMOnuM1dSjzx5VuhTo82zPd76100atOsCxtMpAkCjpVrTtASBHvMZIGFRT/OuQkn1MXCXU2ySSXaGIGM46jiud8feNdS0lnk0aSaFo1/exk5yPcVzKnKWiZPs5NWTO++Hclw/xI8Xi5xlLDTkTB/h8y86/iTXpVeKfs/a/P4l8Q+JdRuU2yNYaemPpJef/AF69rrnqJxk0zz6nxOxxHxKZk1HwWyzrBjWXJkYZ2j7BeZ49cZrNup4tWvMM89vp9mCJpZflkuiRwOxAxnjjr0AxVn4uXv8AZ0ng+7wMx6w5GRnB+wXYB/MivL7vxJYz332MXUkkkpZvJhbccnJZpGPTk9Bz9KdOk56o6cNT5zT8WeOr37YdJ8JQLBbqMCVCBk98H9M+tc9pnh64gk+06/qIdpSHWJPmPX39+5q5HJDaGeQ5GDgMoHJzjp/n+tOuLmVtm6Ml87Rzk8ev4n9K64rlXLBWPWhTjDSJZljUOm0NhlypYcfjWloGBfqLqUCJw2VZRtHHuev1JrLRbgavslkQBpQgUDHy45B/WnW63Mup+Q85tlVHCiNVGWByAc544P51MldWG2dFvs7UTtBIk4LHEKkYY4OAfUcmsTxDe3NtdwTzK0gjj3lVA2ruOB16dR/9em3Uhii83SoY7nUZwxttx/dAj+In/HHSjQxdxXKQanN9rJAtLqQru8zPP5ZHB9KlJR94zSdzU1OwW9lsHijtfs8DLPGZX3BQwB28EcHjnnkVEi2mv+JruBjIsFiytM0bfI54JTPY42g/Wm3mqHUYbq00+9MdtbBD5HlYfG4Ddkjkc9OetGnXFvp+oa8k9ofst8p83zCBnaPmY59AufwqdVHXciz5WzKjRbXU55JftUb3Fyyw23nl4o4lJCeWP4Qd2TyRnp3w67Cx6hPaSGQ3aAtCGAKtjk4PYinJYXUeu2ccM4hltfOWWILnag3AbSeMghcZrPitNWhtoL7xA266t52RXZiPNh2qUJB75Zhk/wBM1d1fc0jaNootXdrN9hWOaKTMuQpPHPHft1x+dY8kkUdrbJHmTy3KkvGuB1IxnopOT+FW471rWRxqKSSLcSARJnoSeWGPYj86r30Mul3VpDbLFPBPMsMvmI7PtAIBXnAOMk9q0jfZmlyxemOWOKezKRwNEu9M7lV8ncCPTIz7VDdRR3QyltFLPbM09oqrgZH8OB1Hyj16VYshDeX0VtZsI7cqS284wwyc/wDfWa09PskaNHtJECjrJ2DHJ/8Ar0nJRH6nPWaa2bKKXVomGqO++Py0CFRuwAVA64/HBrRupLi41BGh1N4YVn86aFZMJPGRg8DgngY9Mmty7uI5NKlsJZ2jvXD58tRuAwSOSCOnf/GuatrB4bIDTBCgiAALqH2gLyefw/KknfXYiOqs0aNlA8SPHcq4ABy8i7tx6jqOaS8uBFhAqMpjLEYwGAzkD3xUV+Z3dEtZfNlGAzrxuIAH0q05AsYW1AqWZmBA524xzR5soydUjXVdLlhiQ7XyqHOCrYGPp171t/Dm8ntNP+zyHfc24MUsDnl1zwPcYqmkVnOrPEWzERvCgnHBGevJ4P8A9filsJVOorcwkLKAAxdSOAeD0+vPNEvei4ilHmjZnYaVqjadHIlrFNdWchLLb4+dD7Z//Ua1LPXb0yRpb6NexRrnKuI4FY9snceByfeufTXY7dmm+zXEdyfvNbSYRuO6H5f0Fc5qOs3mry/ZxHcvFuB8qUFVAz97aNq1xqg5vVHG8O5Pax23iTWNPhWFdSudPMm7LQRMkrA+7sNsa+pOW9D2rkpNe02a7+z6UumpLnAeKNbtz9GfAArEvLG0F4jzWqSZ42FguB6+n8utXtLmNoseba325yUQbxz0Un0A9QPwFbQoRgtNTWOHjDfUZceI7J7oQvr+rRTD5StvbhVOOCPvKo+ord0i2cwtJYJJrMczfMZ5wrJ9dkhAH1Ws+72RwRnbDkglRCCqr7celA0m2ubVZLnzYyy5DK5UjuenNOSi12+7/gFujF7M077X9V0aJzLp19ChA4spzMoz6gggn8qh0vxmt3KoTUZbWW3O4RXkCxqwP8OVyP1B+tc5d+HrFoJJAXlIzhclR742gVhwaAI5/M02d1mUZ3ZYr0HXn1P6HirjRpSjrv6B9Xie4QeILCVl+02saucEvG6zAfXPPXsOfSs0sr/s/eNnjOUaPxCVPPT7Td+vNeManpWr2n+nabeeXdoMmPkRyDAzgdAfbpXqXhSSSb9lXXpZ0Ecz6frTOgGArGW5yPzrnnh40tYs87GUPZWOf8a6LLrFo+ZGjZxllHT8q5iLwpbxeHPI1h2njgczIY/l2+oJ5r0kXgn1HyJiPOB8vPal1WbREiuNFubhEe6HKgZ2k12xqSS5eh1yUeq1OK0LVIdUsvJso/LitwI1ROgFbk+n/wBneHZmhukduNi91B6g+9J4f0K08MmWKG4ilhkfcZAMgLjv+tdF4C0zQ9aXUZrC5jukaTBDNna39BTnJK7jsJz5UmzL8CNGId9z99zuAzwB61g+KtCj1bxBHqkreXnkBRjIB4/lV3xL4qTwTFeS2tos9wHNuiuflX1JrU0zVf7e8MaVqDWiJNKpGzoFwemfSkuaL511Jc052ILfU9PGnRzTyO1nF8sjDqr1x+v+K5dC1q3+x2UM2kzKGDYJZx35B4IrsLbS7W90rV7fTZ7aeQ8tCjfMDivOtPv9S0vTtRihtpmMA4Ji3lGzjIHrzWtKMXcJS7G74ntL1tUS5gSZ9OmQSQgDhcgcEY61h+NQYrbT471m+1+VuaIg5AzwTW54BvPEa6Lqd9fRXGRh4vtH3pD3CqR6d6d4w1+3FhZXWs6YslxcJtI24cD+6TVxbjNLewKXNG5ga/Dcata6Tp1rNI1rPECJlUlcjsa6z4e+Ep9DtLsTOkk0xUuwzwq9vxNXNBvbCfwnDeWEYsYwrrH5p4WQe/1rL0aHU31YXs17HLCDzsmDD8RUSk5Jx2sEUm+Ys+I5W8xjH/Cw4rR8P21ncz3U6oFvhEFfngjOc/WqepwiZm6EMcZFbGlw2tpZAh41vnz8pI3SJjnism/dsjonsile22jQ3MdzrNjb3DR42SMuXHt71taJr1hdXe1URoieh+8FridZmN7I0TfKI345wTU9pYG0to9TnuIoLdSGMrNgAZ5H/wBam4JrVmbitWzu7wwNv2qTGDjB7Vh+KdR0JLeKEzP56H50Tt71N/ammyaTHfWl9HcxyvsBQEgNjoa4HUtJu7m9nO11LEkMo45pU4a+9oTFKWpzOp3WqJ4qkk0W8k6jyismCB6EV3OueHLiLU7XX7m/jtzcxobmJyRh8AHafeufuPCyS3sUckkkcqgEyKOc/wCBrrtbntdU+y6LM7RzFB5cxBPIGOR9K6ZzWnL8yPZ2d2Ynh3wVpMevQ3qX0sqwSCbyWA6g5HPpXoljJ4f8X6rci0vGt9WXKEKwG/HfHeovD2h22mLErKHkWMRmRv4sVyWl+AbjRfGr60s6iwt5WmCDO/nnb7jn8qwclUbvLbYiUbfAegxTtp9ldQqn2iORvLG9eA+DXKeC7W/s9K1t9fjFolw5EYzwp9awPGnie6tIA2jkPM0uTGPmYAjrirHhPxbYay/9l6+JGuVUMSeAPb60lTkoN9y2lexyt7o+sw2kt1H/AKQgfIlibeevXA/ka2JH1a68MxDUoZMJKPKDKQWG09vrXU6bNo2jeJ5ILRzJCD88fVd1djBrFvHIJ2hExXoCuAPpVzrvTQu0lqkeYwRL4Y0KIXkTNNefvHVzhk+lYXw+sdVvvGHlDzJIixYSOOMdjVjx/wCLDfeLZ7a/sQ9ihAVlJDr0+Ydse1bfwY1O5g8U3Wn6naO8EILJK642EHjPsc8Vo+ZU3JrVmcp29Ueri2U6eFukMN5H91uitXjvibQ76HXJ5GR5Y5zuV8Zwe4NekeNL+WKW8ntYpGZFZlU8gn1Fc1oniNdT8NzTS2wW6SULgnoe/wBRXLScormRdNPTzOo+DFnDY+K/EUNtGIkGmacSo6A+beZx7V65XlXwjuzeeLvEEjOGYaXpykhQMfvr3jivVa46jvJ3PNrq1RpnkH7TEElz4Y8OQwnazayoJzj5fslzn9M159oOlw22oTfZpvtLGNQ8gTCrxyqnnI6d69V+OCh7XwkpXf8A8Tr7ucZ/0K64rgra5jtI3fC+a7hSQegweMenFdFGT9m4o9HAfw2/P/IhS9SbT5lMCNGiM/ykA4yDz+Y6fjVDUjqdzpsH9i3H2G8DHaMjY4PUH3/Crj3DqxWEbMk71Cff7Yxj3rS1PyItjTtHFbRxKdqg5GPvYI7mtLqLOxq6sV5LNL+xsrqScXmpRxq07Wz4AlUZYEDjBPUYBP6VBNqlwmmedcaXdy30kBLJagqykttBGQT0+bPt71bg0Oa5sIY9Euljjl/ftPvzv7bcYzmpL62uWtLSyv0ETyny5NRnn8tYQoyvpknGKnmW25D0WjMzRNN8vw9NeXNnNAxuANpyhDK27I9Du4PrXQXF/FGbm4lVVlWLLySsIoo5MfKCW4PT9cVaGmmDQ5459RWQyrFuSRyytj+6B0LYJ96ivtMk1TQdOg8T6FHq2LlXWG3neJYdzkByVI3BUI69efas3UTd33/rcznNpe7uUrdrmFpr1Y7hri7n2yx3CCBSRD8iRMeJFZwxyCSAo+p2tSs5dbFzZXttLHE8LQIyuHYiVSH4xgFSehPNaN1bpLqlu91PZw21sFdLaWFco4G0SK2ePT6HFY+i63YaVevDplnq+p29xc3JurlwxW3eNckHjkNggdM471HM5LmitTLmsrMj061+wtFod/a3F+Hhe2kuJrXMckQUfffPAwB0PU9ar63pr22hQjwtb6fPH5qp5W8LEIyfmO4scY/E+1dHpWurrenT3M8EmmRup4nT5lHPBz1JHIPeq17b22k6TE/h8WVtaG4V7hsDlP4gATgt04qeaSeq1/ApSttocgbuy1SfUJLIyudHG3Y8WzgA4Jz64789Kl0++luNFs7xo0cyO4J44XjJ6+xront764sHNzZWyGUZMMJI3LkKu4kdcZPpWHYCLWIdStIrK5tra0ufLE8vEciqDkqeORxkH+9mtVJNeh0KehUg0/8AssTSiQzIzGNeDkL3rKOlodNa0srplaKcXKEgkPhdpU+2OfrV6zu3t9JlinZsSMwiMg/ixwenSsTQLi70ZI7XUBJNdXTsY23DEag4z1HJIPrW8eazaeppbubL6XJp95a3OpNJugTlSvLcfKM+nNaSJo1pE1nesx3r5+8kgLkAjPOOMdKjvory9trVpJp5BPP5jiZiwTgLhVxwvBPHc1Q1+GbU9X1O1t45D/oaNvVc85UZz+B/Ws/i3ZKd9GVtQvY9Jvby4uoWkLsscEMJALuxzw3QADdz7CnXtg0+qXc0ck8du6qRGBlV2L9fcj8KvaIwvNXn0i7tfNa2gQRzlfmSRUAJB/FhRNNJb3gnuLiPybcMjwlgC+cAHH4/pVczT8xq9yG1tRbOz71aFYi7HIBIP/1yPyp8NxbpEshclycHgcYzxn8TmqurR75bm/knSOyYF36YAI+7z74pNLW0k0lD5r4MrbyVC4OBkYPtg0NaXY9DQa6lMUm2EAEfIwzyeO1PnW+sbR59SiKEcKGwCSfTGQPWm3N7HEsMmnqSobYpduexOQM+oFVjcpZ6YbKztHkRJ3uJWmlLvLNjGefurj0qLN9BXelhUjD28UhdUW4Y5QIpYheOvXHX9aRron94ZJAyHGzjYBj0781qaZBDdW8ccrr5y8+Uh5UH1/nj/Gob2GOeQIGEbEZK55GD6j8sUuZXsCZmSzXa2ifvGJJJ3JwScDgH0z39q0IJpWijt5jumWFh1JIbB/xpszyoTMgBt4PvKep54/lSWN8L+c3UEbQyRyc5wcc+uPSqe3kPqQaVbW8SSwXUxG8Bdg7Y7578H9KluYvIheO03SFjzzgkccD3qrqEBKyOpOWYFSDyMkZx+v5j0qS28230pZGkBlE2wFuCoILAkemAfzpvXUexLb+dPA8cisqjOxd2SBzwf14rofDylP2X/Eisu1hZa4Cuc4/fXXFctHBGGu9St2zeXEIEsYOUYgfKxXHbpjuCa6fw15v/AAy14h+0kGf7BrfmYAA3eddZ4HHWsaux5+YfBEwNUMtlJ9sY7VPzFmHHNU7+1ttZuBqUDt5wUNlDn5hXVSwQarprWkiE+bwexOOhHv7VLoHh6PTY44YGeRGkBkZ8fTGO1dKmoq/U1cu5yvibWbOw8LmO7ldLm9jaNMLyvBGTVn4DeF7jS9L1DVNSl+zx3YEcKE8nHO7jpXKfE7xFpr+LG0rUdPP2ezIUyocOOM8CvWNOvrS08J2UNoWa2khDQsf4gRkE1dT3aSS6nM/3j0PH/GI+2+OVgYGQGdU2nndk/NXojXFtb2n2KCIIka4UL2pkS2ESyXdzbKt5Gp2SlRn86xbCeOe7YiTzMngUSlzpLsdMYau5B4L8M6hpXisapb38a6czFpEY4Yj0NdjqFxby3k8lnmOJmyWXgkmub1S8NqG2oGcDOD0AqTw/cS3hdbkDCgEdqmfNP3mCpKLuXgiK5Id5j23nOBUWs2Vpf2gtL21S5h4YAkgq3qCOlajxxW6lvMAHXHc1lXK3UzN5KMdx9eg+tSnrdFWT32MXX1I0y3ggiWGztuFiTsPU+tYuhxSi7jaEbkRSHfHGPSu5uLeS205ruRVbZhSQeMmsa01Lz2liliCZ9PTv/OtYzfK0ikl0Ma51G6+1wuG2W4bAT1HYmqms2epWWtWOrWyyzgzrjAJxzyv0waWXT5VmkdhJhcsST8uB3FXtK8X31td6bYxxJNbyyBZC3UAnGB71slbWJNT4S74q06SK+knt1LYJ2rmsXWNPvtY0kaVFJscyrIgYnaWx0J/Gu5W7huL+WPyw+1uQR1961by9iVY1tbaIyJ/GyDisFVcbKxMo8y5WeUa5FqXgTwfZ6cxQXt9M8zsvIjUAAAH15rsvD2oal/wiNpd3SGS6MBKqRjLDJXP1GK6TV7Q+IdHtJkit2vre5G5ZVBBXvjPSsfTb1Z/F11o88TxJApKzg8DAHUenNDnzx213ZjTXK3cy/D/jR9alEWp6StmyRhnui21SfTBFdTpd7oWpagvksrXEI2q5HWvO/FGlRadqjx6XIkkLHdwcjn71WfD2iXXmi5kDRx+g4JNVKELcydjRQurXOn1e31t9ZQKC9ruO0xt8uM9xW5qV75MTQzsojCgMWbH61k2mrzabdLFLOPJY4O/kgVyXiPTdd8R6zdWlquIiRJDngSDHTJqIw53rokEvd3K/i/SbTRdf069M8uy5yxIXKqMj/GmnwQo19NQW7ieGX94m44P6VJ441bUNKXS9F1TSVmhht4w8xB3ZwAQpH0rX1Tw6suhaXc6ZcyCSKPP2dzz64Nb8zUVdmcZ3exJHo7nWpLpQG3Nkj1967ae1SbS47eCTy3LBmdRyo9Kg8OX39peHftdzYG3mtvk3nID+lYc+p6nNqUsAgCWZGFYHvXK7ydn0NudzFutAsryQXF1bBrmB8KWHDfWm+LJNQk0uaPSgkc7449fbNTeGobm1knN/OGjB4WRtxrfWeyPSNgCOO4o5nF97Dlr0Mb4ax6i+nyWmvzKxYfKByQPc1y/xS8P3UUnk6POIlB3nZxkHvmuyuZIALiC2mC3EiYXaeRXn+tfZ7nSrnTdY1AwXhYHe8gyBngc9jVwbc+YhRtfsd3+zhaXVnrPiOK9k8yT7Bp7Bs5yPMvK9zrx/4HacNM1/WrdLj7RF/ZGmtG/+z5t7x+hr2CuGs7zbPMrO9RnmHx5i87TvCke4ru1rGQcY/wBDuq4W9sItrMz87vNJHUjkZ/nXdfHnP9n+FNpIJ1rGQM/8ud1XFXDJZ6PCXXzZbrzERWJDMigF8EdwGyAe2a1o35dD0MC0qb9SSGe0ttPudVcyi1jieRig+cA+nvkiqljYSz6bO8scksYhEvkykEsrIcgEfn681bttN857jSmY+WLh0kx1ZSowR9CP85rrdF0D7GtrbNcbrmKMLwckjPORn6GqnUUDrc1HVsz/AIZ2trDZwtCZxBMXwshyY3BwQPY1e8Q+bNf3Ghx29tN5kDSiSRizRuCCcrznIY496100u1sftZshuuZP3hjDAFmAbA9smue8H3MuvXH9v3yQ2moyqbd4kIbaykjaTk8kLnHufSsObmk6nT9TknLmldFzTvDdrqWnrLHAbVVkikTMflsWToWA+934PqatR208HiNLiWDOY2U3AlIUAN8qBM8nHJOK30kCthjwOCDTnI5AKhjnHHP1rF1ZX16icn1OQ1bU/M8R2GkSLbpDdeabi3ZQ8kyBSBgdlzyTx0qO/wDByTzW1xpt5c/a7SA2sLvMW8hSCNwXHLDJ5brgVryHT0WXULT7HdXio8TXabMJsydruOQN3bPeuM0S2b+xL+7fS9PtI3W3lguDdmdpJCAWDOWPSQlByMkd62g3a8Xbp6he7sjt4tEb+xorHUbhr6VI8NczqS8j/wB4gYHHH5c1z+n+B1vdDt7TxmLfU5be4klieNmjCq2OPlxkdeue1U2kn1nxRpOn64bFI7WH7XCIbkxXCyKwADLuJKsMnGMcdavaRp+uy3NvLqOs3KPaTsGARAl1CwDBWHQOp+XI7D3qbTpp+9br+e1hWezNGy0KLTNQu7lbq8uDdspWOWXKQKg4RB2Ga5bTrNNNvLrS7aG10zTriSbfA6O0k0+5lV0csQqbfYfjnNdTdaVex6escVxJNKLlJA0rdE3DI+gFc9rls+k63f6xfQQXkFxLBBarGMyLlcOW/EZH1qoPmvd3v+haSumcNHFqEtjaabJarbTQRuEjV9yFVYtuUnPBAI69qtaVIhvpGv3LGG4eML5O8ktwBk9ACucDrnrXoyaQftyMrxs0MXkrGwGQD1Pr0NYviOO0tby4srq1Z4jB9taaND8uxgAoP8R57cit1WUvdsdaqLa4/TXg1u3ktPsmo28cRERM0YjLY7oN2eo9q29M0qGzWIxsVKIYhls/LnJBPc5OaqQwalqOpWb2wjh0KS3Sb7UrkTmQEYU542kDBGM9eRWhdeGYZ/ENjrEskiyWcTokak7SXxk/p3479q5Zy6N2/EwdS+xjXnhRZ9dt9RS9GbWQTGOJlXc3P3zgkgjtx39axZrLRfEmsN9nld7q3lRbl1J3Mp3LuXPGOCM+oraXQNMTVdSvtPuJLS8vGQyeVMPmZcjIUdM+/U9q6CexMey4sVjdwvzfKFL/AFNP2rh11t6Bzvdnk99ewa3pD3dlpzxW0YaN4ZGByQQPX37+laWjafMBbBGMNnJbSSuvruUgk+o6V3x0q0hSS4YmAMA0iE8Z9z071z40mKO8vit80s2pKWSMkklV+8QB0A+UZPtWqrqS5Vt95rGotjJNlDJo8i6Tu84PtBIwTnG48dCRxiqWnXK29rc/aAv2O1KQNIQSzyEkY+mc/hXU2WmNDHbQxq0IEhYnacuNuST+JxVPUvDRuLGC1uDIFa4Eq+XEF8s8ZB9ehOfehVI7N6F8yXUxm8vS9budZtQyy321fLUcAjI3c/QAUmlWEM0bwSXBa6ibfL5jYCKT1Y9ue1Xr22ex8XLdQqGgkxCgx8oGAOB+R+tQ3fhG3liS3uI5bmC4uw+XbBwDzkjt6+tW5K2/QNloFwh02a/mgmCW6ykyyORt8tcn9cgVmst8YtIlXB22q3TshG1mzk8++0DH+1XS6j4cTV2lWT7RHClw0rxKwRJPQMCPmGfp3qS9tLy0i05bS0d7WZCkknlhUijTHXnHOePpUqqtF1/4AlJdTD0iWS9tbeXUnjjcgkFvkDDcQMev4VLZWCxtOsqkxsx3ZOc8kk/THSrWqaPNrR0xHlkiRXLNt4AXJ7dOVyPyqlpKXbhLiR5TEsxZlbkYwPlJ9MmqUrptFCWcNzbwXMyKjzOhBUcjLckk8ev6V0OhGRv2YvExnH742eul/wDe866z+tcnbNPrOnAPclHilNwEVQD5ajJ/Dt+ddfo0nm/szeKJBj57TXW4957qorX67nBj/hSK2kXl3q8FjJsNrf7MTKeQcdGFU7HxlHP4iuNJkV1lTdukPcr14roZbGbTbSG6VGDA427emK5FLHRm8XtqrXKwTtktAzABieDiuiPLK7aKdnsb2pReDvG2iy3s9pDJqNrgSFl2uQPUjqKwp9ahubyKGOEQwInlwRDgKAMDArQ0/TNNs4NQnhdLeAqXLnoBmsfQk0m40DUdes7p7qSyJVoyB8p7MPzqklra9ggo03ruXNWBvdKlSI4fZ+dcNY3jWOpJuiKEHYykdfetzwvr0moXypMFdJsqCoHyn3xV3xhoIVHdzIrw9ohnIPtWkfcfJLqbJp6laSW31CQxCcecwxgc59qmjhbSIpSoZ7hxjnsPpVHwVpUUWqRznz2ki5G9MDmu41c22oIhEapdLwWAx+dRNqL5VsVzXexw0Ml3eXRaeVjg9jxXQ61Z3174aks7G7WC6KAh9+3pyRuHTisvVbG6t7oPNGWjI4OOK0NItJbiymgZmCSqybgOVBGDim3tJCkro5zwZcW1jBNpmp6ulxPdOAu0syRn0LHgk57Vf1SbRdMmNrDfLPeyD/VqD8p7Vmab4D/s6USXV3vWGTerBcBgOlbtpoWhz6oNS8qRrpTgKTkfXFXOUOa6ZEeZJEdjaPLZOs+QHQg57Vj6boskepRF1DLE27fjp71193FJHlYxiMnI46VagXyoXJjBwM+lZqo1t1NXa2pHYWsZ824GEESHc59BWfbatYzwz3NtdwzRxttZ1cfKfep5JpJYpLS6VTbygoGjPVSOQff3rhLDwTfW99qdqbhFspICEmVh+8OQVyueDxThCLvzMylNp7HXXl7qJurN9PZBCXHnD245q7r1nLqmi3EdlIkF87fNcFeWXOdpI5rktH16ztbuLRpEnE0D+SzsuAT0yO+K7y9Wa1tCLP5W9T3pSTg0NpSOB8M6VrGjNez3qperFEzxwB9xdhz1FSeFPGmt63rvlzw29vYxqWeKNMD0A+ua6nQ5blp5WmYg9/rTLyUWt4PsccKSScvIIhk1bqczfMtTN09VqczqV1F4o1AwacZLC6Utkn0B6j0rr7K6a2it0aRmaJAm7oWx3qrpQjuprid7aNLlTtaRUC7h1zU88SmXcepOcVE2n7vQ2iu5szXH221KSE46sxPNRx6fONjQOjKylsDk9elVmnFtYyyHa7D7qnufSsLUvF2o6Rol1c2NsgvTMiklNyqmCScdskYqIwlLSJEnyrQ6ttQuZIkgkbEaHOzHBPvRbRm6nZ53ww+bgda5zwt4kXxDbSzz2/2a5iI3BT8jg98Hoa6Q3cdvE0ryRxL6v3/CplBxdmNSTXuo5Rort72WRJXR0JDrIMq3PGPpW9pV2s1vCSUG3crD0bvWZfPFqqPPbOreUfnKtwfY4pujyx7PL3x72YnA9a0lqg1NiWG3E5nhUKzD5iOv4VwvxB8KaVfsdVvLySzkACMduQ/px612GsXC6dZvdP8AMIgOAeorl/Fuk6r4ne3n0qUm0mVdisuVHr+NFJe8neyCSUo2lqdj+zlJatq3iCKwleW3g0/T4ldzyf3t4f617lXkPwX0lNG8X+J7RAARp2mswAwNxkvM169XFWac20eTWspux5n8cldrPwoIm2udZOD6f6Fd1xekw6dqN9cQSXNpfS24zJCHw9rKV2FhwM9cHGRn6V6B8W4GuZvBkSDJbWzx7Cyuyf0rLi8KRMyiNEtlafz7gxqo8856scZJpwqKMbHZhJWp69yj4R0u7tbkS6zcpczylyRsCnGQBx7E/wCcVpak50vW74WuyTVros1slw55+U7QCOi5rbutLt7prZpJZ8W5JVFbCucYBfucducZoVTZQTXOqXcMzBmK3EkaIYkJ4TIA4Hr1rL2vM+Z9ehcpuTMfwbpF7DJLrGtSsdUvIo1lgVv3dvt6qmPU8nrycDpUlsLe8vrj7Lpht3sHZ4WkyIvNywZ9o4zyeeuD710lq0ZhSSFgY3AIYcgjtiqWr2cWqWj2Uks0KORuaEgOQD0GajnvJt/18iOpydt4iabUdPW61CK086PyzbLExEk27BZWHUdODWvrdleX9rLLYX0mnzGLEM7w7hGQT820+vHPpWlpekxWltFENsjQqVSRgdypjvyct71U1P7dcI0Ok3lrHcxSr5/nxmQeXg/KACMHpWnPFy93SxV03ZHJXujaczahINRjh8OxwvMINOgxJHPnLTCRfmLcn5Rxg4xU1tqMOqqmnfYTNot3bLJaTwxjYwz8yvgYVgdp+p9quTXq6FqdppsypAl7E8wmB3BZBywA67cHrT9Jv5YorGKxa2S1u0kYB1KAs2dnykA8k+nrWrb5dfl/XcdlDVENna28Pi2zlsNBhvJZLdo5dXW43eSVGAjJ0DHjoe/1rS8OX19dwQjWNNmsrlnbaZFBX5ehyOBnt3rA8M6JfS6jCdYubFru2ilkurGyBUCVyQHZs/N8pxjoM8CtfwJpWiact9BoOTZ+enmgyEiOYDIAz3we1RU5bPW+3fz63E31NTUtUbTbWWa5ilmcypHCsZGWZ3VBjJ9Tn86ta5YJf6dNBnyxIh2sihmQ9Mj396saqlvbwS3l4qOkIDj5dzAAdh2qC0ubi70pbuG3VJZIiywtJ37AtjpXP0UloJSvqENlBHO1ysY891Cs+OSB04P1rB8LW0U0N9OdSfVoZLmQRtNDt8hc4MS9yAR174FaFp4l02XU7vS5ZRHqFksZuRjCAuoICsetW5bm5e5uFttPeRIog0bs6oJpDyEXr+J7U2pxun1HfW5k+LbK9uNEMGi3T2N3vQRTIgbbhhnI6YwCK241JjVC29sYJwOv0rze58Rz6fIuoa+NR0W4N4qyJHALmGaIKAEPcZ5weoIPWuvfXtN0/UrGzQSmXUm3xnYcMSMnk9PpVzozSStff+rlXbYw+HbSPVo7uK2tzKcmWR2ffnjGADj161uHKJhBgAYCjpWWninS5NX1HTv3yS2Ij8yQgbSXzgDnPp+dUJ/GNpp2sQWWqwy2yXdytraPjcZmwCWxjhQXUZJzknjvWbhVna6Bt2uWdMkhmN5ZXN9aX1wHzJCGTKL2Ur6e5FUtE0iTTtbv7u41K4uoZDiCGUApbr3VDknnj0HAra024guXuDGhDq+wkqBuwB39OtWL2yS9glgmZ1RwA2xsEjOetJz5bx2uO5n6s2rK9o2i/wBnmJSBNHdq4JXP8JXofqD2qxpNuY7d1e5e4dnJLt0znsPTitADZGMDKrzjHTAqHT7KGytkt7OJYYlJIjTopJyf1J/Oock1YRizoZdbNudNVYgvmfac8E8Dbj17961/JBgj3oGZTwOyjjpViZ0hUvMypGoJZmOABUgMcqq0MhZSN2fbHFEp3sNyMKzu7j+07q3On3EMMQGJyvySk9cetXr8xXyG0O0EDcVGM4PPTt/9ar7pjBGCVxWXDp9tBf3V5HbRpeXCqJpV+84XOPrjJo5k3fYE9bmfLAbcgM8HnFj5a7sMTtOEUdM8cVyXkX+q6LZtqFsdMMd01yLdWLFkjwV3+5Ib9K628sNO8S2sLNK+22ulkSSE7XimjORyR156Ed605bKGeOVCcO6hc9hj0rdVeW19zRVHfU4jSdCGnX9zqDSbzdwCFIVAG0EAN9e/atW1CL+zp4wEKhYxBr4VQMYH2i6wK1JrS6M1rGFG1RgD2A5P6Vl2ylf2dfGKspVhDr4IPb/SLqrc3LVs5sa7pHaeJtT0/RNML6lIDFjHTOa+dPHdjYaxrSXei3sA+0DGyRtv5cda7LTdYfxfpd3Y6m3lkH7xHT3rg/Eljpsdgtvo94Jb63JLAnnjqRXp4aHs5W6jjBQWp2nhyxmh8Oyadf3SmS4iaMkchAemPWqWnmx+F/hG6S+MV9qOol0CR8hl6DOegFYfhfxlp00dnZ380n2tRt8wL8pNMu/G3h/UtQ8jVtNmkijk4bIOD647VXJK7TWhU+SVmnqdToMUKaZbSQWcdtcSpumAHQ+grWK3Usm6OUA4/iNR6ZNBc28N3YqXtZD8oPUCruoFoE3RHG4YB9Kwk22dWi0RJptrKiO8wSR8/wAJrUu9CkkAubNd6sPnC9R+FYGn3byGMBuc4NdrHdTadPE8Y3wuBux24rOV0zKo3F6GJDbzIqo8bFfRhXM6hrF22tzadawrHFGxDBRt/WvRNR8W6PZ39pFMUw/OSelL4j0GznjfUtOjiW4mAO8nANKMrfEtzONWzXMtzg9Xmmm0+OIrwDjArndM8QSaLr0Vqtn54PMmeo/yK6fWobvTLe2PleYshIeRRkKQOM1ieETaeJBfateWjWU9orRszE4Zf72Mdea3hblba0Nm1Yfca79rvpZETETNwg4wK1oJVngwWYhhyCa8ze+ntL4rFGr25f5Gzwa9V0iGJtOglkwism4k9jRUSjsbTpOnFSezMuKzd5doViSwPPQc1Fr1qI9VVlgUEKMvnB9K09c1mw0bTvtuHuQF3BYiP51Bpt/D4w06K9hbyHC/NHJycZxmkm/i6GN3uUPA3g/T4tQhllTzszBg0o5THar/AMb72z0NtOYSzFrgna0GMBRjOefetSaNNP0qR42yQpVSD3Nc/FpVn4m0p9O1eX5oj5sEq9U9etEZ3nzzehnKDa54vY2PDUdkdCe+1S7ie38vK3C4w3/16z7rTI7qCS+0q6W4CYcqOGA+h7VzXinwx5Phu107RLqSa1WVppQTxKc9B6YqDSJ7u002RJIfssu0RhFbIAzxmr5PtRZcU2rsxr/xhdWupS28ZWMl/mPZQO1egaV4q0jULRIfL3ycBp0PQ/SuU1TwXbXuk3F5ApN3wZRnGfcD61n+A/DOqW93IZgyWR4ywIHXrWk1TlHTSxUU7+9sbOpeJtPOovYq7eZE5XcRxW0/kQWCmSRJxMvK4ByPQisfWdF0SDWHvGgk8x2BIzxnOOlaMaRTSBI0jKAYCyZGM/TrUvlsuUSv1JrGeKSYQxxGFgu4J5YUY9eOKm1bTYtRhWKS42ENkkjK/SnhIrbdJM5LhdvyrgD6VUFxHOdikgdiazvrdGkY3WpatdNsbHTpba0d3klwHfsefSo47ODTm+0O+0AjDOQADVywtHdN2zcO+KsX9nHcwm0v4d0Zx9+o53fVj5Yx0QukDTvEFvNDOhmjdGUg8ZHQ15X8TF1DR9V0+3017y3sI4/9HCOwBbccke/SvXdF+x6aZDGI0WJCm1R1ql4i1qxSwhkvbffEH/d9jn2q6U3GeiujnrRcro3/AINvcTeKtenvG3TzaRpTvnsd12D+oNetV5F8FtVtdY8VeI7iyUrGum6dGykYwwlvc/zFeu1xVb87ueVU+JnGfEME6t4Ix1/tp+3/AFD7yrTMAyiQhQeBz1NUPia7x6h4KaJWZ/7acAL15sLwVDo2k6lFc3j6zexXkM03mWkHlYNuvYE9zWMkrXbOig7RNt1wuB1yO1cD4j0vW9XuPDiSxsYXncaiiuvkrC2DhkJyx4G0jo3bmvQWJDMrDaMd6hK5fMeMt60qdR03dGyMJdUXRre7l1dIdN0q3ZYLd5HG6QAYBwPfgDqaik0a6u/F6ap9oX7HHDtjRAd3OMjrjB68j0rXn08zPONR+z3dqzK0ETRhhGQOpz3z0qTV1votHnOirbtfhMQxzkiPPbdjnHt/LrTU7P3d2HNbUmuY3EEvku0T4zuYEjPfj0xVLTNQjv3dI1lyn3meFkBHquRhhx1q1p0l0dOt/wC0Ej+2eWvnLCTs34GQPbOao2GlXdtfXk7Xcs9u4Jht2GfLzzj8+KhW5Xd6iT01Mjxpc6RaRR3M0thNqFu7fZbea4VGkfGCoB7846dcVm6ELrWk025WPTbKGzmc3SMTM8bLt2ouCAvG7O7JBHTjNEZj1DxFqMOu6Fpr6Fan9xeXkABadtpZVLjnJycj261Lp/hnUtN8WzXGmvZWmgyuZZ7cRkmbIIOPQ559Oa6bqMeVvXf/AIBad1ZsSZtP0Ow+26DBc60mp36rcTWMiuy7iecgfdBwMe/JrorzT5YdQS8gG4j5RCxPlpjqwUdW981Z0WytLK1WDSYEtrdHLBI12KSTkjHpzVfQ7jU5nuYtXURyHcUSHOFUHAJbGct1x2rFzb1XTvuTdpj91zeSX9nLC0H7sLFOcOr5HJ29sE4wetO0gTR2qW8xcmD92ZAgQSAfxgA8A0zxBq/9g6VqOqXKSS21tGH8uNNzHBOT+o/KrVtdLcWkE6b1jlQSAMPUAgGod+W9tAQ59Ot5BNII082RgzMyBuQMA8+lZdrYixkuGmnaRptqqrkbRtHAUdeckmo47C/f7I8WoTWwiuDO8ZGfMUggRsT26dPSp7uymk1q3mmObWOMsBn+PJ4/DA596Nrq+hS0erGWcV/LdagNQ+wT6c3lm0XYfMGAd+8nO7npj1/LTWPMeEA+XAAXgZ9BUNgl0PtX2tk8szD7PsG0iPy0yG46hg+PbFWFONoYqSp7en/6qznuJdbHLarpmp3+rXNtcyRJpMgR4mgjAmikXBw2fvZyTz0xUmr6RpmnWdrqM1vJeyWEwmiErFvnII3tx269OCB6VBZLN4eN9f6vqD6g887PEI4yqxoSAq7fYd8VLZalfeItBaa3s1srkXBhljn+ZSFPJBwAwI9u5ro97Sz0XUvW3kadlqFlLaWtykkax3RXy2B4ckZ4/D+tWL29t7QRi6mjiMjbU3uF3H0GTyfauJnIbx3bQGVtQs440VbWEjFlKG4kcA8ZBI6diOwrrtW0TT9aEA1K3iuUt5BPCJATsb1/+tWU4Rg03sxszdN1u+ibVB4jtorK3t5lFu0QJ8xCM89SSPb16Vt6dcG5hMhgnt8MRtlXa2PUjtXP6rptlZa7Y6rdanLavK62yw78JNIR8i8dOnTpXS/NtPscAAdcUqqjo4rcSK2pafDqts9vchjDkMGHGSKsERWVmqZ2pFGBjGflA/wqrHZmC/luI3cGYBZMtkYGcYB4Hv607VbNtRtmhhnmh3Y/fRNhuCOM+9Q+19A/Ij0fWrHVbZptPlEyD73qD6EdatjczsDldw4xnoaraLpFhpVj5NlCI42O5iTlnb1YnvV+PaGYoQzD+EnGKJcvM+TYDnNOkvB40v0gltZdHFouYkZWeO43tnIByPk6k/QdK35EDYO3ocj61zraDa22q3moaZGLPU5kKmZHfazdiy5wT74rdsRefYoTqBiN0qhXaMkBm9Rxxn0q52dmv+CC0dyG/Mn2WZIHMdw8Mkcb4zscqQGPtnFc8oYfs9+NA5ywi8QZIGMn7Rd9q6PzGaYRGEFWBDHrnnqM+lc8f+TfvG/H8HiH/wBKburp3Whz4vZHlfhXxHdS3k1jNGjLKrKpRcEMBnFctpl1pnh/Vmv5453vXLqIpR8ik+vqOa9htvCVjp+ojUEXDuPMBU8DPXArhvGP/COeJSs95qH2WaB/L3bMFgf59Ote5CpGTfKtDeorq63OCsbmzluby+awt4b2DEkUauViPPoT1Hpnmup8D6Rf6ndXc2uWKGzuF3eY8So27PG0gZ9a3dd8F2PiDR7GLRrqG28ofNK6bhKMYGSvP/666zQdOXQ9AtLFZ/tMkMW2RwpGfpmipXVvd3Jp0mpWexS0WSLTx9jtFKwRjjv+dX9U1O1MKQvNEGznIauZ8ZS3Z0aa50mMxmMjzGJweuMY/KuUbTLmS1stSuJBmYHIJ4465qI0lP3mzq5tdEeo6ba7vmXO3OQwr1nSrGC70OFZIgHxgn1NcV8ILi21XTJEniTzo2wCBwR7V6BfyLptqx3bITkZAztriqt83KcWJqOUuVbnz9488HR3vjiEQa1bwEkAxyPgr9O1dJ8YtL1ew8E2lrpJmkjgC79mSSBXGeIfB2vajr1tNZCS5i84yiZ1IPXpXvd9L/Z3g9EuZEa4it1Uk9zjFdFSpy8mty5+41ZninwOk1jUdTmt9ZtJ/wCzvJIbzFIDHt1711fxm0CK08Fix8PXEFjJPMHkVpCDKo6jP1xUvh7xUtrfo05/0b7pIHLH2rD+NFqvjDTILvRrzy1tCRJG/wAnNTduqnsiqlOo5e9exkeAPDFta+ErqS+e2vrlG3mNZN3lnoM4qjp+qXepXeqWd4qpYRZRMZXkdqh+HAGkW9/dte2xvWiYGIOG3N9K5648TXPiGWXS4YI43l+V5guCBmuhRbm7nSm4Kz+R09hBHqGg38M5dbW2JaN4z6/w1iaLdpAtzpmimaSa4hbM8koOwntjHHSo5bbVvB72tqpllaUZZFG5HB65rp9O8NzXFhNqOkWCwyux3EnqfanJqCve6exrFKa10M/4c+Hde83UrHVo7iK2kTgs+fnz1B+ldT/ZkejEBHL7eMMfzqfwgLuC0mmvhNE8IKlH/iJq35KXEnnysuOwPasJVHKTZl7P2TcL3RHazwLB5bOkeOSrDgDvVPUrW2vLSafT5I7ho+VWM96g1Ky/tSFzbghhmJwRzimeEtLuNHjnnvkjjTkBUJ+YfjRole+oWsi7Hp0d/okC6jCUc/M6A4ya0I1WOFIYeIRwFNMgnN3C5iU5C5APWsmS6ELsbo7SPu45pask0NYscstzDEglUYKkYDj/ABrnb+3ke6aOGP7Pcph8da0dGv797me2usPERvjbOSMGrkj6dp91LcXDqs7juc1Sbi7AvMsTWgvI8R4banzNnvVCLR1CFi6o+cDLAZNXo76zVokhZT5wyWB/Ssvx35sFxHLAR5fVVBxkfSoV72Nab1tc3bbSNRhQkqyIRkkVtRxNLZmO4IusJhR0IrlPBnj2T7PHah0lCnBSUcgeldHrFzb3U0MsG+DY+8CNiMn39qiUZJ2kZTc+azM28soY7aaSJHwBzxypqh/YS694fMFzumJG5W24ZeoHHtXRJEZre8WCZ/PkG4b+R74rl7LXoBf/AGeG6Zp19SQDVwb+yS25aGn+z3Y3GneKfGFvdqqyra2HCntvuxz+Ve4V5P8ACS38nx54ulEgf7RY6dNx2zJeDH6frXrFctV802zyq3xs4T4o20d3e+CoZl3IdaZsZxytjdkfqK1bDaIl2gpjge4HfH4Vk/FMXLXngoWLqlwdbOGYZAH2G7zx9M1JrWq3djc20dtZC7BjkeYx4BXaAVAzxlm4AyKwmnL3UbUb8thNR8Q2kGtw6QheXUZxlIQOSACSST2rN8Q2Wux3UGpadcuba0R5p7COMNJeYHyoCfujg+vWtu0gU3jzPbRi4C7PMMQ8zH+91FSS6pZWt3BYG5g+2yIWjt3kG9wO4BOT+tLmS+Feps3ZWQ6wuJ7zS7Ke4tntrqaNZJIJR80RIztb3FW8E87txPJx3pqzwSB0ZwWA+dQckD3Has3Wo7kacYNIZYpcZjZgT9c8+tZpXdtiY32NLGDwTyRjipdjYyzZwM4GKoaG0osI0vrmF71F/f8AlHhT6d//ANdZHjeDWL7TBDos6wRyK6zB1JkkUjGEPRDjPPNCjeXK3YN3ZEGt2OgeJ5rS0u4xeMHfy4jK8f3epIBBxUuleKrHUbZpbNw1hDctZySnKqNvUrn7wyeorJtobXwZHp4KWVuJnMLS3M+xo41UkIhY5IGSSOec+tXNOeKaXTbbRdCmuNAmTAuo2jht4lOfmCn5259uc10OKt1a6a/eU7Lc3NCitraGf7PL56vI0n7s++cD161HpWu2OpXk8FrI0U8QDOsi4baDj3GM8VzXiOKfw9aXkH/CR6Zo8d3OkVpN9nZ50BOfXBY4IHAFI1jpHi2QazpOryMYZFguJIUZUlZCD0/vcjn0xilyRd5Se/WzFo3dnU+JNWTRrFWktby6jlkEJFtb+dsDZ5YDnb2yAetQa/oFrr+kS6bqkTNZTlWOxjGw2kEY44PA4PvWqjyPKwdMIBjI+XHrXO69rF5p1xcXD3FnBo9rEJpXaKSeYgHnCrj8+QM81jG9/d3/AK/EEnsWtG07Urae8Oq6qNQt3ctBGYFjMQzwCwOWwOOfStG/ZEVJJJIEjyFBkJHLHGPqar3NtcXGpWF3BfOtpHuL2/l4E5YYBJ6jGc4x2rnvFXiqNL2/0PS5CNUjgLG5kT9xbsRld7/wk4IHHUimoupLT5+Q1J3RoW99qi+Iriyl0pI9KSIeXeGcFnfIG3YMnAHc1bu7uVGO6UJGvQ4+6MfzrmLhryc6fol1ql9BczfvDqFsu1SVXO0j+7+P861ZL2+XWdOsV077fbTozT3yxt5ceM9RyMnHUn8KuUNb/wBfezWyW5T0rUL+eKGPUngvG8xt86rs2R44yO54P4Ypya5YS3z2yCe20+2hW5TUo1HkSbjjYv8AePJ6DtVe9fStG1W9mlvbKztvspN5ZCFOVLbVlyozn5sHqDnmqWl6Ht1q5sm0ue5skiSdL6acHzWxkRoigKFA/lg1paMlzPT8F+IO3obN5Hb6fq51KCwjCMmLq6APmEAfKAB79T7d63Y3E0amE/K2DkH24rJ0a7lv4Lq3vrnTU1CEhWgsnMphBH3Xbpu4PHtVfSbfUNP16589Znsmjx5znCs+R/DWMo8271RSaa0N2+sLe6WI3UCTNFIsse4A7XXOCPcZq3tPlsIxz3PvTHYKwLsFGM4Jxxnkj6ZqQ3MZt0e3ZXVuhByCPWue7ZDZAjEqq4y3+c1lnw5ZzeJrbX3WdL63iMEbLIwTb83UZwfvH/OMaEkMxubeSO5CxRMTImzJkOOBnPHXJ4NNnxChmuJ3wq73eRsBRjqew4rSLafuvcHZ6Db++j06Dz7pwkO8KTjPWoYWMl/DcWZiaCSEliWwckgr9cjd+VVpoYNZtVdnhuLbzVlhcDcFAHUH1znmtKOMobdHw6sScnuMetVolpuU1YhF3drrLQS2Un2NUyLkyJgnjjbnd3POMcdasHM8Mg24IJHpSJcJJA5JBj3HPHYVPGfL2gYIx1NQ9BWaOfv7cXWs2DW00kGo2TK5LLlZIjneg57jv2OOtUj/AMm/eNuo/d+Iev8A183ddZMhDCYnGBgf3fxx9K4+Cdbn9nbxlPGGCSw+IHUMpU4NxdnkHkH2NbU5XOXE7IfFLumVnI2+g6AV534j8Bade/2jOtzLbvv3RJjI6+npXoRiktpSsyBTgEY6YNWXsYXt/wB8knnMPkCAnJr0YVHTd0ds1F7nk+nWOoaboFtHokkkyo5MhZeeT2HpXZ6XdSQ6PDLq0TrcN1A44z3FbBhsNOle4ZmjHl+WY3GMn6VkTW2oa5bM9ig8ktt57Vcpqe5UfwLSS2F4iWwtyYmYl2U5Jz7fgKzdV8OSXrJa2EBEMRxH8nGO+RXf+BfCC2dsJLyUPIRwo7VuX2nGzlDxnMR9e1Y+15X7pk68VLliYXgXSk0C1SJxm4c/OemK6LxdZJqujmBpJETcC3lnBIFUJldWEgPI5Bz1p2p+JEs7ILLCd5xn0rJtuXN1OeUZSkpLc8/8e6hq3hzwkraObhgHILOMn68V5/qOpeI/FvhSGSW4mgmibHGVDgetfQN1qOn63ojLEm4H+ErwK5OVbWFGthGioe3Arpp1VFW5dTWHvayR5sdLv5dAtIzKJL1E/gznPY10XhTwzf3WmXdrrEjFJkwPlxg+taIsjb3wnRwVU5A7iuqXW45LYwxALOVwCRwDROpK1kdVSbUUonz/AGfgfVNG8USJcI0ojYmIxgkuO1M16DU/DGv3V/Jpca2oAIxH1z6muw0/wN4uuPFMmt6vqaiOJ2lQRuSWAyQAOMDpXIWeu3M3jBg1z/okRMTwTDiU88Y+tdUZOXW+hFOd4pLRnrHh3xToF/4VttS8QWsEOSEKydPqK5/4reI559JtJPAk+6xTG8W45XHtXOfFC9+1xaZZJYG2spApURJgK3t6812PgDwtY6BpnnaheMU5kYbeGHtWPJGCVT8DOUXzO7OF026137Vb6hemc+fH+8JBwMjuK04LrUrmWJbdmClssx6YrpdY8QWeoXOy3sykLMVTcMZFcPr2uGz1D7FBHvbOJUTO6NfUVcE5PY7JVeeKctLHpNnLCke+JwlwfvYxzUdy/nOvmMXDDoeteX6hbX+nzK0YkdH5DqDx/wDXrttBTUJLOJ7pTvYD5z3FROnyrmuZpam/ZQi1G5SQTxyahvdNF2SxQEqMkjgisjxxqLaDZ28lxA5jkPVOMVzmrXeoSWDXFlczx291HgOWxtOOmaIU5SsyeZbo9B0/Tlg/1cMpcjGSO1c/4+0wWWnSXJhc3JVvlYZ+lbvwkXUH8MS2dxNcte+cdqy5JVccAZ7ZzWrrtrHfade2d/KYdQCMqBuxx1qLuFS19jP2t3qjwvwOl7LfvM/meSvXJOM16lHoNj4r8qC4kkhvoB+4k3cH2rmfCHge9spp1uL9Bu4MUZLGuxkt/sFlbPbM63MTA5b5Tj1NbV5pzvFlx1jY4TxCINA1xohZtLdW0mx2Zti9MnHrXd2+oJcaLaaiISjSqFCd8VU1rUV1KYzX8EUjrgDaoYE+pNQ+INStY7iLThc7ZxEoU7MIHwDtyOn5VDfOkraiV005HSWd8qR+bAo+cbWQ9VyOa8r1u0k0DxLDLGhaFmLq3qp7fhUXhzWL2y117a8dw0jFGDk4DV03h/RmsI7yPXWF+k7+ZGHyfK69M+v9KtR9i3ce+x33wgne48YeJJJE2/8AEs07HuPNvea9Xrxz4HX6ah4t8VSRjCx2Onxj8JLz/GvY682orSaPKr/xGcb8QQf7Y8EYGSNZkOP+4feVF4f1g6uuoEWV3ayWty9sPtcW3cV/iUZ5U54NR/FFXa98EiOcQH+2yWkzjCixuyw/EZH41Zae/Z7yOGJlMSHyGd8iVtpxn0GaxkkzSivdNJWBPBUH27VQv9H06a+i1KW0ilvoVKxTfxKCRkD8qwtE1O/0/wAKz3XiyLOpwQvcXKWu1yVUnBABwSFxwDT9E1vVdVvbSe30+3fRp0Eq3ImwyoRlcqTnJ4qfZyjdp6Lz0NkjasLU2kkmGmd2bfJNL8xfPOM9gM4Aq6ZraN28y4i3KCxXeCVHqaybrSLGOLVp7gMIr0FrqSSQn5QMYH90Aelcxovhrwzd6XLqGg39xBDJJh7mOUqSBwUO5eR9euBTUIz95t/cCV1qzsdJisYklazWIiVt7snO8+pqW+nZBiAF8ccHHXvWXJC+nWNufDNrBdO00YkzJgeWT8zA+ozn86t6nqen6LPunZ/NunEYCoXZmPToKlRu9NfzDroc/IwuvEFxqeu2+mXujWxSPTJmiEs3mso3qvHcj8MZ96t+Iftz6b/oBkgkWWNVihyNsWRuUKCM4Gat+JtBtNT0qPTLie6iAcSLIny8j1IGOhpP7Ahle0a4iylgV+zPIWJY4x0HbpWkZw08v6/EcXFK5znhTT5p9V1O/n0u/Vri6kiU3gVkQIwIkCsP4icAjP3fxq19t1RdWez07V9KkklXdFYrMgdFz88zYHPOeB/Sp7+18SxeH9NtLvUQ+rSSkXMllboFePJ+XJ+4uMAnGTit/SdG0/R7eGPT7G3tlRPLXy4wNq5zgfiT3qpzW7s/68wUm9S65dYQGwzfxAHp61BtjZTviAwCTu4yp7Gm2101zczRCJ18rIJcYBPXj2qaa0FzYm3lKDcjIRnPBrl+F66BdR0ZzvibXb7Rba6vYtNa/s0C7IrdyZmYkAnGDkDk8Vlapp8a2mp3Wu2suq6fqMcaNbQ24WXbncu48Ebc/UHNa0eg2emJbacVvZbLKmMbGcBlbcMuo4wexNdJuCFlKlsY+XqcVtzqFuVDuuhwH9j6zd2di3hvUYoNLG2Pyb5Ns0MSgDb86tuJx1JHataLTdcbUbWL7aFs4Izv2S73uHIGC4CoqhTngA54ORXQ3cLyqUgmSCTPJ27sD8xzUELCI/ZYTPIu3e7ycE4OMZxgd+BSdWUlsvuBNszLbQrJJbaTVfL1HUY1ZftBjAOGOSvA5HtzitqNpQ5YOiIT/wAs15/P8qY1uskJQ5WNgfkU4J9hSRoINsauI1A+6cAj8B/WspSctx2T3My0srLSoZxpNpFD1dlVNm9vcj+ZrQtd7KrTIFyA2M5IPpnvUOs289xp7xW8vlTFcCU9vpwQRxj8fwqp4Z1Fr2yWGaV57m2HkzyONp3Dv0/wqrOUeb/hyr3M7V9Mur7WLd7aW8hcRE/aIZlC4xypTcDyQvIHauhtohDZwxrGse0ABAQQAKuxBHTgllzjcR/Kq8yGGUl88Y7dBUupzJLsCfQo6pZ3N3pl5a2V21tdSx7VnC58psY3e9Ouv9Q8ZYTbkwUYD5uMHI6f0q/Jv8sAHg+vFZWpahDYXlnay5867by4SI2bJxkjIHHTvinC7skVHczdCtbjSrNY44RJvYExRgL5e4jOPUDv9K1EN5NeyeZHGLeIAwOrknkfMCCOMVyc9hcy+LprLVdVv4/tcTPYRWE0sYaMA7vNwMBl4wQwByBgEZNy4tLvw9bzXd1ql9e6RCuDZpAZpzng7pGZnbk59e1buN3vqw5ru5raxHctYy2mk6gtlfkBvNSISsi55wp4PbnNaccklhYNLdBrjaP+WScntwM+vNcUkEmmR6nYeE7vPiIBJVgv7qWUJFuU52sSACGOMAda3vCh16GC8Him5iuHWcvA0ACgJgYGO3OeCamcLR3/AM3/AF6kvUtafrU2rGSM2N1aQLx/pEfluScgYGSCp9sf4Y8mf+FAeOM9dniHP/gTd1rWGuW2ox3VzZCVRZzPDciaIqQ6dQAM5/Cuf02+j1P9mzxZfwhhFdW2vToGGCA090wyPxpxi4vaxzYhKysVPDHi+HxXZXEMMJE8IADj0rZvNWS00oXFzIIp7aQbJT6dwa8h8Ranc+BdZs7fQLZI7CZA5cLlpMnBGfWu1vbnT/FanS2l2XDbdyfdG4V6k6STUl8J1Jp6EHjy7uNYtl1CwccJkpGc5966f4O6pLrGmyWlzGBNAOvQEV5bq0Or+GfEsO1CtqmIwV5VkNehvfWnh+7truz328suFbb93d7inUglBRWt9hy96PKj0iC9EEzRcxspwMjg+1arTR3du0bgZIzx0qnoN/a6xpwDBGkx+8Q9c+tSf2RFwIGeJcdVY9a4H5nDK1/e0aMQZxsYnANQ6hp8d/bNFL3H3vSrPlfZbowXC7jn7w/nUjbUkZckgVVzov2KGk2H9n6aYA+V55rzvxVZve6pvhkIKdiSBxXo2q3QttPmlZsBVPXpXjuqXGs3t811o1wGhAJ+XBw3uDXRQTbbua076yZs3l7PZaUzzbmdU4LDrgVR8GaxLc37RzSbyQWyexHpVbxlrmzQrK11mQQ3M0YfIQ5Y9zgdOa53wTDPFemZGEkDIfLdTwcmuiNP3G2bqSeh7y2pQW6DcQzBc8GvH/F+s+FdM8QyXEukK92xMm9CQC/qRWxY3bS6pHnlSpBOenHem+K/hmmoSQX11dLDuOdvcis6SjCXvMxlHl23OT8J+LNU1fXUj1OBLi2bJUAbfIGOq/4Gus8Tal9l01IOXXjtjjOa1HWCyght7O2VmRdpkIwWqrcad9tiPnLkn14qpTjKSaVka04tL3jjNP1Fp5owsbBEcyMTySfSrk+g2V3rR1WdnWWQqRHuABIwPr2rrLLR7G0iVW2eY3OPSnPpTDf8m5CRtPHFN1Vf3dB+71JLe0ilsyGJwSTyORUerapBpunh1YSmJcYHH0qW6sro6enllk3HYCxwD7V59qsd9Y3sy3JKmJh8rchs1FOCm9wvdnWaDr0Hi/SZ4dTspZkhYAKR1B9D7VY1G603TrEW13bK2mqAAnXJrX8P6aLHwnb6zYqpeZWM0ajJ+gryTUvF/wBpvJbO5C7FchkZMDIPT1qornk1HZEwjGSep7F4a1meW7ubvTV3Koyu4BQAcYU/lXP/ABe1DXbiOzvNOjtzcIP3ixjcxHt9KwZNSsdR0s6Yly9lKGEn7tzjOMYbHboas+FNMfRdNutV1G7F1b275hPm7tyHr+GRQoKL5vwIqUmpbFOBNfuW0e884QF8POpwpAz+tWPH1trU2oJ9lu0S0uwCMdUI9akuL238VmLVbJmhEAOYjxnHpWfPO92T5oYyNxnrVp6p2LUG1qzW+HUN3ai6i8QiF7ZPuyZzg+tSXvhey13UJLnTLxftDYDKeje4Paiy0S+l8L3kMZBlkAwrZ/DJqto/grVLuwubdr2O0kljwpSX5kP4UnJXcuaxDjYn1jwtb3eqWa2lzE9xCgW42nJLD0rqZY4LW0WORkJcEDcehrm/APgMeFb99W1zUGe4jDGOKNiS49eK0NSuZ9Ykke7hWG3Z8ooXLn6D+tZzd2kndIVNuS7G38D4Y7fxj4uSLbj7Hp5OPXzLyvY68i+DKJH4y8UrGCFFhp3Xqf3l5XrtcNT4mefiP4jOF+J+z7d4KEgUq2tMuGGRk2F2B+uKzmvNU1e8sZdBuIItNzIlyZFG9iMABVPToTWn8S45JNT8CiJo1I13cTIoYbRZXZYc9yAQD2PNc5r2oaNqS2+o2V21/bi7+xgWikrBI38T4wQMjr71CV5bGmHatYWfQYdB8N6ZZya5Jo7m/XfPa25QXDsCojKksEDcf7ORkAVrfYvL8WT6kNfufsqqIZNPbAhRtoxjjOe/HOe9agkxExkkzHEFYSStsUkY6Z4981zNr4n0i7e0/tnSLjTrm6uytvDODl9uNsp7AHOBnuO9TFzmm3r939f5GiWupo3+rXjeI7SNoZhoQtJbi5l+zbo2wMbGY8DucdeR74rQ6lpOs6Xp4sHs49Bv4mIfKxMrg/d2g9RjkY9c1v8Al21vLKY5Sk04AId+emF/yB3rE1LQnt/DbWcem22pTmTclu8vkIMnJIKjOc8nHX86IuOnT+tw0WpVWy0u0uRc2OrXBktLdt3kMHQ5BGdoByR6D0FdNYXUz29nd/aVa2aJvN86Axyu3G0gHhe/B/Cqeix6ZZf6Ja2cCSwxIs/lEsqNjlQTy34/jVnU47y6gCWt0LRieXaMSMR6AHgUpvmdn+I5LmOCs7rS7S4Ov/8ACWanq+2d4flmUQEEEiPYAfu7hzkdq7nS7aSOzJjlunW4xKRJKSUyM4BPQVLpeg2FlaxRRWNukSNuCrEFwxGC2OmfpVvVLa6l0u5g0u5W3umQhJ9u8I3Yle/elUqKTsvx/wCAJyilZEsUaJ8xbnqxPQfjUzyRHDKyMDyCO9ZEtsZbW3t9RnkuGjUCRlO3ccfeYDgfSrdraWsFqfssSpGoxgnNYtLe4rdWTQTrI7LH0B5ytY2sahqguxb6RZAqGxJO4AUDucZ5HWpby2mm064FvK0Mg5DAn9cUzS1vSfNmjKxBdibhgnpljnoOKuKS9405IrU04dxG6Rzk9AScUsoSZcl9pUDLKc7DRCI5JPmmRiBjAP8AXualVAhLMq7yMctgmsutyW9SsAxTbiKcAj7w6fhQyT/eJCoOmDjP4Cns6K/+rUEdc9/oaV5XYR4AK9/p6+1F7juytdXFylu/kWqyTYyoB+8ff0rAtLjXV1Rlv0sLGyYYitjtaR29cg/XsTXTn9/bTKsbDI5AHJ9qy9P0CCw1SWeWX7TPklJXRQ0AI5AP41pBxUXdDUkrl0ShZMQIkoA5+XBPt71NBJHMeCq542kfpig+V53lMJC0eX37uTj/ABqNo2kdpIjuAOCQOfofX61lbQnRiqzedKDGFjUHa+8BeOgPpUJhhSRmW6yHbdgseD7GrBieVSyom/OcEYBpz24l4ljTA68gii5SaTIWVywD4YfwsD96qd27WtzPcTTxx2vljAcABW3dST9QK0YYUjGFChc52jtWT4siin0a7jmspby2A3SwwN+9cAggKO5yOnX0qo6ysHMU4dVfztSlvoGstPs22iechQ6gfM+B0UHoT1pJtRkXX0tzbF7OeDdb3SgtGrjBwzDoCCcHpkVzQ1XVr7V4NF1vRI59N1KQkNBG5ijtefllYnh8AnbgYyBXReHpLY6clnYWjW62kQEUFwS5jHO0Hv07eldLpqKu1/l6lp3L+naNZ2+r3usIjfb7lEjlYHIIXgYHatIIrOPNIBPAzTEkDksOADjB4rFttX0jVNdeO1lSa6syUc8gr64z/Ssvem2+wWZpTWf9mRTSRunkSMZXZ8BVJ6tntXKW8sU/7OvjGW2kSWCSHX2jkjOVZTcXZBHsRXS6vfFS8WoeR/Z2whmdtqquMHcTxjrXLafFawfs2+LYdPCiyjtteSAK24eWJ7oLg9xjFaU72uzmxCairnAar8StLtdFlt9MtHuLuAqEM0Y24HGR1P8AKk8G3Vjfww63Mgt7qSQpjfwWHXH51LYaBp6+G7/XdO0l5LyaA/upcsiZPzYWuAuor3WrFba0hMc9grXEMcCbQy8buB3GM/ga9xU4yTUNDdSlBtvU+jrfUrC5s1tLgqZsF1LDn3xXC3WraV4oS8sdLnb7XHkYkXBOOuK4yw1y6k0+zuLoMsojC9wc5PP41pazeaR4Y1HTdY060b7TeZMrZJUA8Ngf561lGjyvz6GjtHVbM9I8J3E9tfRW28+aIwCw46AV31hq72ibLlWdc/eHWuG0S4gW9iuCAQ6jYw9DXWTr6/pXHU1epFWKk7NGP4z1947qKa2ibyx8pyOTVzR7w3tqJGXDUl3ZxXMeyZSPTim6dbJaKUiLYJyc0tLWHaPJZFHxorT6DeRx5yE3fl1rxvQ702WoyoiuYgpYoD949QK+gWto7i2mWVQdwI+oxXhOq2cejvqFzJE7JASVVThiewzXRh5KziXSd00c/wCH9Rl8VeIXsvEEZmSUv5TAYMBx0X2rvNI06z0bTksoRIRG7MWkILEn6VF4AvV1CE31xpot5C2FLLyR6g4q5rs8kt+kdnBuiZ8ySY6cVtUm5S5UrIqEbM0vDulQtcC5lDCJTu2Z64qj4m1+4vL1lTHLY+g9K29LUJps0rtgBCBnjFYkGjrcT5LFRncWrBNXvIpWu2TaJMHcrc/M2e3at+1jedZAE8uAg5fHGKwNVaPSYFNmhkcnnI/WtnRNfEmkyRuu8yHbsI6etKSduZCld7GXrGtQaTFbNpUXnSuQrFh1J7VzHi3xrqME7RWFuqSYAYuuWJ7gelbOm2N/LruofIklohDxKw+4ay/GmtJpN1a3Uek2890+RNJKTxjtx/OtqUY8yVrinoi4k+t3HhdtLvX8sNGlxFMeCoJ6Z/Gt2LSrfUFtry9CS21siCbOc7sdfpxUan+19FsLmJDBBNGrMjPnb6j6Vz1lp2vJ4iWeXUHfRi5DCMZCr6cf1qXrfoEVeOh2VzcW1wwjsCEtoF2oi8Yrmtb8K6FdA6lqCRQTZGZSdoJ/2h3rI8eLdWZhm0+STylY5xkcdiaz9dgv/E/hT7PayF7yJ1cRMwHmLjnBPGelOEGrSTsElyrQjvfhxc3t3Nd6ZeItvPkFVGcZ9/Q06Twb4n06Wzs9MJltSm2TLgR4zyGBrV8D3lxp9jbWaXy+coAlhLZIYdq7u+1o29qqzIN7cEdx9KuVWcHbchpvbqcjo/hM2N86RziPTIlZ228nb9Kh1PxTE13FDY2UMNtFgAkfO4z1Nbst21vZrDbqHhc4bP8Ad9Kyh4Eiv9etrmG+RYI/nMbMB7jPqKiMk3eoaN21Zhv4wvzrFxZTxnyQ+AB3x0rolW9gsTdAOAFL7B147Vc8R6QsGptPp9ukgjAUyoMgHHNX/DukT3Xz3btHARwx6sfSonOOjSNoytC9zi7HxmftiSsGa4Y4VSOlWNdN7qc9rfaOVLqcXKbjlh7Vv+ONIsI5V/spbVJihxKAOG98VxdlNq3h3SbvUNQiWWQMPLWEht2TjnHStI2fvQJi4yjd7npXwS8z/hNvGIlBDfZNP6+he7P9a9irx34ITtc+K/E0rrtd9O00lT1GXuzivYq8+p8TPIxOtWR5P+0QlvJo3hSO+uY7Wzk11I55pLlLYLGbW5D/ALxvlHyk9evTvWH4T+I3g61iXSbPWdPtYVtmZJ7m8iCq2dqgsz5ZscnI+ma9X8WeI08ORaeTp99qM9/c/ZILez8oOX8qSUkmR0UALE3f0rI/4Te+/wChI8S/9/bD/wCSql+9HlexEKvKrHlknizw9pAur9/EOiarqsiET2tvrMa2pj9g2Nz4GcDnPT1rs9I8d+AL3TrK6HiHQ7fbGGjjub6FZYuOQQWyDxXQf8Jvff8AQk+JP+/un/8AyVR/wm99/wBCR4l/7+6f/wDJVKac9xuu2cnL8UvA0F7ClrrdpfPPj5hewxJEoOPmLsuPXHJNSTeIfh5daxJqUvinRHuWXZ82qwqigegDV1B8bX3/AEJHiT/v7Yf/ACVR/wAJtff9CR4k/wC/un//ACVSUHH4boFXa1Mi18ceB4Idkfijw3HD/cGpQ5/9Cp0PxH8Hx3MqN4l8OrAq5WRdTgJJ9AN2fxz+Fav/AAm99/0JHiX/AL+2H/yVR/wm99/0JHiX/v7Yf/JVS6V9wda5yl74602bUJHtfHPhC2tsYiVryKV/qSXAH0FbA8e+DYrSFZ/GXh6SVBl2j1CEBj3OA1af/Cb33/QkeJP+/un/APyVR/wm99/0JHiT/v7Yf/JVN079PwD2xmL8QfBbwDy/FWgBW+bD6nCpJ9/mz+dMk+IHg4gp/wAJb4fOTkhdRhC/nurW/wCE3vv+hJ8Sf9/dP/8Akqj/AITe+/6EnxJ/390//wCSqXsRqvYzoPH3gtPkPi3w6TnOf7Thxn/vqlHxH8GPJKB4p8PlDkHdqcI3fm1aH/Cb33/QkeJP+/un/wDyVR/wm9928EeJf+/th/8AJVL2InWu7mWvxA8GKWS38UeGkKqdrtqUOAf++qj/AOE58FnajeMdBExGRKupQkL9ctWrL47uoVzL4M8RIvq0+ngf+lVQD4jkjI8K62R04u9O/wDkqmqL6DVZ9CiPG/hJVzN428NyEdD/AGlEePpvpz+P/BZjG3xdoaZIOV1GAk/+PcfjV0/EV1ba3hPXAfQ3Wnf/ACVSN8Rygy/hXW1HqbvTh/7dUewfmHtpFZPiF4RCsp8W+HEJIwf7ThY/id1Nv/Hvg2fbt8Y+HQn/AGEIs57fxelSn4owKcHw5qoJ7fbtM/8AkunL8TonYqnhrV2YckC900kf+TdL6u9xqq07pCL8QPBUQ3L4s8PtIFCknUoOf/HqZP8AEDwXKgc+LtBEijOBqcOPp97mtEeOL0qGHgnxIQeh83T+f/Jqj/hOL7/oSfEn/f2w/wDkql7An2utzLh+IHg82m9PFnhyOU9M6nF+o3etK/xF8HyqyHxV4f4OM/2nCM/+PVp/8Jxe/wDQk+Jf+/th/wDJVH/CcXuM/wDCE+JP+/th/wDJVHsB+31uZz/EPwWqqB4r8Pt651GH/wCKqu/j7wWzH/irNBORz/xMYRn/AMera/4Te+/6EnxJ/wB/bD/5KoPje+/6EjxL/wB/bD/5Ko9gNYixxn/CU+ENKsbk6P4n8NzSgPNFFLqkI3SY4Xdu+VScA+1YPhnxf4ZtvEl1czap4at7maFDqF6mqIEnuAOkKlz8gyeTjJr1A+OL4f8AMkeJef8AprYf/JVH/CcX3/Qk+Jf+/th/8lVslLW/UPrLvc5qbx54a+1xbPFvhgWgBLg6hCWY9sfNgVUtfHXw+GpFIfEGiJO2S0v2lFXnqd5OP1rsf+E4vv8AoSfEv/f2w/8Akqj/AITe+/6EnxJ/39sP/kqp9mV9afY43xF4q8F6i6Wt7r/he9sAQfLfULdlJ9T81S2ctvP+zl4vlsXiktJINfaF4mDIyG4uipUjgjGMEV1n/CcXv/Qk+JP+/th/8lVetvGVnL4Gv/FEtnfW9pYx3ck9tIsZnU2zyJIuFcoTmJsYbB45ppNKzM6lb2iSfQ+aNF8Spo3w6uIG8T6Wb9pNyRJqETuqZGRw3Wtf4W+PtCWSYa3qOj20iksLh5o0aRT1U5Ne+/8ACUav/wBCJ4l/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdTxLaaa3LWIaVrHztr3ibwhqF2IrPVLGFgTyZ02YByCGzituz1PwjH4bCX2v+HbuQZYQSX0JKntj5uK9u/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSqTxMrJIp4ptWsfOfgj4iWV7Hd2utarpkBgAa3keZIwy5xt64OOMe1en6R8Q/C7wD7T4m0VWH9+/iH/s1d0fFeqhwh8DeJAxGQPP07/wCSqf8A8JRq/wD0IniT/v8A6d/8lVFStzu9rC+sytZo5yX4ieCprfY3inQg+OCb+Lr/AN9VVTx34O6/8JVoGf8AsIw//FV1v/CUav8A9CJ4k/7/AOnf/JVJ/wAJRq//AEIniT/v/p3/AMlVnzEqs10OMuviB4VXPl+KdBIPYahCf/Zq4XxXrnhbV4rqBvEeig3CkFhexEA9QeGr27/hKNX/AOhE8Sf9/wDTv/kqk/4SjV/+hE8Sf9/9O/8AkqrjVcXdFxxTj0PDtG1zw54S8KhX8SaFqUyr8kcF9GzKT7Zz3qx/wmXh68s7J117SIGkyZEN7ECvsRur2r/hKNX/AOhE8Sf9/wDTv/kqk/4SnV/+hE8Sf9/9O/8AkqqddvVrUaxcl0PKJfGvhaS1NrH4i0dVBHW9iAx/31UU3iXw09tOLXxVoiv0XfqEQz+bV65/wlGr/wDQieJP+/8Ap3/yVR/wlGr/APQieJP+/wDp3/yVU+1YLGSXQ8bbxx4W0XS913q+k307yYVIbyOYquOc7WOK17Xxr4He2iuE1nR4ZyQdjXsQ/PmvTf8AhKNX/wChE8Sf9/8ATv8A5Kpf+Eo1f/oRPEn/AH/07/5KodW/QHi5N3aPG/FHjTSDpty2h+KdGgvARkx30Q3jPOPmrm7bxvpd9psTahq2ktcRP5biW4iHmj+9jP4V9D/8JRq//QieJP8Av/p3/wAlUf8ACUav/wBCJ4k/7/6d/wDJVXHEcqtYPrTvseH674p0W+8PTWyeKNHDlMRhbyJTHxjAw1cn8Otct/D2ruz+JtL+ysMMhv49rHPXBavpz/hKdX/6ETxL/wB/9O/+SqT/AISnVv8AoRfEn/f/AE7/AOSqFiWk423H9b0+E8g8SePfC1/Lsk1fSBGi4Jju4zu/I1y9r4y8M+cEg1KzSINtJe4Rcj1619D/APCVat/0IviT/v8A6f8A/JVH/CVat/0IviT/AL/6f/8AJVJV7K1io42UVZRPnbxL4o8NeGdRtLvQNU0vUrybDmTz0kSD1BAbqfet/wAQ+NPDt4bG4h1vSC0se6VBeRnYeOCN3Fe0nxZqg/5kbxJ/3/0//wCSqqXPj24tmCz+D9ejY9Fa507J/D7VVPEN201REcRO97XPIJfFnhgLHjX9JAbjb9sjOD+B4rC8R3+h3rC603xXpcFwI/LA+3xAdfTdXv8A/wAJzd7Q3/CG6/gkKD9p07qeMf8AH11qf/hLtTPTwP4k/wC/+n//ACVSjiJRd0X9bl/KfOnhTxNaaYWS88TaWz8guL6Mhv8Ax6u6svGvh1mDT+KNIZNjKd2oRArkdgW5r1L/AIS3VP8AoRvEn/f/AE//AOSqT/hLdU/6EbxJ/wB/9P8A/kqpnX5new3jpNW5TwjWPEXh2WJ2g8RaTuHpeRkn/wAerJ8O+ItHtLu4S58QacYHB5N5GR+pr6N/4S3VP+hG8S/9/tP/APkqj/hLtT/6EbxJ/wB/tP8A/kqqWJaVrEvGyfQ434LXem3vjPxZLo99a3tuLDTlMltKJFDB7vIyO/Tj3r2Cue8N+J/7Z1S/06fR9S0q8s4Ybh470wNvjlaVVKmKVx1hfIJB6etdDWDd3c5Jyc5OTOL+IvGq+Cf+wy//AKb7yuTvrp0t/Gmuav4q1nS9K0S7WJYbKC0ICfZLeT/lrC7FmeVhy3cDius+Iv8AyFfBP/Yaf/0gvK5iXwqnjbw18TfDzzm3+26rGqy4zsdbKydSR3G5RkelP7JHUl8NafqOuTIraz4902KWAXME95baWY5UOOjRwvtbkHa+1sduDjU8CX1zqngfw9qF/J5t3d6dbzzSbQu52iVmOAMDJJPAArc8JJ4qiSC38Rw6LHBb24j8yxnlleeQYG/DIgjXAPy/Pyeoxzy/wzJHwz8KkAsRo9oQoxk/uV4pwYpHUUZpBg9DR6VoQHFLzRVLVtTstJtftGpXUVtFzgueWPXCjqx9hk0JN6IaV9EW85Geneq17f2lkhkvrqG3T1lkCg/TJ5/CvP8AUvG2oaq0kWhQSWNtjH2mWMNKw9VXoPxyfoax7TTXW72yobq7JXfNcOztgn72T+Z57it40f5jojh3vLQ7afx1pu7bZwXt52DxxBUJ+rlSfwBqpN4t1m5gJ0/RYoc4w1xKzk9f4Ao/VqhTTV35efdKExhZSoQ44O1cc5IH0PU8VYaFJGVlmlZlBQOSSAN3I9P/ANVVywWyK5ILoUbPUfEGoq5bU1g2cMsFsigHv9/cfyNTyWN1KgS+1G+mBBDJ9oZNx/3VYA1cghRI02xIN2CNgyCQOuRUDzRST3drCjefBGJFDEqpOAR0OR1Geg9cdy/Ypa7Ix/8AhE9KiwU023crk7pPmJOOvP8AjT38NaYSudPtNucELApzx644rWjlk+zwC8j8m4kU7lB4Xk9s+gH60k1zCl1a26pI9zcA7CiEqoHdj2GR2p80u5V5N2MoeHdJjB36fbNgkYEK47ew/SlHhvS/MCR2cCjk7QgyPz685rcne5a3kbToYppsHywxG1ge/XB475HWobdbhIYGvRGLojD+UrAD2x16Ee2eaOZ9w5na9zMPh/T2GwWtptBIY+UvTuOn+fWkl8L6XJAwkskKDPIiBwMemOfwrdbZkIzfMTgL3/Tvj2p8VrILWRUA8zaQgdztLc8E9SKOdrqTzs5RdAOmAtpF/c2AzgRxStGh74KkkE/QU9b/AMZWTYTUYb6POAJbdQR35IAP5mtPWrSO+srO1upohqjBihBYLwDnOeg+XHIzx7VfsraWPS4o5yhu1ADbTw3XHI6naAT6/nT5++o21y3Zlw+LvEVqm7UtJsZwBg+RM8Rz+KtV6Lx/ZJj+0dO1C0HeRYxNGPxQ5/SpmiTY2/AXoV3njpzz9f8AOahktoJXKxiN5cFgmMdB3OCeuPX6VNoPdGbjB9Df0vX9J1cAabqEE755jDbZBz3Q4YfiK1M8815vqmjaVd3r2tysJusjywVKN0yPm7nJ9v0otYte0JWXS76S4t0+7b3w8xTj0bhhj0zUumn8LJdFdGejj260f0rktP8AGtoWEWtwvpdwPvNId0P/AH2On/AsV1cTpJGssTI8bjcrqchh6g96zlFx3MZQcdx/v1pc85FNo+tSSL0rjn/5IB44/wBzxD/6U3ddj0Fcc/8Ayb/44/3PEP8A6U3dZzKidT4qfUrrxlouk2Ot32k2sunX13M1nFbu8jRSWqoCZo3AAEz9AO3PFec+HfHkWs2Oj6hJ4n8fabpGrXBtLTUby00nyWmBK7G8uFmQkggFgAcda9L1UFvihoCjqdE1Mf8AkewrzLwv8JPE8fgjw54O1640aHR9M1D+0Li5s7iWaa5IkZ1jVGjQIMtgtuY8Disyz0/wLNf/AGvxPYalqlzqf9namtvBPcxxJJ5bWltLg+UiKcNK/O3OK6knAya8pfxvp3hfxN45t7gPJePqsUiRDgEHT7QAlvqD61w+tfErUdUeRY5DCuMBUOSfarjTctTsw+Bq19UrI97v9Z0yzw15e2sRXkb5QDWLd/ELw5bwNKdQVwONqIxP8q+aZtTuLiUsY2M2cM7EnP0qZLfUJ0LtGUifvtJBP4CtPZrqenDJ4Je/I9wufjDo8b4itLuQdckKv44JqmfjBDPcpHZ6efLI5Z5Bn8h0ryO30ppIpDJ9pR0G47kAXj/aLd/SrNvoVw0R3QShE5Yw7GBJBxu5GOMetVyR7F/2dh4nuNt8StJA/wBOlW3cAEoVfJycDGQOc05/iFZPJIbaKSVI0LcA8n69P1rw2SynVS7BFCrkEQFVQ+5UDp+NPSEPEnnX8khXrEYXDEdOp6frR7OJn/Z1Lc9t/wCFhWaPsleAcZ3Rln/PgfzNRxeOlM07tLbRwg5Cysytt6DAClic+2PevGImhCIYGuwsb4KJGArdOhY8+x4q/arqk0W6KOZd2W2rIsWMjA6c9APyp+ziDy6CWh7vYeJbe5CyyBbe2ZfkkmcJvbOMANg/pWkdQje58i3HmyjBbHRR65rwm00vWJBH5xtoUB+TbuOQPXB9/wAf5b0GmXSR+c93NLKGBKrK230zhjj9KzdOPc5ZYBLqewruEpLSDBGAuO9SM4UZNeTMEDrELmXef3ZJmbIHXJycDHPP/wBalZhBvZp5HDnGxpc8eg54qeTzMvqL7nog12y8+SMynKDJIQ4/z71opIjoGDDaehrxpdR+xXTyW9lsyMmZXUEnGPXP51Bd63d+VNNJM/lbgqEPgZ6gHNHsrmjy9vZnszX1srshuIQ69QXGRXPeIvFJsF26fbi8lxn5GyB+A6n2rzS01SdrcyXctvHKXyBISoC5IHPPJxWjpt/aXVusyzIXyVZQ2MH2Pf60/ZW1Y44FReup0T+OrhIIXFg8jSvtKlShjP8AtAmqk3xGuLnzY9K0W5nkRzGW3ALnOOvTn0rMj1SUPL++aPyWyyOwbcCBzzwaZJfxy3amOaJQx3lmbhWwB07D6H8KfJHsaLDR/lHSX2qX6u2rPNYyAful8zcrY5bgEE8e/eub1bX7hw7GKwNmR/rEjcbD/e3LjkEcdPwqfWNWuLcPHaywKobrE5/TOcVzRkvFAleBHIBzKcgjrzxx+lXFWOynhr6tDr3Upr27W4s3FsXA8ySFj8/TOSepGM96rxeINXtB5dpqtyisxId5iAR7A01WlxKl1azSnhQMgEfU49qriwcyBmhiit89cFxk8c/jTOtUoW1R0Wn/ABK8Q2zlJroTIPlxLEP54yfzrQj+L2qoRi1tJIUYK5IYfhnP681x9vp06tiWV0UrhPK5HX165qV/DU80BmWYtl87Wflhnuanli+hlLDUOqR6Ha/GOF1An0wrITyFmzgevT/Oa6XSfiVoV5Cn2qf7JMeqOrED8cV4ivhhS5HmurJ99Q3FVpPD7qrSW9+r8bgDg4H4dqh00ZSwGGktND6C8I6haan8RvEVxYXEdxD/AGRpq742BGfOvuP1ru68L/Zygkt/EXixZm3FrTT2BB4I33fSvdKzatoeBiKapVJQT2OL+Iv/ACFfBH/Yaf8A9ILys/UfCPhrVLyS81Pw7o93eS43zXNlFJI2AAMsQScAAfhWh8Rv+Qp4J/7DT/8ApBeVb5q4bHNLc5v/AIQHwd/0Kfh//wAFsP8A8TXQWsENrbQ21pFHBBCgjjijUKqKowFUDgADAAFSAc4A5Nc34k8VW+lWk8sRhk8s+W0sr7Ig3dQQCXYf3VBx3K1pGLk7IFFydkdKvH+c1zmveNdH0ctE1x9qvOi21t87E+hPRfxOa8xvfE+veKAYzcC0sSOUtxsLD35JxnjrWn4d0BIypKxxhVAIUbmPTgt/h/KuhUFH42dSw6Ws2XNQ8a67qyGLSraLS434EznzZPwGMA/gayLfw499cC61W8nuncBg7sd7D/gX4cf/AKq7CysYkdV3eWsh2hSMbsZ4568849vxpl4JYJUYlds/AOwbTjoc9c9evBwBVqSjpHQtNR0iirp1jFboEQMoydx9eTn1x/n0q/vRGRNhyCAuAvt/n8KpoHHHOMnntjnryPft/jWhpX7y9IwdkeScDAJNS+4pM0pIUiUySyLGvUlzwMdKkEEStukQ8tjn5hgDA5/x7k1TeW1LzCRgRDJ8qtyd21eR3/jAz/tGm3t6gTEbZmIEqnbuAyDjHXJ5AOOx7ZqLNmRbltSGiWKGLyiWDszsCuemABg/iRj3oNpbtdR3awoLxFIX1zg8EjoPfn8azItbVl3ukix7iMv1TAycggHdgn5eTgfXC391BIsgZY50XfvDruMgXJ2jqSylenvmnysauiWPzLyMi4i+zTrkP5TbgCOM78DJGc+nbnBw27cx6e7mCSS3t3CZEyIJExyRzgjJwVYr0Ptmtfagjt9pjneN438uON4h8zhwpADDdznaSOMHOeKgluri68t5Zty7WNzaKuPM69CRkLgYyOuecU+VjW/Yu6TI/mNbo8MEEUhMEcSEr5eOj5/E5BHJB5BAOi9qJJPMjlLhwCVbkEY69fbtx7VhaZqE0VvFbmBYm27fLQCTAXjqPzzggEEcnir99IHR4bxI5WfAKMR+8XdnaMj5gARnA4H1oadwluXoLWDd1+f+8eec8jJ79PccUjTP+7MLh8uJP4SNpGMD5lOOd2TnjselZ0lwxsxuQ+UEQK0mNuQwyRu5LcZB6d6z9Uu5/JlggkghA5KyAllYHqoBxg7cggD1APFCi2SzolR1MDxtEqrgIPILuowPlDA9Pvfgfbl1xZxTvCi3DRlcyfucA8DAJPPHzH15NYUF+YI9yyNMrkHDZYkEDaR1wvzDnp3Hvp/2hG1pG9zIgJ24LsGLqcZwBz0I/wDrgYpOLQrMuXfkCQtc/KuQoYnAJJCqM49So47nH1qW7wfaisE33GRCmehddwPoeOfzp1nepLdTAOrxDaxi5WVWO7JZSOhA4x1IPXPDr6SeOGWZXJ8pWfao3Kxwcde/OMZ6H/dpWtoCKupD7Ybi3u7VVVseVcK24ocE7ugOARt4yefrirbS3rXavdRpbwRGTed4YSZGdwxjgdz16j1q5NMzTy200oj3Z2fK0bDIU8vnud/T8Pumq4vIbe8cx7J94XcI0CoylQA2c4PGMe3GTjikilOysVtX02OZXXCvuU/MjZwfT3/nWHDaatoh87RJnVCQxhJ3I31Xp+PHXrXbO4ulhYOnkyREkudrhge644xyD6GqUDeWsyKx8yJgzrtySO4A9SDTUnaw4zdrEOhePLe5uRaa1B/Zt0fusx/dMc+v8P4/nXZg159q+iw6jZGbZHtJJYId2PQj0zkcVm6Lr+o+GiLe5jkvNIQAAZzJCOnBPUcdP5UpU1LWJMqSlrE9Uz9c1x7f8m/+N/8Ac8Q/+lN3XT6fe2+oWcV3ZSrLbyruRlOQR/jXMN/yb943/wBzxD/6U3dclRWMYqzIPG/jbwjqwRb7w/Za81uG8h721jkVN2M7d4JGdozwM4FeSajpthrE5kj8M6FaREkgR6fDCqj04Xn8a6q10uLecQhV/wBjgj6k1t2sEUUaLHgA9Du5P1/wrVRUeh9JDD0KGsVd+ZxGk+DEtoSI4reOJ2DbIY9qknAz8o/ziujtvD9lbpvdc9iG6DpzW4IckMGLMrZAHTIp8FsqwFdrJn1OSfxP0pmrrO1lsUBpdtaW4eOBYyi5Tafu59P59KtaaimJhJFGfMbdwuMcnGB0P4j1+lWUVyFaNSSvOxTnNT+WRIfOkYMzZPAUMT/OkYub6lGCyRfMeZmAdwSZdzcAYyR271OIIHiZcRKCuMRLgt+tWptkcmVd2YfJs5wx549+/H+FMkVRIrXEIjw2EYKWzn144/OgnnZQ+wQJCzvvHHPrjrzUMulpEoliVduMHeqhSM5zjHJ9/Wti3EywlHt2ZlOAMkK34nrx9aggFz5ssb2knlrI2CHZuCRjjAz1+gxRdj9ozMl01/NdzCspLdQy4Qf7uMH6/T0qutpIULm1hWQfLG0c+Bx14HUkdq37m1vWuI5bWEEKRu3MwKqfUdzx70+DTp1nEc0hEkhJVVJG0Hv7fjmi4/anMNBqE6YmSXzC/BSb5QAP7oGPwNC3WtRIftM8J2KRu6H8f0rqo9JWS4eZmL7W2B0I2rjqeP8APFSnTraBhIQDcSKSQSGHvn3OeuKOZDVZdjgreCRoprgjzmLZbaTtBOPm7Z46iopT5MMgmHlB3+VdwcFT3x2H4967RLWCUXGYVd1cIAihSRx+eP6fhVGWyTAM7q8hVXVeN0YGQV4HJByM1XNctVb6HMm3uRKZJpVaNUDbgpJXPoe/H86zLq5eRYm82RcHJ3gdu2O3Uda6KaGVxuhfdF8wkjGGA6c5PTgdfao5PJurW2jWKQXKzeWUwF2kHJ5PIBJ9D0FBpz2OduNVa4YtOXVF+XcTwWz9M9e9RG6dJwQ5mLgcgHgAZ4OMEe+a7G88MQQ6nJFc3BtYjcFNiE3G1ShKlR1BBGDx/jWadCsreUQPcLOqFEV4F+Uks2R8w+U8evrQmugo14PYwpLjddnALxMN/wA+WYDaOwOBj19s0kcMszwpGpJY4YIcH6Hrx9D/AErqNG0S1utRjhgxbQzHMMjguFKjJbHp2OcZOcVo6zYvol6tjayRTxllO5UUDcTnGB06dAaL62RLrq/KYGi+Hby6025uJpFuLa3l2yxbQkkZ7Yyfu8jn61oqkqWYEFyyqVO5WjI3fhnI579s5pkcB+1GG4YQNvVyCuA3zfdbA5HJIH05roxaRabbzSP5TgR4JlUyMDnBwOMrwPTnmk3bch1JbPUxkkgYtMuycjJK45BPOR0/PNNljJTy4YY9rfxFRx9O1dcbfT9RsI5FgjW3cDyz5eTnPHy4IrJ8Q6SLKISWUQEDvvb5iCrZGTnnqM8VMWmyVW1sZEEJErKqHCgAtjv7CpUt5Q0gEbZVguXXaD9D3qwoZ9pkJMzMSgx9zj37YHXsTVn+ztz+ddkyKjI8ECR/MqhiM7+MjuV7Zpt2JlUM4QxnzCqA7vkJxg4/CoDETLKqLuCgbc8frWzLo8sCmWHzhEMExsM4G3AYfTAyPr14rMVJpJ5GDuGYbkVcHJz2BPoDTTuCnfY6P4ODb4y8UDaAf7P07OP+ul5XrdeS/B6YT+NfFLjf/wAg7TeWGAcvdnj25/PNetVzS3PGxDvUkcX8Rf8AkK+Cf+wy/wD6b7ymazqlrpFp594zYPCog3PIfRV7n/PFY/x41GfSdP8ACt5Zgm4j1nCAAE5ayul78d//ANdeO3s+oa1LjUZZHlK7WhiYZfJHEknUjrwOOK6cPR51dvQVOj7TV7HV+KfiAty01tGrSx42i0glIDnPPmyrg4/2U692xWJbaRea88F9q04EcaqlvCo2RRLkYVF7DGOO+Oan0HRgqxXEkKFFPGwfInofy7kjoPrXT3PkmFpFModkC7MkbW4OOMHJHPPPTpmuu6hpA6bRh8Jm2UKx28YlVcouTuwMcdQPbr2710Fk7kKY18zLDIBwcZ7D/PfvWIju8qiQo26QFQg75OcDqTx79+1W7fUTasJW/fbCNwC7e2QOuR0Axjt69YkrkyuzUK21tFbxRzYQxMETG13wC5CrjPHU8E8AYJNI1zbO0gQ747zICYCgNy2SDzyHzk4zj1NQT3zXolktplb7gkwxjaEbgcA88Y3ZJwDwB1JGYZzbyFY3eBwu11XDuG6gAEY2j5APYKOAMUKNzF3L00v2ZxIDI8LsUWV4yMHkYPHXI79c9SajtLsrNDI3lsYxiVeu0nIEg5BwNxz14z7VS+2266fIvmK9vhcv5aKQpywXHG7IHUkE4yTzior3TriC3/0fbgpsbKF3VS2cc/MTwOfz5quXuXFqSszprsJqDtbtHALOMlWhkBUlg7AEA4GD8uOO+QTxmlqkkkyPZTR/OVaVFmQyrIM4K5HXBK/KB04IxmqcU7PpEH2pVEiFo1Mj7H/iZQBwQflXA5zjpxTXkTz4mlvUWNW85i4Ty9zFcglccAkjJzz1boSkrGbViKVnlvJ9syw3LSlnUTMoYAkAn0PTtyAw5q7aKk13MUZ3e5ClnLeZ0bKEYUAdz1J744rPt7iVtpAkWUobncpDqASOhDYHITA6fL0UVbSGcus0Oxo2mzk5ydvLkbl4ORkepywPOTTQCnT2gtZBGk8zy5EarIFzzkjZwCxyeq8cnB5znR2cF3DLBawpJCPl3sQIymNo4yQQACM8YHQ9atNeCCSEJBbrdDzJUiBO07MhWAPOS2QQB1Pc0QpKz+aLZlhiADMyAoqgEhiSATyq5HY+/QVx6F2GHzkeSGW3gklSQOQBKF5HckggGNsqCMccCrN0LizgkKybSAFw4MYVep2gnnCg856+w4yzAygyXqwib5hKLUkbSMKOC+AoYeoPXjk1swNA5kZmVpEm2HYN5BduDxyDk5I4x7CoYGYYQsj/AGuzEohTc6knl8KAwIABA6nr+GMVXurtjdrJbk/aJxncCz9GK/exjAIxxnPPFWnknjJnRLUQJIQZmlLEJt7ljwc9cA4xjnqad5DHKJBNGXRpNo2xKu5R12sq5IB4I7DGPWrXmSx1kLiY+XH5aTZ3sYJN6I4AXacIOMjr19SeM3bCYRi3hfdBCM7yudob5Uxxu28so2nB74xzS2MjCXz5ZMiYkgPKRkgY2AE4b7pGcfw5FON8izCNtyvcBQhwS236qucjeMEZzz6YpPXQNhrTteyR3McpEarI0bB8EoDwPnU4PUYIBI3EHgY0rYws3lLEikOPKUw5RGDCTqO5YqwBIyRx0NVtNjWV3nureLzGYBujMS3YsMAhQ/XB+8cGo4L14IpbaAzTnC5ZWXfGQv3sknrgAZ9Tk4qXrohWNWzMLSMkQXzI2K7HOSuWO7HfDAH1x74xTBpVjLD5cEBi3hnHkooRxj0+6ew9/pms3wqUNoJQTGXaN1wFcLnHyg4xjG08f3sjjFaN7fxabOsASSQ7VU/NuOO4OV79c55qWmnZDSvsSTC4W1t49OTegaNGiKgbYz95sdCe35+lQauvkXayAN+7bCkL367h17HBoOtQgNKvmhjkMgOFUg8cYPPPNU57+XUZ13ALGOUGMlvxHTp/kUJO40mTRXXl3S3UpJgkRldRl/LbqwznoQCfbBqlqtitrcyCUfICWD57E5/z71d0pQ16IpSSkowOv3hk5yO/3s+taer2QurH94wFyufLkHAGT0z2zRezK5rM5DS7m58N3X2ixR5bCQlrm2L9ePvIOzdscZ71uWlzHe/s5eMLqDJing1+RNwwdrXF0RkfjWZEp2rnuOd2c7sYq/piCP8AZq8VoOi2uvD/AMj3VY4m1k+oqqW5UsYQ6t8vBY4BGM+9WFRpBiBQUUHJVcj6AjvW9aQ2atHB50f2lQzKiL5p3A4PAOWxzzjFbNk91FZTyXLW8MUKbfu4GQPmLAHA9cA8VLkelOv2OL8uNVG4zRbti/NnOTjjGPXj86dLsEjRiXZ/Fk9RRLJLIxuIQhSSQuqqoGR0ySe/HX2xTpAs20unyOccr3z1x6Cmaxbtdlgxv5YELqj5AGfT6evpURkCmOeaRQmSNxB4boPcD3qY/ZzdIZCvnMx2KWOMjvj1qEynzyo2ec0ir5RO0uQPm68kAMGGPSkibku1jMpYuZWBRtj7kHvt69x7c1dtNOmytzITswNrxru7gdByev8A9erGm2lumZ2ljWVlDJuKlgDjHrwSMe/4VJfXbfZ/KgKKFRYWKKEwSARgbuBg9OvNJvoYuo3oh09xHpMULMsxlmkUbihkxjA5GflJHGemTk1Fd3j289vLaWA33cvlyrFHuZeDtZiOnIGSc1mRXLXN08YMpEKvsjRMpFg4w5BIZuBhetWdNm+zu6QxwCMJsBhB+8oyVzjBGc888npwaVieWxnNe6pLBp/2yztoL67d1njebDQxZxlSOp2ite5ltYbtZHn8zMe1EYkbSAW7DPOOh644zWTEIdIminkE6pHEBcMwMh2kFsDBAAXB5Wqus3NvLD5ralH5u9L2385cKM8AP7fNn1G3Paqtc0a10NCFfNm3Wzx2zOjNJMUILkHJ75I+bI9P0qC+k3f2jJbtJdyx8YYAxjOCRjr0z1zU9vNDuCK8zSAmMRRkxruAyAvPGQOOlVF+1XLtdW0gtWZQy2xffvyeCzEY7dO1BcXqReH7gXRkkuLWM3EbKPlUbkU56n+n6c0+IiT99uRCwyCybQUB+YFScg+/51SvboxPNLqBiiaMBjukATBI+YZ4OCdufftVSK7j0qwWa7RLeCJ5GMzqS3O3jGF4OSuD6D0xT5TRvmd0aNzCIAcLG0Ug2goMYHXrVO7jg+zxYhabJAQDhx+PaphcbdsjOTvUShZW+YdB0H3eOemP51CrwtulTYwlY7g/HbIH1potMqiCC2dvLkWKJcoy7SrDp/EOcj8etUZFa5SQzeZHDI20pDxkON27JGQM9Txzzj16OSBp/wDliHlQZBfj9f8AGqjLskV5YmMpbYFUgHBHVdp5H54ppjuirHbysqLcXIxGrRxLI42nnJyCOQOefQdelLY2hnmjuftKowGAQjMFzzw3PG31556jNSi9sYru1tbq3dppPmiX7uw5ztLDvkdK27GKSOwd71odxmLREx7dgHHCk9M1LbRDlYWzt2tnFyvm3judgCqS3JC5Y559ee1ZniYyWxURhLh9zLI6j5gM9Bwe4HWultNNu9P0h2tZolupX3HYpKgE4JG7npz9axNShs7PVBcK03mvk7WGSCcAsPT6+/FSnqRCV5F/Rby4hiSPUWUyEKFUrgjOdvGSR0/nU+rIJ7YhpVBdQvkE7sN1PQjPAPHoKy9Pn0edZL5PtUsgzvYoU3FCrZbGATnHJ5ODUmnt9pu3jghP2eV0uklJ4JyGPHbP4+uKTVtSWm3cy4AFheFQu5JAyrsYcbhnOecnOcfSuku08qwEiLO5SPA8slRgqARkAkAZ3ZGDxx6Vg6r+51CYchYnMpZTjGOACOSema6O21C5NhD5ciRqqKzBl3B0K7uORjIzz244pz6MmavYj065OqXMN6oI8pTbyDJ44ySAR8w3BRzjGPwrmtYiFjqrxGQSgNvXf1BzuBz9AfyNdtBCWk3OXzI4IjU8RcHn8R1Bz1rkfEqvarp8zRuJgAhZ/m3EAg7m49j0qYPUUH71kdN8OQi+N9f8sKAdI00/L0JM19zXpFeafDNVTxrr6INoXSdNGPT99fV6XWT3PMq/Gzy74+hTpnhXeCV/trnAz/y53VcDbKqXRTKgHjGcE4J6HjHI9fwrvvj2M6b4W+bbjWc5+lndGuP8OWct47yXDMY4zG0ik7SzZ4I9R6En+lduG0g2a0naBeubEJFFBa3MttLJINzxKoBxjglvXBGAc898VMfLsl/eRhFIDvKOEGSNoY5zk7QCSD07c0Gcw6ispm/cRb0aLaDgY3KQTgjOzgLkc/jVW2nkPmXDv5nARIZscDCtsOOvKyEEA8ZwcAA6pMGysWFpqUluWXCA7VVT8wO7t68Efj14pZ23ZZW+YMOvHPPfHbn071b1OxW+geKF4HuBvYICrhwTgBxjPQgZyR1rHeG8XaJY2wxI8zO4H8c4wMfy61Ssy4slhkliuRNEWCswXbvwCCcFf17/AOFXtTUXSKsbQvE5CtuYsGy3AXjJ4zwB3yMkcUbezmWMXFykgaJlZYo5Mk5OMgYIByw479eOlSy3s01xMPKuN8IIP7hRE2CrcEjHABGecAA8kAl21uiJtFCGdgsQE0RZFVirKhVmTG6STHCYfdnjqD0NO86O2eKS2XNpGhSFlLBVIIG0jIc5x06ZByO4tar5QcXRV3upGJA8kFkboNp25KjOQMHJGcmqhtHZyjpFNp8ZVYVZwseAcOBtUDrjHHUHDcmrVnqQ1bQ0badpXkmuY0YBzEG/jHIyDjIABK9cck54AqwwjeMypbPbsIyBLuAChtxYkBmGDgkHB6YwD1xNqzw+VI9xdPvQMC2FAQhuMnJYDr2HTPHNm4a2kSaW4gL20Zhl/fN+8b5ShfcVBJPPUHud2GOJaGWpvJj+xRBgYsGHbG/ll1yCY2B5IzzkMDnA68Nl+VHPcSXsqgTcyxyQp/D/ABBgcghgRhTk9eQOik7Lu3WISkEiKWR4SinCqSzYbI6r8xyOn3iM1pQOIHBZ5vtJ5k8t3B4ztIBIwDlsk4Bz97insgV07opvNZ73kdVktjjyZFxk4U5w25eFG7KkHgZxzim2M9pHNGX8tfKVnGZD+6xk4YbjuyN2CeB1BzyEkgWSI3M807zxbASU807T2+YbsHg4yeT05ANqO2PzEmNZIwY5CkZSJGA4DKTxj5TuyVIJ6/eBdWCzNHOfKVAitG65VCSjY538jIHIPU+hzgGnrcWgu0iKBLkSKpkVtvzMnJOWypPPHXjnjmq8LSW12qHEsXyMxEnKkBgx6EYAVTwMHJ7EmoI7U2kc4eW3t4hhxtdmMYG3llyCx5GTk5yPWosOxpSMwxsUiVdxVIty72H3VOTz1I/EHikje3LKtyqM4AYo67NvAHAzgEYIK9fmHHeq8cyQuIrG2it5LgbiAAN52jlivP8ADjPseORVS1aU6nNIVWLZHIo2MN2N3OCQOBnHOe5BHNCRLLsTOskNu0TZUoTiNWj6soIIJIABP4kdgRS282HaG6WaLADk4O0AfwNj5umeefunnoKqW8KW0MZnRPKlBeQqrEDcoJJ5Zckg5/D8U1G8ltDBbSieeN8MHJEm3BI/u5/Ahj83Xgina70A2H+zLeRx2ssIkLBpP4iVBIAZV7kKQCTj5cYzUh01C0UqukzQ4WRzgnfgLtPHAwQNo/IEZqjp93BBKIJryNI4wF8sqyktkEKpLDJ+UnaoOPboYI1F1exwb9zOBK4ZScOMLksTuHIHGOQpzxnM2YjoNMknb7SVJcN9zzVMYbJwxUHPAxngDO7n1rn7mX7Vqt1LsPMpHOTwOP5Vdvzc6fYb7SUxwKrEqzszkbQFxwCoHBIGRxzk1iWbqu1iQD1+XAzxn/ClFbs0hHqXpbdSpVhkDv29+3qaswLgEr9Djp6/5+pqDzskFCORyPX9fakknMKEHcd3Hcj+tGrLsadi5bU7JYyBl8NycgbTnp7fyrrB8y7uQCOoHrXMeFraa6lN9MQse0iPB5Y+pHoMEe+faup6Juc42jJOcCsp72Oeo9TkteiS0uFnUkx3BK7eeWHX6f8A66XT/wDk27xbwB/o+vdP+u91U/jdMWtoyKzMs2RjLFflI4/X9aq6Sc/s0eKj62uvf+j7qs6/wJik7xR32p/ZLdjNNdToXIDKjks2D0xzgc9sVymuay0yi0tI/str0PyjnPr29f8AOaxLxppJBLcySSxygOU6hT6gnkf5zV20iub65RbdCioR8xOCpKZII7EHHH6+qUUtWenCioavUI1jlUtjexfHzNgcDuT6cDH19KsRtFvi8yNZVUiQMvQZ4B/LP5Ut9oBGyKeR5Ig6bVc54VcH8+/1NVonup7kQRbZGEeJIgwVlBXjGB9QMf0p6NXRfNc0bBI5LyVfMVpSQXG4hTuwqnJ7YUdO59a1bKINHLnyxcREopClghx03HGfqMVW0qwjsIXa5RJPLAlDS9n55J6A45zj3qkdSnPiHy5nARYDLk8pFJjAwR1zuHvUPXYzd5N26EUGpR2FntkL2sKnarZMj7mYgNyDhc+uQM1BNqBs0+0yxGBZLg4hlPmKepPzdiSc45+7wKg0iI2mmq0lyZ7mJyZplZpFZgCcDcd23mMnBAyB71fuDHaXEBsUgHnAKBuUbsk4A54OTnp3FW0kyopMri7lgnRotwR92cjzPmz0DHGDgDk5APHXGYraGL7RO0tswhiVzuZyzAFmOQw+rHjGMgelXb5SGi+2AIkZQs1wY9gIOd3T7x5HUACluooZDM0RWQBdrIzERpjp04A4PGDn1pXBabkF9dtP9o+zXJVxb7oyoztU4JOPU9hyePeqBtVW2iht1jImLqw27nX5SQpJzgDKnpgnnAzzetreS7iPlqjB3EkiqpAwowoUM3Ayq46Crz2cVrdQyuWSfLIhI3hf7zE9ckcZ9qd7aA2loZX2i306BLGa4N5dKgYhiFmlfPHAGA2MY5B/GoLa5kntYLt7OR4N7tH5rhWj2/3mJ9e5z07da1Luwgj1O5u3t4pZGQYMiofLwCd+epHvzWQ1zFp8k5jWWVJoMxz78RyMckfMeFwvfpxQrMuOuqK0Uuoz2zQzW8du8jhPs06iQEM+5nyM7icnrj+tCxxvc3cM3IUjz8wqxLHGM8fgR61NbRGHTJVM5Aa4DqpJVouBvwWxuHOQRjrWbq0s1ulrIsN3btG42eXndK+Coyo4wB6VS1NI+RpXUbyD97azO6YeJBGVbqMnt6H8/cVTc3dvqVzK8Md3aB/LEQVomjGQQSxOWAz0GR9K0kePZsnhlaLC+bJFnEj52N35yMAjHYg81Ff6xZWuo6fBMCYrqIy27KpCAFuAVPfj6+1JX2Em9iCz2ymUC4/drIAqqdzjJPB56sR944PNUby3eXTZ0fdpGxgrOGLCYtj5sDJ3dOn51ryTIZo4bUBsxnChC0e0ZAbdtHPGeORVe7kS9JjiaKaGNgkr7uZHxyCwGBgAD19aExoZYQvb3NmpxqFxD/rZEYDbjjeQOccc55zn6Vf0bUhcT6qs4fz7Vf3N3MFKuD/EgOBtBAJrP023n06S8lnuJHgfDETS4VI8MWUHHPJ6EVr22s28YtbcWLbCojDKdqRnjCnv0pNdiZXZl6VqV5dQxT3moNK9pICXDNDHKGAIB45HI7d+talwInjWS2ghnt5ZNz5Pmx88kgHpnOcgH6Vmxm53XSo5knwZITDyhjzxjIw3XI6dMZOKZ82oWpdZn+ytEoeHG2TeFJzwOScdv5U2ria6o2bC2tLm2WCRY/Kf9/tMJQbc/hg5GcHt04rVgjkibYHPlb9yiNNoC8DaT39a52xAiuZp5GuPtZVm3KoDbEyTu5AOMgc565HHTbkdoE820aVoJEZsblYBiQQeefXAHHNZyIb6GJrEMyavNcMZSWjKqobK5IyDj17YyfwrQ0+OC30uK4vGkWK1LR7S2/zAcrhuuex/yaxHvXaV7iSN3jL7TvkUYTGWI6ZHHQZ98Vr6BqcZ06K2uoXAMSlBJGQCMcEZ69PXPT1qpJ2HJaGnZrdyXovLhkigQ7iqFvn+XjPbgVgeNbiIzR20oAV3DykscEA8YBOB2+vpXQz3aPpkwikiW9AViApC7gB07+nX2rko7GTU76Uyx3G2Qq5YsOcnlT6gbBz3z3qI73ZMdXd9Dqvhn53/AAnfiUzHIOlaYUOf4fMvPy5zXptebfDmRJPHfiPy33qul6cmfcTXwP65r0msnueZV+Nnl/x7YppnhZlzkaycY9fsV17H+Vcz4UusaNdXKSpLMJsNsXkg4OQqjrjc2MV0f7QJQaR4XMoBT+2eQe/+h3Vea6RqK6VqcjOHjglKqzIBlCCcMOvA9yeCa7cNHmpv1NKSvE2pY7y7d7ZdPS42g/aHbYBEDu2gcn1yDnngcdKZLGkWmzZtjIyuDGxieUOQdqlFPQgeZnaMjsWBJN6/gElqL62k8+GOMDy0dtpKktnr94HJzlcg89Kq3Lpe2DJdSzJbhNrPFtMbRNhN5B7B+g6nPRsHHQncfmxYGguILiSG285hM0bq4LFCcMdwbccBlB24GOCAMg1Et7NqMGoCR5vPs7nYVKtAqq7jBZYmOcBcgtjKnryTSQRPPdebsd0LFkLoVCkZI+bG3gYToT1Occ1QuJL1MI8It5X3hZJYyfM65QAYJyTGvBHUlcEZqkrkvTU1BqUM1vNFLNKSiGR3SNXbd90gIdyoMA85AGR13VhRqJNQgjkEUchywKrjbggfKWzgHOzeAc7Se4ISzmjeS7iulgeWc+YIruVHeBGCgrnkAZCgcN98ck80wkyT3EUcsUFtO26PAkDInzFxsCNjIC4TP07E2o8pL11OigffE0sl1NLEz75VhUkYX5gckgD5Rhhz82CCCM1WmYjUEeaVhGrMhjlmwHQjafkJG7sdvQMRyCSTSsblZpJ7hJrl2R1keJfnfKsVY8YK/dJ4II3cjqKmR2bfFJCTIcbgj4Xe3f8AvKCMk+44OOTPLZlb7F2/icRyRxqgaV2kCKFjZiFUckA5YkNzzjHfgVR82aRoGuwbaU4EbvOW80EKCRkAEYwQA2CSccni7DG0kezYjNwkTLISY15GdzMckEHoenrnFU47GOwnjCzXahduAyKsDtj0BBXueMA4OegpJrYqxY8uQJHLGZRFK4wS77lUDYvzls4/Dqx65Livpt6670Z3aKIZG0MQGwWKjfliBxwBknvjipvnlVlET29wMNJDAhBORgqxyd3BVuMZx16VU1qQW8EiKiSIkRi/dlkBPAO7II4PB5ySSPWha6A11LtiyW6xX8jOqCQDaNk3PfGRnbwTgdOwzxUcd7uyklzfsgwi7Y2VSvRsjGcc9c4BAxgcHOjuZWD3V2UZI4/NVN5Kv83AJ6E7VbBGB8x9OdQTefcXEKNCdseyTz85BLEk/KQMEEgHAOcdezatuLoKGVZXtxG8afLucIHJ54PzDGDyeMHB6cVJb2T3IhFvMzqYiocYcLgkAhujHnByOueuWFUrN95ureGeO5ZfkQmMMeoCkkBTnLE+nB6YzVmPUYY3nt2miESgjzQxQJg425YjJDEDIHOOgyBSafQPUZcTC1EccThQysCzqFCgN0QZOMDcMHuByMjNeCVmEhlT/S5HxFwVLk8D5sYOOeBw2SeQSBZjyfLjtxITKGnMabXDAPgn5gowMADBU8jioYDJ9tX7OjpgDbAqh0jB+b7m8FTyw9yDgYwA0J2H3l067I5g3nlYysJkwWALDcHYddrYz8xODuzgGrs8drqNtbzmdtzvuheRRmQDOeA+A3U5BB+UkADpm2Nk8cGEuxc24cMwBJOd+7aMZXOcjnDDB4Axtv2sdxcLsuplQLx5RhUh9rZLbvvY3Z3biT8w6ZwU9NhJFm2JnRA0KMkuIVBbMu/mTJPTgqTkk5A45Jzc063khhKsJlQujHypWRWyoJYsMEDDPk85K54NQBo5llIYrHGvnJDv2iIkHqQW3Oec54HGO9WbFTFZs6i4QPtZTLGGOdmWYkAgdCDk9sDjFZsGTQGNLWSPzDJ5LeXtEYj+UqrMM4wAcjBPJz1zisW5soU5i2xTFSZLe3ZpViO7GQxUE9+MDpjitHUYrqeVLcwt5eSoMLrlQuNrjcdyjIHQMeBjrkW0tEuLa282aIFZAPNdykjZZe2AVOcYx1JBxziltqNOxzckVxbs23ZNEnR4+/Tr6Y4yKdYwz6jJFHGNsTvs3HhR64z1IGeP5V19tbzQRrA1wNoUsCyLhfnJxgknAUgDnjGeat/JDFCkbzowGAFG84weD1HX3GSOtDqDcye0EFkFt4mLCJFjYbs7QOhI6Dqefb2q3C4CLuZSPuqxOd/p+NUIcvNJHMUZN5BXdvJGAQDxx1Jx2zxxU8cjPK7MrJFGSqlsDPuB19ecj6VizFoVyELGbBIwF3H5Tz8p9jk4/CsUf8m+eNcdPL8Qf+lN3VyK8Ms8D2pd4lkaCYuh5I4BByMnIxkA5/Cqa/8AJvfjXPXy/EH/AKU3dZVlZITItL09byAZgcJEjRbM5fYVxz7njAPqDXSSC005W8uNpXJ3mFAAzEsMt+o/KiaNLG3xCwidgIlJ+bc3rjPp39PpWLbPItrDKFZ7i6CqFDkE4zlgWGSMBOijpz3o+I9OUuZm5r13bbFtJ54453G7y+rSIcggDrj3HpVCxsvsyGNLkJNHGB5gUsWypVGPqB/OsuSWaRGv2Z7dt4VIypQyHktnIOTtHGB1HGau/bJHg/0t/KxJJEWA2cAnGCTweM8daLWQ1GysTazMty9nbrOyL5jAFeMkfKScj3IHPOe4qpaPumlu/Ihe4IxKd4K+ZgMAoLHGMLnvnkVkanqUun3jSG2uLtJ5IBGFhDmJBuUnO7kccdPvHrV6LULeGLdZyMxgLhI2Q4dlGWKgDk7toOfU4PNVy6aD5bIW2ZzNHcsfM1G3g8uOM9t65zIF4CljjgHGOTT44pobyBp7ry1itw72hXKKwXp5nfBGfUYpt1HvieNIFiKv50YRMqkmVA9i2SwAz/jTbhD9ga2jgcTRoXkwPMG4EMRkNnJxtPXn1FAJFGHS1tYVfUI0ljVWTZK/mo2G4I3DIOWbgdRjnqK2JYme/WOLLq1tGMs2UCE8sVx14GM568Dg0s1wscEb3UW1rsLyFJ2pzgbT/ENwB6evPSnXcoSK2toZo/s6JxO4XcoxjO7PTBbPA78ii7YNtokWWOWzaOAhJysoDyPviQ7/AJSR937wA9RT44fKnmurhFZsgGJWDPuIHXnAAqg80iSwqptobkEySLNIC2NvJQA4Bwcc4zjvVW4mktjGsdqrM25lHlqdjDnOVz2LeuT39VYIxfQt+KFE0FnBLOI2D7jJGxhKL3IPOCMjr19KzVuILW3WBn8+0jlESmSQo7DhueAH5IPA6GnrNfy3W7dPGHDK5k+ZgMkKOm0dOc84zgjisPxB4fbxEEe+k+xNaeYfLgHmboxhgeSPmPTjOfaqiujNIq2jN+5aS7Hk+U6SSRP6xvESexxkdjWfqTSx3jNYJJdahujk8qeZwmfu5XjAHuOD7Umn65ZX99BZQC4E5t/klmcAMiDOGAyQSByO+Kc1yLVrm/tyI4TERHvzuZVJ5wewJOMY6UJNFEviBhqNkbS0do1eTyk+zR7v3mA54IHvzx1qKUxyizsLK/FxqmnR7Z4JVDsTtHJJ6HI+8DnJpbK/E9kL18LMV3KJIgABkgc7sDqOe4qhDHLPaF2mm065Me9ii7bmRl6Y4wVxngH0PtTsNK2hcbU7iKfS4IXjiNwpme1MO7GQOC65HXuMdeaguxBZXdtBZR2a2M0jXFxGZlBWTPJXJHXkY6ZHarGp+ZeWLahEGjvGiUJHMSEYgj72MbTkdRgHvSXkCzWUkmsNBMRGsXkRjdGXYB8kY55zgn8PWkgLWjvby290kkku6FfKdpvl5BPBzwWC45yc4z6mtX+zrTBWyuij4y5xvLHBHzc9OTxxzzWbbPC+62j/AHUkiKUjkjB+UKABuIwSpJGazf7VtdOvprUwzJdsG/eCXzhtxnPByDk9Bj6mlZvYjlbLce/Q1kgikN1clUcGWQohPRiXI6424U9gOtSXVwLaF7Ge3AtXzDH5cbEqFYLgYGSdrfezjPSqthYvFDK88swnZchXJbdyMMCQQOF47jJqwsUjusc0C/Z4YUCJvVmYg/KT68KME4PHNDtcVixazCO5eO+EM9xDj7jMuUzhN4HQjeQfzPFSh4rl3/0ea3jO7y977iAcg4HPBABHXvWes0djGrXERtxFbk/NIWaTaSSMc5+Zh9e3QUtuZoks7ZFhifyTLEEA6ZBMZ4XjJIBxzSaFbUk120gW0EyRFFRMq+duQQdwxxjHv61T0pYJdS2zQRlZFBQLh9pUg5JzweTwB2zVyVzIE+1XKszqDGjAKWJHKsvTsCMk81lahaPHdrPayw4JVmiZlHD5C4PpyevrTW1jRaqzOxggJs23orT7+W6gjPB4HpWgqLGGdVO5v4R0FcNYXV/EWiaRkKuASSCOv3c8fnj866exu7jZGku+4YnDOq4A4zk+359aylFoynBotfDyJIfiD4o2DG/TNOc/UzXtekV5t8PHd/iF4pLgDGm6dgA54829xXpNZs8yt8bPMPjxDBcad4Wiu5PKhbWCDJx8h+xXeG59Dg14tPC0V1LFcYSaNirk4yT07DHvx1z+fufxlbYPBx2I/wDxO/uuQAf9CuvUjn05615B4thNr4juHXGxiqowwFwEU7SM44B6D616GCejRdLYh02+l0u7V/vxcFgevXkjtnHb3PSupisrO5htCsCmAPvWONtqFiRtcL0ySedo/gOc4Arirlw0e4HAxnK4IGe/vW94Tv8Ay7K8hmuFV0XbESOEBIIDNtI9+cY9+g6Zp2ujWSXU20QxW5hnV4EiZh52wKm11+4QWOAPMHyk9hxxisa91W3mcRySrdCV0ARCfMt2YA+aGIIcYGSvuOnObbX2+ORt6C2hC+QhQp5QKZVA3BPzGMY+Q4XqMiqBY29kt0bwpFHKolhgDZLgYzGclhgEd/mzgc4yoruZt32I1vFBTbAs1pCFZ41RQY0ICjhn7HYD04JwahuYFWITiCWKYM6yW4VcunmAY5JIXY+ckHnrmrBuLhonk1G6fZCu+XaCxBOAFCq2SSe5HbpjmqUbRppomtWXyGBCSC12PmMD92Svb7uODwM8dBaJZM0UbW8lsXSPYrjylbznYMQR8m0AfeAIOMcknOSHw3EkYhNshiO0sJDGV4GTxtU7eCQcdf73UnPUSR6iAxeWYyFgxRWfgNjk8A4yDngEcZxSzWsUVwwlErOimZY4MHy8ZyCoLBeARgnI44qrIV2ay3U8WUmm89ZDtYPiPI3HnO0FshieDnI6c5LbSOQwJITC6MyedbheoyAABhcqu5umCS/fvBaRE2p5uoo4SZHV2zGoIZghYjbuOTk8nBAxnpYnESxXDQTCXcQQYpQoLE7OCpA3DBXG7IB68nMPRlrVBdXxiCRhDLg7CF+XZt2nYQwBJH97ce47nCTEB3T7WYnTLM4Y5BHTcc8464OOWGc98yOdGW4coxeFg8bpIoVSF3KxCIOTuY+3GcHOLYuoUiK26gyBXcrISZFXHOD3HyjggZwORg0ONhp9y7EMyK8kk0Nup2uqIxZgxA7dBgYyM9sDNRSancGVXb5SI/n3/dY5ywCkgnkD+o+anWkjzwwOUG5G5Vdql0Kg8ZGCdo+o+XOMiqTKyp5SIjz7Tv5Ksq7geACM88kjIAB4xmhLuDt0NWKaBd+FDqwU+dEdrMhPBJBHpypAx79KZaiSG2l8jbNcHcjxs2VPJAbcDnaecZIx6ejY44RawhLMmeRtoEkgzEiKDyMEDlTk4PQY61CytNcyK00YUnduaJSUHU5Dfe5JJ+6DjgntNgRpCTaUUzxMXGY3dfmHPDgA4OSPmXAzjrxmn3KCWN5EkeMR7lVkkKsoIU9xtzkd++evSsS3/f8AlTSLvd0IjBwuAwHIzkZ2noMnkjBxWpZzGCENkM6oF3M2QCBlj3OO+Tk8nnphNWKSuSJcx2wjmnRbmMuXMiKygIOCSoGCB8vPG489iau6R50ymUM8yNygWMRpt5Crjuv3j1zn2pqRRz3IkmjiJBJR8M7jn1zkgcc/jxnixbyqLg7BkOyhgVA5C7gDwMYznB5HtzUN6aBZlm4up1nSKYSSAhmAiIUnBBGcgY6Y4JPPOetVJ7hLWWR4Y3mvSxKozFgd3HHbGGP8OTg9+aW8lgl+ZZAfm2hmZvvA7geMbgD0+bHB4qpALWWzijt/JmXdukcsRvfGcgAHktyf8aSQmi7ZmUXL3EwGx2YkswK49QnTbjHIyepPqbl5GsoibzJZZkICbDjDDBGeDg+9ZwO0ox2reMpH+rbYODxkHhQckbj3xnmolvZ4J4iHR/O5XY7yBgfmBU7MYOMYAY/MOfUtd3QrG1aXct0k0YgIVpXWSXdtbgcNwX9MDn0yOxvw5tlkliDs0hLMcBgMD2x1x74J9OK4+LVLs3KgXEQtypBCKF3kcnknCnP4n260uoW8U7K1/PBMI2BHmPv8v5sfKCp5JBGAByO9DhqKx18rJJM88ckKO2MHP3scZI/i46Dj096da6gsrI0i4n25dJF5XBz94DBPPrjmuag1MQRTRqpOzOQAAv1UKTnoMHOTjAqGHWRc3bw+SyOCMv54ZlJAznJyMDPTjr6YK9m2S7HQXes2yTxGKRGJIZljHVv9rg4OAep7D1ot2L/s6+MXYYLQ6+SM5x/pF33rlyQJB5J/0hT5YkClxjG4HlgQMgAkdePXjodIZn/Zn8Us5QsbXXSTH93Pn3XT2rnxMVFKxEtjb1W4EVhJBJAZFQbAqvjHBbrz8wC559arapPdiVQJTGdzbHV2C7WVuC3TPfGDzxjOKjuZogxa4KAj5YhJuZmYbAMJwWyWweuc9cGqlzYxW8ElnJJGbhgHG+feTtDYcg85OG4GfuD0pRR6Fkh0MzJLJJNC6W0amXcwZP3iv8o3HOcsz9OPmGKhtLe1smWznD3UTDEUkrFyd4J+UA5BG4HIzwe3FW7m1uZY4ZVimEkUsZXLZK52hyeoxwDwMce5qtLbi4fDLO8zIUl8yRSUU/KABkYLDHr90cHOTVykXtxtllt0jaGSZmjTGctk5+XGSRhifbvjtT8PXcZ0iKSCY3AjkaGbzclkBycjpk5C9c4ANXNP8+NPM2iRCX81WkyEVflyMAgHAHHXk56VTitILPWJZLYPbvMVM8YZjE2fmVhxw2ePx96kpbWL0Mc6iSWONczAyMwcsEJChCQf932+mahtnMqCRZPukTOHj2qoxhsEchvmxz/d6CpPPu1uoS+HtWjaWXeoUrg5Ut2PUYGe2exqtezbpYVt7DbaxjdG4wwf+PIAOCPkHvznHqAlqaMFzbia7VLl/MaQiMmEqiKVyqgjhuh5PWs6RJboNsXZfuESQ7/lkGRwR2GM47EjBz0qO4kKSaeEvBaxRNI89uYlkaTBxjcPu7T3z/I1avLqWE2ULW8CQSRnZKcFgQSSRt4wBj8aLW2Gl0IftixWpiEEiXsf7i4XPVVXg9eC2cA469qjtbqC7d7OCQulsy5f5g6qyNhORg4XPIyc9qfLA32Xz5Zv30mWSRcquWwASOMtgjGf/wBTbm2gigCXzrFCxIR2IIDELlQO3ygDgevfq9CrDtQX7BZxDD/ZoMhWecxkqVBDHPO4nPpway/tUsdi17eMNPklufmiLE/vGyBuwcHgKw6Dn3zWtpdzFqMsQsmSUYAZVO4MyKoKsxGQPunJHPtWZbzanLrU+lzwrHak7VcMzFSp3K2/POemOCAaEKKezH2kVvbalezTW0aZ3RfaYYdrT5yflKnI2jg1oX1u17dOLmEwweTw46g+35cHAqE2L210olYgsxlQopCgsehfb3IIwc9R3xUF3eXk+rrFPDJG0kcoSEAeY0YXkDnAYEnqe2eKW7ui79ShDYT3Et3O0to9pFEEePezSrIRhRjIUAZzx0+uauWr3Uf2WAtLtYbJE2APAcZGcdjjk8dafqt2lqzNbWsKSPFgSzQ42SspHznPPA54/iH0qraWIaC0uLhXN60AWWQI3llQeQM8g7BjJ7Zx2p7rUV77i2qSOlrK4mNsCbZwpJdsYIJAHGDnv/Op54y0rQXG6OKfLgxxsCec9ScqTxwD+FSeItW02wtZLqcK2zYVdFDb93IG3ruIPfH1qqXu0ghltGjV41CPFwRtLfw5GRnlSp6frS31KTvqOgmEqyJJGXDcZxtkCg9W4zz6VjatMtxZu9texH7DcMLjCnfHuPGCRz0xj1re1m6int0uBaGVljykCwAM7kArknjjH546d6Yki1INbNatDeXaGeSFolWRseoGd2Rk4pp9QTsXobm31TZdSyC7gEJeRAm3YMlkyc4Ddemc8dKivLz7l68LPHFCh8uNiJFLhh3+U7cjB+uaiuFnsY3tdOiS4kdUkktbiT5nXHPlJnPGBwc80tjdST3F1bTxSC2jHkMsq+U0jdck59MDjGCfTpNupFh1ndC7Eey1V4pi2VYrIyn7x3MD19OOMAVFefJdSJfieQyRho5PN+dXwPkAGBwdvGeSOKktIIkspJLNZ7eGOVjCgKEyEfMdrgcDAI545qeK6ivIrVLpljmYht02A6EH5Q3GDnt1/lRcduxTmuYXbYupKyxYhupWYRBpAQVbJ6nbnjJBx71q3UhKC3ETWsYjAEwwFUcAc9u3B61g3f2C1RoGt7aK2eQLNZRAOkJ5BOeMk5Q8Vea6uY2tlE0kh25ESR7UA2jGM5GPlPB5+b2FDXYLbGgIfNaXz1gaBCCoRTuD4ydx9SMVW1K7aYlfJfy4XTiSM7X5VgRjliCOAO9LHfi3MbFplNwS8Y+8AeTtx2xx1NZN5cqGlgljtrSNHSS1jaVlMoxliRk5wfwyO9TbUVr6M7H4WKg8ceJmRnbzNN05yXPP+tva9Rryz4Vf8jz4oIk8xTp2n4OMcebe8V6nWL3PKr/xGeWftATi20nwvMQTs1nIAYKc/Y7rHOR3xXA6XbRat5+nXN9IYGCGz8+MI4wM4ByckjacBieegGAfQPj4YV0zwr9qm8iA61h3ywwDZ3QI+UE89OPXqOtcToQ0UFYYLyGfzAyFRtAA4yu0HcCQqj5QAcfWu7DO1N+o6Se6OM1RJ9MvJrK6OWGSCAcMvY8gGrXhzZPcXKhIhNsR1ZsAqN4BK54+7uHtxWp8RL+0vIYJA8IugBuJXmMAYKgjt3+p/LkNFvEbWbaOWVwHby8q+OD7DqM9q74pyhc1v3OtNxcwyNBhpjGriE5BdU25AEeQSSq7gDg9SMjpiXauRGlq10BKiKmCTuzxu6YZSCCCefUHtfujC0AxLKquqrC+8bUx82xSQCDk4IGDhRxng1pGjXO26GwKeCw/eKwyrBwMKN24bW6An1OHHTUx12ZtI0E1kEnB2BRAZizj5wqqA7DcMccBgG3AcHOKplXtbeCKZoSYlCz7E8sl3zlmVRnJQBRlRzzwTxmTy26OskkKzryoC4GzIOGyCQew684yQe+haXCLAY2jjdJo9vlrJvHXjBIBLYIOemPmPWptZFLcjlj8253SQi4KIDJHFEJCxyMZzgnKgHBPJLcgcmK7tnntY13s8Al+6qSq3AOCoIznaucdM46ngXDdQbTc3kkazkb1RtxPIyGbcccdAc46YqrJeESPuW2f94UjJUkdeWVgOcksCcjPPPcibKUUylDlLhYik7gJ9njBlICkHaADuxx+BIYHByctkvoweXaOSKQOpIYoAWBwx+9xjOcHPtxSTyTMIjFJFscFi8ShAWZueSMtjJXHPHr0EGozXLOJZgsq7FRn2lFAC/xA4wSOOPU8E81otSbWNg3MItiH3LHOVkzF8+G2svJZgxGMe/cj5jmrFDBH5bbQyFy4aWLaigcq3PGPlLY4PYDPSrHqSiJYlQM8bfvFQhMnGMMpO5j8vYjtnpU8s0EaMix7cBJASzs20BhkknGM8fd/vccClZopx6o1rK9jUQMvICr8pwCCoU/K+4r05OSMcfQTpLAsMssEisqjdtjVMEAhskZKnALY+n41zdmkwjZgQrONgaTDnecnnOcn5eOmfStiFNtqsdxFcRjyRl1c5DE/Ng9gAccAc5z1qZRSJjfqTLKzC3MYj8pd2Czls46bc8t8wGASCORgUq2klzvaUOiLt2+YmdwwD0PDYCrx0HTOOaQRK803lMYwHZU/f73VueATnPzEgZPr68S6pHLJbPCschZF+8CGKncPmYswPIGB2wG59YvroaW0I7H93btLHKnmPnfOcngEfOoUjqMHr0J5xjNiAJLF5kcklx5i483cpK4GOD1GADk9RnPHGKFnYX6RrveZbZJN24yOSeTkAcHfnPQ46dxmujjtC8skjh5VBAQ8jHJ9zz059velNpdQim+hHbzES7nCjEewK4DuwLYXP5D6frV2O5mmmJkDoqjC/Ny2c44I/Xn68GqX2yK4YFMnBznoPbnrnvgc+uKZFP5gnkkO1HYlWZ9oYEDscdCAMdDkHrWVr9DSy3L0tzGoCSHYeWwVzkZP3sZ4Pr79aruxuG81JMqFA8zDfLnJyoA98dsDOD6Qee/ktIrPvyDhmRUVeDnnjn6nrUNy8ykxiQmPPyshQBTjOMf3cZHPPT600gauaFufshIj+ZgcHklgN3APU9+mMfhVK+Zhagyb3bhy6oeSoJHGQB1JxnJ9+lU47iJFfEkTqgH7zjAGc/dA479j1HfimSK8SqWcjfGGaVVPzALkgk9d2T046DjBq1GzuQ2noX3aK9toiok3OFDkIUbOehwpIOcY45xn1NK94sHlf610ljWPMTEqOx2sBjAwev3uvAzWZNKMmOSOaCJo8uyqEEi4IIU5Iz1GDxgjHFR3mYAqXCj5V2M+7czE/Mu5Rntg55HXvwKUTM0zLPC8f2mUzq+fvNkLsAI3Nu2kfMvzA8c59Kmkjl3RiWOSNhFvKfc8perKfm6jDYyCcAf7WM2KNVdBJ5SNEn3ggcDDN8gOQvOM52+g5qz5Sm8hdZdqxkOZkBDIdu4nd0Izz0PJPvQS0THUrgK0Cs8NxKwPlhQxb5QrAKBwQR1AwOenIrrNJYv+zR4qZiSzWuvEkjBJ8+661xjrLkSSym2LlykZ5I5zt27cnABHdeM8547HRht/Zm8UDJJFproyRg/6+69h/IVx4xKysZy2LN1JLbXKLG0ayTyv5ZVWkCruQYJ7Akjr06DpxVj8iRgs93JJe+bIF3sR5ZYAMSDt3EKCeAMAcYJqC3s47OyH2xo3uUdXC3EoI3FzsAIUlcbWI545FXru1gtprZLyUTLKJdu7K7zjdyR1Oecn1IHtGiPTsXbaCWXTDBFO/wBquYQSGl27wTlnAGcHkHA9cZqW0VorUJeZluRKkcJBw5bHB5PXqSM9KyhtgmhERV5WMZkJOAxCjaFJOeACcDP+GtcpugV7S4eGBoX+ZEw8eeSxZsY6dPzqGNppWIWe3thboiGSWdsKzgE7WIBwDz1Ck57moLPy7q3WaKOeJCzeYpHOASSc++3AbPGagv76OOC2kuzK4gkTdI3Mrxno2FJ6nH4CrccBt4Z1jVf3ClolZiQ24E4K5PJB9PfFPoVayMq+ifTdPMsaPexW8OVV2HnAsdpIYdgAoOOPxphmursWkcct/aJcQpc7xGrCMrkGInqS3Xnk4q0SZdXs73UMQXJjaJVjmAWJcbircD8/eor20iOq6lcFJbeR1VBNE5zLxkbRz3xn2B9cVV+5XqXbXzGvmZ7aNJHHyKrKSW25VsfievXb9Kzo/J0mG5aT7fcA3J43rI8LNk/L22jjjnmtq4sUggs7O3T7MMBxKkKkBgOBk9Mcnp257g5MvlR30k8aRyptJ2bCBIWVeQR2PHIxSTuJK+pf0qaRo7maKCaKJJGiZbmNYg+3ncvGSDnrn16VXvYbTUEij1C2aJZ5OX84Dyic7Dn1bA4Geo71Zu4b17jdJidgQVdWOyPIAJwSxJ44GP4uvWoGklypjbzVjYEsGWYH5idwJ6Mc468dgKXmhK72Kul2VtbWlpb2q3SKJWLbV2lyVBHPBxxyMc98Yqzf+Va6P9pN1HDKkSqXRS7q+duCOvfGKmvbkWrLJtuo/OC23nLGWLSHIzsA+XHXPTkUakLd1s5FmEgUkSMGC+Y3QnHHIxnI/DvRe7uyr3ZnXUc1zDDFcy3Mb+UZCzqMKxPGcnKkgfdA/E4psFq6z3byq1t9pbekkTYJZgAXPH0/H86qeJLrUbSaIaULiSLyNguhGJXL5zhjg8GrE8TG5EcFwkV5OIJpAjnDKgwyjr8u7AAA9TT6FJaBrdtPJp89vIbidIo9ymKT70gXG0HqR1znPWp4rktY2zTRSwXCYCN8pAOwZXGQQSpz1/h/Cm2ls82uAxoPs9oHEczyZTcw5Dx/xdR6euaW9EFlC7qsUdwjuZpI7gExgspAI2kKCcDaccD2peQvIkeRdUCSBJ4Z2kQwPIuFmK7sKO4B5/SsLSHSfT9Qazu540M5WEsm/wAgghWAbuDkjn0FWxfKl/qb2l3PdXQQFLNSVQunB2Y6A5zxjp3p8TXsFyJL5xHcyYcQ42rFGAQz+/LZOSMgH2p7DsaEe1WdLyMPFueKPCZJcjk4HQkKxwP7w4rPaylntzBayR20hQ28EgRQ6Z6yHdztyduAe+eeladjHcG2tpI7pHiQfeX5sMSCC/TqCBj0qtLmPzSZN8kchTYSu5sYPUEYPI/CpuK3QyYrGJtejurzzRqEUUQZGKoEK/LlQMkKSM9sZ96k1W9t7bVoJLuaVFugI0lAMqYJ68HC5wvQN36Vct022FxdBobP5doZeFL4wMsQcrllOe3I7c5TvcQ2y3fiSW1sJGDQPDCwBwAcZUfeGG/DIIqt2Pcv3cxVBZmCE3zKyrDdXO4HCnkAZxnt0461QTTb7dZ3t0GYpatHJbogyXLOVKH+HoOeMcetXG0mLU4d0qCO4Xi2vUDE4ZCSVDZ4AxjPGCec1P8AYo0uo99x9pLQeVcyEnogI3Y6Bgw5C+o/FXsK6Fnmmubu18y4hiQqsgWT5ZGcg7lcDjrjp71PNdjyoDLGf3zbPLLfMOoIBxx+Paq0KGRrZ5JIQESTd5pO/crZxyMnH64zxUEkrCN8PGbxmVpCrtskGOdvPB6c+1S0WrPRCX0ssEE628/m+WzFoYFztdujFmzgAMPlH8gahms90ZF/bwg3CgI3Ro3AwrcD7vTP/wBertzLOo+0uZHi+SRk3bTGcYJLdCAM1Bai3lvIJ2ZnSOMuskud8aK2AOT7Nk9/bpRfQnVHRfBd3fxZ4kMkgdxpunBiuMZEt5npwf8AGvXa8j+DO4eL/EysI8Lp2nAbO48y86/jn8MV65WMtzyK/wDEZ5N+0WgfQfDKkE/8TkcAZ/5dLqvEbtYyByAcDGD3zmvcv2hFDaP4XU551nHHX/jzuq8vhksjbpb6mgkQthZ5XYtyxLcjLZwfZep5r0MFK0H6mlH4SvZQf23ZM+oiSWVTtScEAkZ6knuO+T0PfisWfwzcReVdQlzcRHIjCHeACeflyMDBGc9QR7V39jo1jpwuTFIq+aocguGXZuGdp6ng4PGOfQ8ZOtoYrlY5IpzZxIpRo4lPlyYDAHkZwCynBxhhgE8DqhU1tEcnbUoXeoLdNeS3CbRNvcwyx+WUYoeM4KnleB15HTu1Ss8UYlmC28ZBchirqyg/cUgZ2hAcYPQDpTbbVA0at50cN4oKjFvgOhAC7geGGQFIJyMnFV2uHuZfsd1bRWsw3rDsbbskIBBBbLKvy5wO2TnIINpW0M99UW/9MuYLcwSwvIib1bzPLZFJwGOOOCeAMjr82KIbmS2lDTlJVQbAXiyXxlgBg9Mn6bmBGT1mhbbEsiearPnzY2gUqrEqyt3yODySpUjnHNRanPKbApjaZGZEb7zNx8oyOoI9iM4znrU76FpLckhmRb+eaGd4beVztRW4cD7pYZAxgcliMcjsaoyErDItoqxwvja8pCkZwTw2Sc/Ln0xxxjMFs0oTzFjvPNkYhQWEnmK3faRhyQT8p7EjJAGNDTrUGAxXO5JopTkNiTDkAbB1yOemc5z6ZqmuUUbsrXUl3DcTuYVXzEIXahiSMoTlSQMDBAyDj9BVRbdpZ0jRW6/KYGbOSQQw+XC4Oe4B7E1qX0UEtoITESVJ8wBQAuMBe5PQAAHB4A6YqK10+N7RSI5QGZJGC/MWYdD0yBz7jp6kUlNJF+zk0YphF/IbqSWP7UOrNMpAYcDIAHB5HYDIOcVLb2pzKtw4i2MSI2J+Zs5AJLDuvbP9TPBYxoZIY2m3Nlidu4KuOOe/Q+3Q8kg1Z0e1e123EDbyUYDncWTcRwoyDzkdT/jblpoStC/Yx2887AKs0jsZFYuv7tj8xABTnJznv8p+tWo45JIvs6RSncxMmxiQTgfd2jJ69skke1ZltCWEUsDtgqWu5g8eUwG4AzgDnGBgZ68jjZighMqzCXzIUBkV5UXAHKtkDoBjI5wCM5PNYy0NIiwx3KahKJZB5ZAIL8sQcDBxnsRx3wD61faSGYCMqksLYQktgMPoM54/Gqkjp5TTGNgJCBkoFye2BjP59M9OtZ95cSfaGkeTy7UAgxo4XjIJJz19MDn09azs5M15UlcuTXDF8xl+AqkynDBRwAFIwBwRhQQOuOaiik+0IjSxCSSUqxBi2kkEYJI49TtA+X8xVdRIYQ7kuHRYzvQFyAQRuKjtg5z6fm6RZpdrIwiYlmJAwSSec4xx1PBxk+gqrJEJNst3ccYBmgwflVXz8z46lSR93GRjjjJ9TUUFvaqwZYIDLGqorKm3AAPIySSeW569qbb3Zl8u2SZ2yMbuVP3ucZx0wf5+tMNxGJWjO0RA5HlcFvr68n9PpS12LUVcJ5XhgUKiiQZQ7XAVV4yMNnPA7/h7MmEhAcAJFhY2+VZERi3uMN8qjqOBk08SrcSBIiJN33fNA5BGCc8jn0x61XkceTJblALmXiRYsBX7nJIwMem3n2qokTjciuWYKjBkBHzCQsG3KVPQOD1UjpgeoPIFfUri2gaKOLy5Q7LkEbc8YLNkZ5ycbiCAw461dWFHhuGtO7IHkbnCqx6A/KpPt9MYPELxqr4gC7HURAB+WUsBlRgHDAkYBweR6VpFoxmmtS1dMbZ4JPJizOiyqVlwWzhgMDockHdzn0GacXlmncMkshiOPNVAAUOD1bOOvUHBziq95bxR20S3cuyLG1pN7SDy9xYHAHzYyeP5cVYWYGGZgjOxkxEpIPA525UZ4yRgcZHfFLoT1sEFkJkmhtjLJEiGPzAcbgvU4AxyMDgZwAP91RqSz332QlRahhzJIgBJIzkA4HDM2RkH+cdlDNqV2Ujtp3mRg4ATaVUKuTv3HAHqePU9a2Gs0iRWSKaV2YOu0sF3DpkdAcnPJIHb0pSaW4JOT0Jo9PaRPkk4QII9p+XHHIGfdiDxzgY456LR1ZP2ZvFCyBA62muhgmdoPn3WcZ7Vkw6S1tPKsUQZHVl/ezySBgc5XB4AJx61tafj/hm7xbgYH2fXuP8AtvdV5+JldIdZWQqF7rbCfsSWLM6AyqxJdQ24bcc/MGOSfw5pJ4VlhhDmJrmcbvlRXSNc7iSTxgnHQU63RG09CrC6baF/dpgFZecnAxgkEkjpnmqzWjoTA8/kjG0iJC5iIYMASQeoYZxkDb2pHoJEhgkjeESPhbiULuSFtyrsy4XHzDpxjjBPGKtyEW862iJAhdmdw0xJnAJySW7Y2n8+KigvpbeC4EJEsEGYzG0oMmBuOeOpIxxgd6j8yAXBEiuZPO+QzDIbeSoIABx1bnjtnigEhk21y7+RsjkV1kVXOcByu7APOSfTuORU2oSwyXc+n2f2aO4RS80W8AgEg5wcjpk/0qbTFlRrWOZYYY2LK8rEFQqjIJOMdSfzHeq9/potPEVzMkAbUJFCyTKoZTHlccZAz1z9BjPSjqCetiOPT11PSY11G2lV3yUjd2+VcghGK9egzmlggntLcJaRxHFyg3bWZQmNpxgclQAMn6Zq0qyhz5zZCvGREh+bgFgM9PmOOPf8qltdCNGuECQRsJGmUOWVlTbuO0DIIG7IB6+uaNSrk2qQNpD/AGq4vZHsZI4kRXYlARuJbrktkDkdjzmq7WMMsKyStmJCdpMQOVcnC+pxuyMdu1Q3LaXq2ixRalLNLBHEbrzFkJWNFAywBG4ZB+7jg1o31/YQNZxMFt0ljQwF5Qq7QcKeOSCDnkUaii7adSmXlmVv7PuLeOdZsyRyRk4G7rgE4z688Y6VPZaa1paTRWsQjtkaRoYiu1RlgRxg5wSTk9/bpUy1zLeLPEi3crYRozndiPnII+6SCPT5venK0k9s8Qmksgk8ZjljlA83seCcZO7t146nigp+Rjlkacy31uYEe9byHjnk+YupD5PQclR2Ga10tYvMja5lkaVAPmxgRu+QfunsxOTxz70yaK5aJ3exbYNsoG7YY5FbGFHQKV5yPpU1/d2NlJJqkJV7drdcoFJYxKcFevJ3d8etNu+wErW06yokqb5FEfneURiSMbiyjPJyDjnr+dVb/wCyJqNlFp8d21vHljKsiplx03Z4OdoAC4qfS7uB9RubeRZB9nChxJFkKHAMao/BI6Ajtn8atGVZ1DBUccfufK3FeWJyMgAcDBwanZk3K62czrHBeSC4lZhIzI/CnoDjsPl6euarXWk266hPcRQeXd6gqoxeUjcCoZnC46g4q2ohms1t1DqPLO3KBvLG4bHxjJI7DH64qBtUNuEh2RhwiGGaWTcNp+Xd6jPAwcHPXnqJvoGtyhaRvBqUIlnLGJAZnYANOOzZALFc8YzjgU3V1uZdLa1+eWSV94hmkEbSZbIRWPB425/IipcyQ3lrdQumFmALzMIWaEKA7EHoe+ODwcDFZkqyNqsb600UljBIHtbhrgL3BwSM5yBnHeqS6lrV3ReOm3P/AAi1lBeIEuZHkEzRybfK64GQQDjoatW0mEYzoSsDLHFFGXPmADIyefm6ZPQ1bF9NNYRReR5LtIXeXy8KQw3BQD688n05rGVVaK5uXtYzDEGjhfeDs5BYDJBJyD3zgYAqVqtRK/U0r50mSBo50kEUjAKWwVYjGCQRx34P4HFQ6vo9jrM9rA/2ZxbElVkkcN02nBH3wNvU8/LWcIXjtZJtJVJmkP7rz8eXIzAg8HknnGD6Vq6ULi3SNSssf8W2VGPVST2yBuJPOT16di1tgkrPRlponiZRay4jVwkMcatuaNVz5ZPvh/qSOaY8Q/tSH7RF5qQ/JEWh3sozu3NkZByoHGecGmteFrCXzLlIocNHLcqRGFYkAYYng84xgHIPSqdzfRqhs4NjXTea0MkjpIQpGeAOnUgD0UZpWZFrsu6vezJeyzl2kaNgqxwgElCcFmXjp6isbWZrW5v7XTZLydG3eYEt4uHGTkZJ6cEkEfTrirlnYPpOjbVZZH2mWaVx5eQV7Y5BztH4VX0i11Moj38tveLLlVeBWQwjvyBjp68k8ZppJFqyNKxguwmy4MQuEYlSfuuoYjB7bsc4rKuTbi2vVdbQ3KSY2xHHzHnkEjrg9CaZpdxHBNcyiNVnc+WY5flyowC5OeTkZ7cVMySXEkX2m2TcHVQwGAxAOGXGe5xzj61NrMqzOi+DRc+NvFhdg+dP0zDYAJG666+9eu15D8GILu28beL4r7eXWz0/YXBzs8y8x9e9evVjLc8ev/EZ5R+0Q5j0PwwwHI1kY/8AAO6ryiOZWYJJGQzjIDcEj1r1H9pLI8N+HCCi41kH5+mBaXJIrxm9ljhisvst891M8YaeFkH7hv7qt0xjP3fQZ9u/Bq8PmdWFjzQZu2tze6POJrF5Htz8z27HKH147d+n68irrn7XaLe2LMVbcksLXLhG3bfkIJwGy5wD7YxkVlWcpkhIfBPQZ5qbS7kafqoiOFt7tvLdvQngNgnHBP5Ejmunz6iqU0VbeGRhLDboyM0bEof3jvtUP8pAUnHJx1wx49Xidbx1a0aKQtH5kZHRG2jIU43LgqemB1IU9BY15Ps1zOzw7IJZWEm2RhtH7vqRnC4XGevJzkNVV3RIxHvlhkQhBMm1G56rtYhQORg+qdTw1arVXOa1mTIY5mkk2wMGUMwUrhWDBQMjIBxux05zwMA0y/v1keJY7iK6ZF8xRNnzfXlhgMDgEFiRycdOX3CW0kBeOKZZWACY+Qp82QBg4B24G0/7OPaltljjz5k0iyqFIS3ChPmwc4HYYHAwQMDpSSTLuXpLa7kWaBUAJ3BY3ZxhMjJyuDtOR34DcdCacNPnidr63j2Qk5+WKQYyeATkjPzbcHggjqekv2cpeL5NrNHuI+dAGky2AzbskZ5Jxjn72R1pmpQ2qyMjFHuldpMI5LsxGAFLg/NtCjOedq5OC2Zv0LsN+1jyUZD50i4d9i5OAvLgLwqZwM4B+9welMFwZr0JNbJldxeEsrk4bcEKg4GFHJYdCMj1fI0kKzz+f+6m9CgaPJBbaxzyWJGcnA6Y4q3aWrXK53SpDIySNIZd24jJOVz0PPp244xSbSVwSlJlGxtnaJ5YnglvN4ZBKyziJAG4LgcEnaQAP4eeoxdj07y87S8TH5wjqxDjjGATkdB0GOPyEuvKtIUkDyzLIAiGPB6kc85HXqSCc/no2+FiQoBC3DuVVMHgZyDnH8+OoqZSZrGCSsNgtiluqzSyvIwBAkLyMeuDhjzkjpwOOmBSQbmDxmJZSyHHmsST9OOBj0zjPFOmVCQXAYuMMVPr069P89aa0geNGAAC42jA+XnIIyOP/rVnc0Uew8KZSIim4FNzEcMOnXv25PA471BFb2sSiA7doOdj/MXJHv178fWpDudSX243cM3T159T+dU3nLIqRIwnAy2W346/T8P1xQirdyWWQRrmJIgq8fgO2P5fWq8MKSQGMbsKxwBkc8c++MdaP3wILrufJAHYj6dqCxBIkcow/gxwT6AmmOyGRWNvFcySRBGcgMDtU/N3PPqB+vQ1PNa2+8yAqqno+c8/T8ulQhhBsEjM8Y5Yk89c8kCia5kZiMsi/dUEDj9ad2wUbakctsWmMqIol2BFZG5Iz/dPqOOQD702HcoeZFn8xBl1kBXcQO2Txxn6+tTOyuDjG0YyWI49evSgxyJGpmwrk4wpAOPUAEkdev8AkO+guTW9xluhZcyxBCi7gH+6nHHYYx+NNuLNTeRkRwsWKBAAPvAgA56nBwSeD25zVl2WKYqCsi4w29jxntjPP0qxEySSKInKxOvzM7HGPxzk/SkptO4p01JWZRSOfeA8cqearN+7Ub1yAfvZ5J/HHc5qSOy3I6zTLvySpKM0u713buOM9/fHODaRIiWc7Vbopxx+HBB/HFMlOxMyAY24KqOCffFP2j6ELDx6u5OkzlvJtY2EO8kwR7QDwOWxwcADAOcdK3jAFAlYjZguq/h+ue1ZNjJujgZgEBHA78ev1q6WJhCGPbGpGflAxjHfoOx/zmsZO5bglojS3RPKkLbeF3Lnkjt+HX9fSp9PAX9m7xaFGFFvrwA44Hn3XpxWVDeMskkAnRmb7oZuVyMYHqRz7Z9a1NNx/wAM2eLMAgfZte4Pb9/dVzV9kcuIVkiS/V5Y4ni3KqPuXdwU3MSWHvg8Z7VGsMEziLUneJ3ZljPzI27ccAnp0APB5OaiknEl5OkkjQWqYWRinAjcAYBLcEYXkj+dbOn3Vt5witY7iK1tmZfNu12KuCeB6gH1Ixx9Kb0R23a0Mu9WLMsMAjVgu3IC+aGHR+ccYJX8D9aLto45YGEBZg7T20W8qTIq8Bsfjye2K0bS2mudRm8zy0hiVEGxG2P8wZvvHDdDyP72O1Vby/a2keN5JrdbyUtFKUQ7QEyQAc4AxyfU8UddBRlfQyZIHNnDbaescVnG7hnc7yBklgSe2O34UunGW4uXjt2IMzMpNuC5TcoK5OeBjkZB68Vet4rs+VdWohgtyys6sxRkTILE46/xc99wrBu7bXN8sGlvbnz2/wBMuGBOChGM9R91h05PtirWppdbHSy2kcWoWc7wXH2uFdzvk7BlQjYYY3np1xjr6CoTKLa3mht51EMc2x4mkIYDZyQAAd2Qx69yc46ReIIZ5rG4jEzRyyrvRwNypIhHAHXccKD9fas0Wlra6p9sAEV/qyyRy7WbDsqfMYucAkHcD+FJK6M/U255oIi0MLi5muFXzpljXDqeqkEYJCgkjk4rnPFGiT3s6Xcyi3t4snnGRuwcYJ68njjpWk4S61O1mijlJaJxmQ7IUzIADsPLNnHPQgYyaskZtZ/tENveXDwxy2ok/dvKwxksOwO7ABxyPfNNPl1RUZcruRPDN5mgeS4MO4xyBTj5VBfcO+X8tRg9OlRWjR3VrAsC5k84h5Chj8qTAyp5z6fy9KbFLfzwQXNtC1owXMlqcGRF3EZC5zjg/XPepriZriFpP3LB2+0kyRNGwODsO05LHKnqKRW3UnhvLqS1nYyo644XZk9ewB6DD4z1GOe1RWcz7riyeyWO3tpBFBM+FWTMhBBGAOOuO9RXdwtrZpAZF+adOIi0fHy5HUsNuc4wODxxzWxcQL5krRS8eashW3Xbtz0Jx94Z5z7GlsJnPz/aru0/tS3jSzvjatAvnMNv3ww+TnOQSQffpVLWAgs2jubn7CkMYlWa3XBZ14xjIGMNwOx4rpbDTLJ4ZLe+EKqZQFUHbggYUfXHaqetRJffaLZlSeIY823zgBQCvDcDPOeTx+FNSVxrcoxadeyaUGiD3ZLMFmlY7gVJIB2NwCVU4zS2VratHC6PMhgZy9vIG3RnILc98AnB75GelO043IsrqxknWSKZAu1ZcKCWGFwBknC9Se+MnrU9pb3rpukR2UsWO8sogymW2cEfxYJ//XQNtmXpq6hqOg3zXTsrxOURGtxsl3A5BDHDAFh83XqOeKs21lFHbWgNtHALGMKEZMqZCTzzkgZPBq/cq5gV5Fnu4mtjueQjykjIG7nBJbjPueMVBaXCu0EzgTGdAI9zFQUC5OFDdRgnkdARSvcSZFYXCTobW4luzbqhJm3uvzDnABHB5AVu4z6YqhqWqahqGlm302FTBEXcxeYW3DHI5zjHP51NJKk7FjGSVK52odkiN86KMryByCAeOPXiVHtoI2nhKMy8DCFnLDGMLgDd1z2z6dKdralLvYtaMoXS7bHz3UqYVNzFVIByPwINQ2thaWemiIXYEvml7hN7AjcNxAIOSwUcY4HtUktwFmjA8x7hXY+dcJny15PHfA3EDHriktZY1UiWYGEPMzEMDvAYHCkHJAI54wQeelTqJ36l291CPaYUmWGIYbIUv5akMSWzx/C3fr1rJ1IyRTHyLbfAuQr5Xdb9AMDGBj8e/NaDwtqCiKFYYSzII2QkN5fIbOCOmc5z7cGmavpRGiy6vHd3UE8p8oRuhgZDuwH2nrx/P1oVkSmk7My7dZJVjSJg8rqS3kyEnG4Lnk4zjk9e/wCGjfTyaTfGaKArNKCTId0nm8+mcA8AnA9KbpscdrZQKbnzL6RNxwirjJ7dBnj+dXbG4zII2uVaUFgh3F0dcZUsTn5uR0I4P4USG3Z7FG9kmxCZoLfzLlWM8SxAN5e7arcD17Ec+oxVTWY2APlSRQrF82Ek5IXBIYY7bkOM/pWy9lcXRMsggSaJVQMuCkxHOeDxjOAD6Z71lTF4bf7HJHCUJCvbgF35BwS2TgfL1IPNJMUXodJ8HZJn8Z+KFubl7mVNO05S7ptIHmXhA/IivWq8i+DMxl8ZeKsnOyw05OoPAkvMdPbFeu1hPdnlV/4jPJ/2ik8zQvDK4BzrIH/kpdV4/wDYwAvHyr8qj0HoK9d/aPuoLLw94auLuSKKBNaG55WCqM2lyBkn3NeLDxToZCt/ath6gfaU4/M13YSVoP1N8PJKOprxIFjYfMM9B3qHUnwEYNghgFI45/z61ky+KdF80+XqliUycZuEBPUf3v8AOam0/VtFurpTea7o0VmDiRnu0LEDnhc554/WupSitWzSU09Dp/EEZiuba+mlZrW5geNIsjC+YCHPOQTuKnoPuDnpWJGJ2nje3U20m/czMxILbjkoccKD1GP0JrZ1TxP4Zvmiji8Q6THaR5jkjF3GAMKArDJBOMZBXOcD6jAuvEPh6CXfb6zp0skpDBTcxjJA5ZnXBOWHQlTk596VOorWOeSV7mmjssTpdpCyhlZihbBGd2QysckHcBuxjOT15nF1HF5yQxwlDLtlYhGxnO1ySAcYx1OODgDIrDl8RaBLIk02taaN8YSSEzx7Spxk53Pgg5IwM8AZwau2Gs+HfKLz+IdMZ2DF4/t8YAYE8K3ynnP3gAep5zim5w6se70Zs27S3CQzRDzAzKx2xqjs2NuB3ByCN2MgbOxNO/s+I3KTalCkcjAMkSs7kqSNxK9duWOCSq4I75zA/irQIyGGvaG7F/lAvE4CghMnPOOSWYnnGB0NZja94bN00UWuacgVg29L9Y1bKjLZ3n8evPp0GaqLuaNJnSIFhRtkZDoTFGjYO1cAY3gcr8o7DPHrSyJiIvsljYDcdsYLEnvgZAOTnnPGeOtZf/CU+HY4fJi17SESP7jpdxAjjGRz7n/9VQp4p8PI0h/t/SVDsCw+0o3fqfm9PT36ZGI5kaq1rXNO1gw5e4zIpUmGN3LeWAADjoN525J28Z4xzUksjZkYL5kbYKoy8jg5445z3PvWTL4w0ERIP7b0h/lw5F0g59hn/P61WPinw6ySN/bOkhnAGVuUVjg8AkNnHXrxzRzJ7stcqRqlp/tS7Wcxjh1C4744B/Hp+Zp8/moJNqDKkbQ5HAJ9R/njmsGbxholu29NasJArDJju1UlQCRjk5Ofp161nDxjpHkSoNU01Gchd3njIUduOD0B/h5HJIwKtWfUmVWMdDrZWf5QzAZG5lDcAHrn/wDUOlU3lCoxjLseVLL0YjOeAPWsG88SaIBGBq+n/acgM8M8JDbiM7iX4x6j9OTVF9b0BfMMmpaeFEpZna6WVn+XjhWxt9QAfc1cVHuQ6yR1UV2WYAxzZZS7Mq8IB1JxnHTjrnj8UubpHgSMsS5Od6yeYeBkgDqDnjJyT1wOtc2Nc0KObF5qWmSSkLJ5i3ySZfuTjAHcZ5I98jDzrGkmUsuuaOQcLg3cY6E5OcAgHC46dT6ZL9zuQ6zZvJqYRyiJuJYBlKc5z0G4dTjgY5z0PWqrasyzHeiB8AhvKKlSORngYPfjj8az5tf0YwJGuu6a7ZbzALxVLj5cMX6Fhlh3z1JPNMbxRpE8En9oavppjVSIF85HKybl7KQANpPzY7dCc01ydyXXZ0FqDO4aMK5Y5YrtBb1AOepPbqalkljyux8kjaiFgCzenfn6VykXiTSRLBHFqmlJJje8r3CNjneAGOBjnHYgjnikfxBoVvHi31axQkhTtuBIHTnIOW4GOMc54ORnhOMe5ccT5HYxtHJIqb1Z1YFmB5XOcdfpUkhEhlWQAgLncpz9Dg++e1clF4ksBfi5OtaQ0rZZnNxEARuOR97gkc/jjnrWonifw6Yw7a3p+XJY4u0z7AgsBnnkmspWXU6IVFLc6K2kEcJKp5uBwFbYOvc8/oKjkjMs+4eU67ssuQc8cA4xyPesSXxXoC2zwwazpZ3feDXaAHscHdxn1H/16ltfFGhxqG/tnSQpGQP7Sj57YIJJ6Co5lvcu8e5tC5EMkZacxANjOB/3z0+nQdqtxyidUG9gyndjHc88noe3euePivQHd1Ot6QBjJ23iDJ9M7uf0qeTxV4e8nyz4h0iQDBObqI/lk4/MGk5Ilyj3L8UcsLPeiRjEkgJVgHVlIzjGO2O1dVpUiy/s0+KpEGFe115gMY4M91XDHxRoGAq+INLG7AXF7DhfX+IY47D249O30WSKb9mTxPLbyRywvaa6ySRkFXUz3WCCOMEelYYhppHLimmlYnkubWz1CV54LUOrhFfO3zGPzbcY5PTJ9ugqza3TpbR2zQsYmXzGSZRuSVypALfxfeJz3PvxXO3Hi/wosqzf274ea4JDyH+0kKEA44UP94gn1AqNfHHh2e7lnGveHmaTZbn/AImKRlQpbkliBjngr/8AWoumdDcDoZ0W2s1EiTPZeQ4bzHG/ahJw+Tgg5wMAde2Kiv4LSa0trK9gkggKlokKhtgKkYwQeV64Ge1Yl54t8IzwrI/iPRLtXlkkZ5LyEPGOQF2scnjGCQfpTk8Z+FX05/M8SaEZQGABvIl3nBABAPA6fz44ougTW6ZtywwyM0aW0yh0jiiKgBh945IByQc9Dj7vrirC2my/ilWZI/Ki2TM6hfNLAEHA6kHH1yRXPS+MvC00sM7eJtE/d/MP+JhH9/aO27OB82CcfrVEeLvB9rG3leIdKIMKSRhL2NcFSWCnqchcDPJyMDmi9x867nVpcxTQRBpGEskkgjAOSqup+aTI4wCvTpkD6sis4IriGNZ4C9vEhhfbt3PlmZlJBUfxdOgBFc4njDws93HcReMtPQi2jiCNdxBd+7lmyeSdoz6Dn0q/r3jLwhPZwwaf4r0eUybuZ79NsRIORgtkA7mA7DPtRdbEuSTsXtRsUXWtOnEro1mjlkLgbxICFBHpuxwOOaZJdFNNj1Rre6a8uEhSYKudhGedo6dBn2rm9R8aeHLGDePE+lX0toPPMMdzE3nk5+UNnBwSMAHgIOKvaR4o8FytHD/wkWjQIiNIzT6jEMSBgVwc8/54ouVzRSvc1rSFI9ZVpZZpbuQuPORQVjjIDBGbPTOMYBpJt0tvBHDah1lWMzGZiAoDYxGxPBB5weeRWS/i/wAGpqCNB4g0VfIEiQzw3kcZDNwTjOMc5yQOnes2PxR4etl2Wni7S5Jrq4S4Zpb2IBTnLjcG+XLIDzxjAouh8yfU6DTYpJC7SXn2hBJMphhOGuPnOSARngFeh/HvVrS0me/RmDCxjCi3t8MjRttKsTnk55PPf9cL/hLvDEUsqxeI9HCnKpL9vhLAsW3EKGxwNpzxnHequv8AjHSGtZpNP8VaDJcGSBGzeR/cBPzLk9eV6dMUXT6jU4vqdFeWbQXAaxJUu3mGOYKCrblOTwc8pwQcdzVsajaXMtraSPbrqdyglaEjas4OchScg4x+lc5H4u8KG/u7hvEOhmRxhXF6keSp5P3jgHjp1561UTxho0tzEuoa34bn8wyHzv7QhzEp6KDuz0/rRdMfMn1Or1R49PuI7YJb3N3KAwjYBViB6KWJ653AYH4VQtra9aK7hgvLsp5xZlnZsxgZwDg4IJHI54IJ61knxX4Pe5QLruh5tZkdGmu1dSeFDKd4IwOo6c5wcVoaz428OXYgP/CTaFDO0wWQpfxMCuOWyGx/CME+o47Uc1tCfaJaXNZZ1P2vT725kmtUjO5I22CPOMD3yVbDcdSDVZZQLlgZJWWVlEMfkqRHGqnILjg5Gc8+lY0fi/wY1o1u+uabbv5RjYJfRMGByRhg3BG3r74I5FQJ4r8NizlNr4n0oSQosMLtfQo7I3JblucNjjqPxpXQ049zSlFtqFvD5BA3QyLDIzFB6EbRj/a4HpTNAs2aR2gWRbWMOqpg5X5s4bJOW9yfoBWYvi7w/PDZm61/QROU/eOb6NgrjGOA3Hr6fSon8YaOLlriTxFojFWA2xX8Iyc/eGW6EZB4z1qr6WuaKS7nXXkNtfTRIgXMLq5+UPkf0+tUoDcxtBBbtceWrYQyKGVGxnAxwQcFc9QfTPOQvjTwyYkmh8SaWGiYoqveRqTlcDIz8wB5zWNp+vWEesSTSeM9He0mL4hlvoDGhwdrbd3ZsHgdqStbcluPc7vdJI8kklgd0sYiZjERt+VflBDEEbjzj079a5u422KRI8kTOFcmTkiMAngA/wAIIAxyfasbUfFPhyW3mtdI8Q2USRmGRRJfoIpNqnIAJyCfy4HSrem69oa6Fb2mo+KNFuW3ySv/AMTOLO1gSseWJ4B/n7U7pa3FGUY6tm9axXEVwZGv4Y44MSSRmPI3HvuP0xxWhq9tcQWltNBFm3Dlp5IU3EHI3cZz6n/9VcrD4q8NwBEh1fQ1jkcjyP7Rj2oxHBLbh8vXPHX2NV18aaG2pnGtaOivJulDXcbIQfvAMWP5DH1qW9SuZN3TOmh+zzxXH2WPbZzMS5eJiSACSFDHB5J5xgj1qKZ4hdSB7iBWuCDFvgKmKPvk85OM46dayp/FvhtUi8nXNGhVWPlot/EQOvJwxxTbDxH4Qks1ebxDoz3ESeVG7XgVhn+8GPIGOtK4m4LW523wUhWDxX4kVXV2/s7Ti2zdtB8286buf/r5r1+vHfghqFjqXi/xXPpsli8X2KwVvsVyJ4wwlvP4h0JGDjsCK9irCTuzyqzTqNoKKKKRkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Early perivascular lesion.",
"    <br/>",
"    (B) Neutrophils within and around blood vessels are characteristic.",
"    <br/>",
"    (C) Mature wedge-shaped lesion.",
"    <br/>",
"    (D) Advanced ulcerated lesion.",
"    <br/>",
"    Early lesions have a perivascular lymphoid infiltrate. Mature lesions have a wedge-shaped appearance. The most common type A lesions have large Reed-Sternberg-like cells and frequent mitoses in an inflammatory background. Type B lesions resemble mycosis fungoides (MF) and may be a papular variant of MF. Type C lesions demonstrate a relatively monotonous population of large CD30+ cells with few inflammatory cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Panel C reproduced from: Kadin ME. Primary cutaneous CD30-positive t-cell lymphoproliferative disorders. In: Hematopathology, Jaffe ES, Harris NL, Vardiman JW, et al. (Eds), Philadelphia, Elsevier 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37080=[""].join("\n");
var outline_f36_13_37080=null;
var title_f36_13_37081="Prevention of smoking initiation in children and adolescents";
var content_f36_13_37081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of smoking initiation in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Marianna Sockrider, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Joseph B Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Martin I Lorin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37081/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/13/37081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15124707\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tobacco smoking often starts during adolescence but can have important health effects throughout life. Because of nicotine dependence and social factors, initiation of smoking during adolescence is closely associated with persistent smoking in adulthood and with the many adverse health effects associated with chronic smoking. The long-term consequences of smoking and the benefits of smoking cessation in adults are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is vital that pediatric health care providers routinely address tobacco use among patients and their families. In addition to evaluating for smoking and promoting",
"    <strong>",
"     smoking cessation",
"    </strong>",
"    among their adolescent patients, pediatric health care providers should systematically aim to prevent",
"    <strong>",
"     smoking initiation",
"    </strong>",
"    among all of their patients, as detailed in policy statements from many pediatric health care groups in the United States and elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. As stated in a comprehensive review on",
"    <a class=\"external\" href=\"file://www.surgeongeneral.gov/library/reports/preventing-youth-tobacco-use/\">",
"     Preventing Tobacco Use Among Youth and Young Adults",
"    </a>",
"    that was released by the US Surgeon General in 2012: &ldquo;The tobacco epidemic continues because youth and young adults begin to use &ndash; and become addicted to &ndash; cigarettes and smokeless tobacco products&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. The report clearly highlights the health consequences of tobacco use by youth, high risk of addiction, and the need to intervene early to prevent onset and use of tobacco.",
"   </p>",
"   <p>",
"    While there is good consensus on the importance of preventing smoking initiation, techniques for doing so are not standardized or adequately studied. Nonetheless, some general principles arise, extrapolated from health provider interventions for other risk behaviors or from smoking interventions in adults.",
"   </p>",
"   <p>",
"    Preventing smoking initiation in children and adolescents will be reviewed here, focusing on interventions that can be performed in the primary care setting. Management of smoking cessation in adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link\">",
"     \"Management of smoking cessation in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124714\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking in adulthood is closely associated with smoking during adolescence: 90 percent of adult smokers smoked their first cigarette before the age of 18, and virtually all started smoking before age 26 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Every day in the United States, almost 4000 youths between 12 and 17 years of age take up smoking, and about 1000 become daily smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124721\">",
"    <span class=\"h2\">",
"     Prevalence and trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of tobacco smoking among adolescents in the United States gradually declined beginning in the late 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. In 2011, 23 percent of 12th grade students reported smoking in the past 30 days, as compared with 37 percent in 1997 (",
"    <a class=\"graphic graphic_figure graphicRef79503 \" href=\"mobipreview.htm?18/63/19454\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Approximately 7 percent of middle school students report that they currently smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/10\">",
"     10",
"    </a>",
"    ]. The World Health Organization reports a wide range of",
"    <a class=\"external\" href=\"file://www.who.int/tobacco/en/atlas7.pdf\">",
"     smoking rates among youth in other countries",
"    </a>",
"    ; some countries including the Russian Federation, Peru, Bolivia, and Indonesia have rates of 30 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tobacco smoking among adolescents in the United States varies by race and ethnicity, with the highest prevalence among whites, Alaska Natives, and American Indians, the lowest among African Americans, and intermediate levels among Hispanics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,14,15\">",
"     6,14,15",
"    </a>",
"    ]. Smoking is generally more prevalent among groups with lower levels of education and lower socioeconomic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to smoking ordinary cigarettes, many teens use other forms of tobacco including chewing tobacco (dip), snuff, bidis, kreteks, snus, hookahs, and electronic cigarettes (e-cigarettes) (",
"    <a class=\"graphic graphic_table graphicRef50718 \" href=\"mobipreview.htm?2/25/2461\">",
"     table 1",
"    </a>",
"    ). Over 50 percent of white and Hispanic male tobacco users reported that they use more than one tobacco product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. Some teens may be misinformed about the dangers of smokeless tobacco. It is important to screen for all forms of tobacco use, because teens may fail to mention other forms of tobacco when asked only about smoking. (See",
"    <a class=\"local\" href=\"#H5188977\">",
"     'Smokeless tobacco and alternative nicotine sources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124728\">",
"    <span class=\"h2\">",
"     Persistence of smoking into adulthood",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 80 percent of individuals who start smoking during adolescence will continue to smoke in adulthood, and one-third of these individuals will die prematurely due to smoking-related disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. In most populations, the overall prevalence of smoking increases from early to late adolescence and is fairly stable thereafter, with approximately equal numbers of individuals initiating smoking and quitting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/17\">",
"     17",
"    </a>",
"    ]. Predictors of whether an individual adolescent or young adult is likely to quit smoking are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of smoking cessation in adolescents\", section on 'Patterns of smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124735\">",
"    <span class=\"h1\">",
"     FACTORS CONTRIBUTING TO SMOKING INITIATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124743\">",
"    <span class=\"h2\">",
"     Attitudes and beliefs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attitudes toward smoking are an important predictor of smoking initiation. As an example, in a longitudinal study of adolescents who had never smoked at baseline, 40 percent became experimenters and 8 percent had an established smoking habit during four years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/18\">",
"     18",
"    </a>",
"    ]. The absence of a firm decision not to smoke was the strongest predictor of experimentation.",
"   </p>",
"   <p>",
"    Attitudes toward smoking are influenced by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peer and family influence &ndash; The presence of smokers in the network of family or friends is associated with less negative attitudes towards smoking and is an important predictor of initiating smoking during adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,19-23\">",
"       6,19-23",
"      </a>",
"      ]. Refusing a cigarette in the face of social pressure is challenging for many adolescents; among adolescents who were occasional or daily smokers, only 44 percent felt confident that they could refuse a cigarette at a party [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &ndash; Either positive or negative attitudes toward smoking often become more pronounced during adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Misperceptions &ndash; Adolescents tend to overestimate the frequency of smoking among their peers and among adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/24\">",
"       24",
"      </a>",
"      ]. Conversely, adolescents tend to underestimate their own smoking habits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marketing &ndash; Although the direct advertising of tobacco to youth is banned in the United States, indirect marketing efforts and positive images of cigarette use in the media have important effects on teenage smoking behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,19,20\">",
"       6,19,20",
"      </a>",
"      ]. Many advertisements use images or other techniques to suggest that smoking is associated with good health, thinness, and social acceptance. (See",
"      <a class=\"local\" href=\"#H15124877\">",
"       'Advertising and media influence'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124750\">",
"    <span class=\"h2\">",
"     Nicotine dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotine is a strongly addictive substance, and many individuals develop nicotine dependence after days to weeks of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/26\">",
"     26",
"    </a>",
"    ]. Youth are particularly vulnerable to becoming dependent on nicotine, as compared to adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, experimentation or a light smoking habit can rapidly escalate into daily or heavy smoking, and many adolescent smokers have difficulty quitting although they are often motivated to do so. Nicotine dependence is an important factor in determining which individuals become regular smokers after smoking experimentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first symptoms of nicotine dependence can appear within days to weeks of the onset of occasional cigarette use, and often appear before the onset of daily smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. As an example, among sixth grade students (median age 12 years) who smoked at least once per month at baseline, 53 percent experienced symptoms of nicotine dependence, and 40 percent escalated to daily smoking during the next four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/28\">",
"     28",
"    </a>",
"    ]. Early emergence of dependence symptoms predicted escalation in smoking frequency, and smoking frequency accelerated the appearance of dependence symptoms.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The specific symptoms of nicotine dependence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of smoking cessation in adolescents\", section on 'Nicotine dependence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10239848\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous level of experimentation &ndash; In a study of a group of adolescent experimenting smokers (defined as those who had had at least one puff but fewer than 100 cigarettes in their lifetime), 31 percent went on to become established smokers within four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/31\">",
"       31",
"      </a>",
"      ]. The teen's level of smoking experience at baseline was the strongest independent predictor of established smoking four years later.",
"     </li>",
"     <li>",
"      Depression &ndash; Most studies show an association between depression and smoking initiation, but it is unclear whether the association is causal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,32-34\">",
"       6,32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poor school performance &ndash; Skipping school and poor school performance are associated with progression along the smoking uptake continuum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,19,35\">",
"       6,19,35",
"      </a>",
"      ]. School misbehavior and low academic achievement can directly and indirectly contribute to the risk for smoking initiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse experiences &ndash; Adverse experiences during childhood are associated with increased risks for initiating smoking and continuing smoking. These include parental separation or divorce; emotional, physical, and sexual abuse; having a battered mother; or growing up with a household member who is substance abusing, mentally ill, or incarcerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/34,37\">",
"       34,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Substance abuse &ndash; There is a high rate of smoking among adolescent substance abusers. In one report of teens undergoing inpatient treatment in a hospital-based substance abuse treatment facility, 85 percent smoked [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/38\">",
"       38",
"      </a>",
"      ]. In many cases, smoking precedes the use of illicit drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Therefore, an adolescent who smokes should be engaged in discussions about other risk behaviors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link&amp;anchor=H32#H32\">",
"       \"Management of smoking cessation in adolescents\", section on 'Drug and alcohol use'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124835\">",
"    <span class=\"h1\">",
"     SMOKING PREVENTION IN THE PRIMARY CARE OFFICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most chronic users of tobacco began smoking during adolescence, preventing smoking initiation during childhood and adolescence is a logical strategy to reduce chronic smoking and its health consequences. Primary care providers have a special role as a health authority for families, and there is evidence that adolescents view physicians as the preferred source for information about smoking and smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions to prevent smoking initiation through counseling in the primary care office have not been well standardized or studied. However, the few interventions that have been studied suggested moderate efficacy and feasibility. In one report, patients who received a counseling intervention given by primary care providers and older peer counselors were more likely to remain abstinent 6 and 12 months later, as compared with patients in similar practices receiving usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/42\">",
"     42",
"    </a>",
"    ]. Among nonsmokers, 98.2 percent of those receiving the counseling intervention remained abstinent at six months follow-up, as compared with 96.5 percent among those receiving usual care. The authors also reported that they were able to deliver a brief smoking prevention or cessation intervention during the course of routine primary care visits, following a simple intervention protocol, and the average intervention time was just under five minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/43\">",
"     43",
"    </a>",
"    ]. A systematic review of the literature that included this trial and 12 others concluded that interventions that were conducted in, or accessible by, health care settings do help to prevent smoking initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    To prevent smoking initiation, we suggest that pediatric health care professionals should give anticipatory guidance to all parents and to all children five years and older during routine health care; this suggestion is consistent with the Bright Future guidelines from the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/45\">",
"     45",
"    </a>",
"    ]. Additional attention should be given to patients with risk factors, such as having family members",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peers who smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/4,46\">",
"     4,46",
"    </a>",
"    ]. All patients should also be monitored for smoking initiation, and for any who begin to smoke, the provider should take additional steps to help the patient stop smoking as soon as possible. Staff members in the medical office should model non-smoking behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended steps for effective smoking prevention counseling in the primary care office can be summarized as a mnemonic with five A's: Ask, Advise, Assess, Assist, and Arrange follow-up. The focus of each step will vary with the child's age and the smoking status of parents and child (",
"    <a class=\"graphic graphic_table graphicRef52025 \" href=\"mobipreview.htm?39/1/39965\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This mnemonic is parallel to the steps used to assist with smoking cessation in a child or adult who is already smoking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of smoking cessation in adolescents\", section on 'Six A's'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11571243\">",
"    <span class=\"h2\">",
"     Ask about smoking habits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric health care providers should ask about smoking habits at each health maintenance visit. Some providers have successfully employed a brief questionnaire to facilitate this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the child is young, the provider should determine the smoking status of the parents and other household members [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For school-aged children, the provider should additionally explore each of the following areas:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The family and child's attitudes towards smoking",
"     </li>",
"     <li>",
"      Whether the child or",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      peers have experimented with smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adolescents, the provider should ask about the smoking habits of the patient and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      peers at each health maintenance visit. Clinicians should allow time during each visit to speak with the patient without the parents present, to facilitate disclosure. The clinician should establish confidentiality rules with the patient at the start of these visits, to facilitate disclosure and frank discussion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33466776\">",
"    <span class=\"h2\">",
"     Advise about the health risks of smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advice about smoking should focus on health risks and be tailored to the age of the child and the parents' smoking status (",
"    <a class=\"graphic graphic_table graphicRef73345 \" href=\"mobipreview.htm?12/2/12333\">",
"     table 3",
"    </a>",
"    ). Patients and parents who are not smoking and those who have made clear decisions not to smoke should be given praise and brief reminders of the health risks of tobacco use. Patients who are experimenting with smoking or who have risk factors for smoking initiation (eg, smoking among parents or peers) require a more detailed discussion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants and toddlers, advice to the parent focuses on the health effects of direct and secondhand smoke. If the parent smokes, the parent should be strongly advised to quit smoking. Limiting parental smoking to outside the home is far less effective in reducing secondhand smoke exposure than complete smoking cessation. The parents' importance as role models for non-smoking should be emphasized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/21,51\">",
"       21,51",
"      </a>",
"      ]. Studies of smoking cessation interventions in adults suggest that counseling for as few as three minutes results in increased abstinence rates as compared with no counseling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/52\">",
"       52",
"      </a>",
"      ]. A practical strategy for addressing parental smoking during pediatric health care visits is available through the",
"      <a class=\"external\" href=\"file://www2.massgeneral.org/ceasetobacco/index.htm\">",
"       CEASE website",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link\">",
"       \"Secondhand smoke exposure: Effects in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5194262\">",
"       'Guidance for parents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For school-aged children, the health effects of smoking should be explained at a level appropriate to the child's age. The short-term negative effects of smoking, such as smell, staining of teeth, and decreased athletic performance should be emphasized. The potential for rapid development of addiction should be discussed; the provider should emphasize that it is not safe to \"experiment\" with smoking. (See",
"      <a class=\"local\" href=\"#H15124750\">",
"       'Nicotine dependence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescents, the provider should give clear messages describing the established health risks of smoking, and state that there is no safe level of tobacco use. Instead of focusing on the long-term effects of chronic smoking, the provider should emphasize the immediate effects of smoking, including chronic cough, exacerbations of asthma, greater risk of pulmonary infections, atherosclerosis, and the potential for rapid development of nicotine dependence (see",
"      <a class=\"local\" href=\"#H15124750\">",
"       'Nicotine dependence'",
"      </a>",
"      above). Of note, smoking by adolescents and young adults is NOT associated with significant weight loss, contrary to young people&rsquo;s beliefs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"       6",
"      </a>",
"      ], and despite the evidence that smoking cessation causes weight gain in adults. The health consequences of smoking are discussed in detail in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=see_link&amp;anchor=H2589684#H2589684\">",
"       \"Benefits and risks of smoking cessation\", section on 'Benefits of smoking cessation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with chronic illnesses, such as asthma or cystic fibrosis, often smoke despite their special vulnerability to the adverse health effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/53\">",
"       53",
"      </a>",
"      ]. As examples, smoking is more common among patients with asthma than among those without asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/54-56\">",
"       54-56",
"      </a>",
"      ], and 5 to 10 percent of individuals with cystic fibrosis smoke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/53,57\">",
"       53,57",
"      </a>",
"      ]. Smoking also has important disease-specific health risks for patients with sickle cell disease, cancer, diabetes mellitus, and juvenile idiopathic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/53\">",
"       53",
"      </a>",
"      ]. For adolescents with these chronic illnesses, counseling should be personalized with discussion of the risks that are specific to the patient's underlying disease (",
"      <a class=\"graphic graphic_table graphicRef61284 \" href=\"mobipreview.htm?31/6/31852\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33467654\">",
"    <span class=\"h2\">",
"     Assess risk factors for smoking initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking prevention counseling can be targeted to at-risk patients by assessing risk factors for smoking initiation, including the following: (See",
"    <a class=\"local\" href=\"#H15124735\">",
"     'Factors contributing to smoking initiation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous level of experimentation",
"     </li>",
"     <li>",
"      Smoking among peers and family",
"     </li>",
"     <li>",
"      Attitudes and beliefs about the social implications and health consequences of smoking",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Poor school performance",
"     </li>",
"     <li>",
"      Adverse experiences",
"     </li>",
"     <li>",
"      Substance abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these risk factors are potentially modifiable, such as parental smoking and lack of smoking ban at home. Other risk factors draw attention to associated health risks, such as depression or substance abuse (",
"    <a class=\"graphic graphic_table graphicRef72938 \" href=\"mobipreview.htm?11/33/11803\">",
"     table 5",
"    </a>",
"    ). If adolescents report difficulty resisting social pressure, targeted counseling to foster smoking resistance may be helpful. (See",
"    <a class=\"local\" href=\"#H11572038\">",
"     'Fostering smoking resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10240060\">",
"    <span class=\"h2\">",
"     Assist with parenting skills and smoking resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric health care providers also have a role in triggering parental smoking cessation and teaching practices to prevent smoking initiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5194262\">",
"    <span class=\"h3\">",
"     Guidance for parents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking cessation &ndash; Because children whose parents do not smoke or who successfully quit smoking are much less likely to take up smoking, pediatric health care providers should strongly encourage smoking cessation in parents who smoke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/48,58,59\">",
"       48,58,59",
"      </a>",
"      ]. The provider should emphasize the value of serving as a role model for non-smoking, and offer referral or assistance with quit attempts. A meta-analysis found that interventions that motivated parents to stop smoking for the benefit of their child achieved 23 percent quit rates, which was modestly higher than the 18 percent quit rate in the pooled control groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/60\">",
"       60",
"      </a>",
"      ]. Studies of smoking cessation interventions in adults suggest that counseling for as few as three minutes results in increased abstinence rates as compared with no counseling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/52\">",
"       52",
"      </a>",
"      ]. National surveys in the United States suggest that the majority of parents feel that this is part of the pediatrician's job and that most parents who smoke would welcome such advice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/61\">",
"       61",
"      </a>",
"      ]; 64.2 percent of parents who smoke reported that they would accept enrollment in a telephone cessation program if the child's doctor offered it to them [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/62\">",
"       62",
"      </a>",
"      ]. Telephone counseling can increase smoking cessation, and all smokers should be given the number to the free national quit-line. In the United States, free resources include the National Cancer Institute's quit support line (877-44U-QUIT) and smokefree.gov, which provides links to local and state telephone quit support lines (800-QUIT-NOW). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A practical strategy for addressing parental smoking during pediatric health care visits is available through the",
"      <a class=\"external\" href=\"file://www2.massgeneral.org/ceasetobacco/index.htm\">",
"       CEASE website",
"      </a>",
"      . The strategy and materials were developed through focus groups and use the \"5 A's\" approach to brief smoking cessation counseling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/63\">",
"       63",
"      </a>",
"      ]. Resources include",
"      <a class=\"external\" href=\"file://www2.massgeneral.org/ceasetobacco/national.htm\">",
"       educational materials",
"      </a>",
"      for patients designed for several age groups and languages.",
"     </li>",
"     <li>",
"      Smoking bans &ndash; Pediatricians should encourage parents to maintain a smoke-free home. Household smoking bans can be helpful even when parents are smokers; a smoke-free home communicates non-smoking expectations to the child, and also supports decreased cigarette consumption and smoking cessation in adult smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/64\">",
"       64",
"      </a>",
"      ]. A smoking ban must be strictly enforced in order to be effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parenting skills &ndash; Parents should be encouraged to give clear and consistent messages to their children that they expect them to remain non-smokers. Parental disapproval of smoking is associated with lower rates of smoking initiation among their children, and improved resistance of the child to peer smoking influences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/59,66\">",
"       59,66",
"      </a>",
"      ]. Of note, parental disapproval helps prevent smoking initiation in the child even if the parent smokes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. The provider should educate the parents about how adolescents are able to obtain tobacco products and encourage them to watch for signs of experimentation. (See",
"      <a class=\"local\" href=\"#H15124884\">",
"       'Youth access to tobacco products'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11572038\">",
"    <span class=\"h3\">",
"     Fostering smoking resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques are used in school-based interventions to foster resistance to smoking among children and adolescents. These techniques may also be helpful to guide an individual counseling encounter, although their use in this context has not been evaluated. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encouraging the child to value good health. Talk about how being a non-smoker helps to improve sports performance, appearance, and self-worth.",
"     </li>",
"     <li>",
"      Correcting misperceptions about the frequency of smoking among peers (most children overestimate this frequency) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Teaching awareness of media and peer influences. (See",
"      <a class=\"local\" href=\"#H15124877\">",
"       'Advertising and media influence'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Fostering resistance to social influences from peers by rehearsing refusal skills. Teaching of the mnemonic REAL (Refuse, Explain, Avoid, Leave) has been successful as part of a school-based substance prevention curriculum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/69\">",
"       69",
"      </a>",
"      ]. It has not been tested as an office-based counseling strategy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pediatric health care providers can and should give messages about avoiding tobacco exposure and use to children as young as five years old. If the provider counsels the child about these issues with the parent present, the parent may also be able to provide reinforcement at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11575502\">",
"    <span class=\"h2\">",
"     Arrange follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up for smoking prevention varies depending on the child's age and risk factors (",
"    <a class=\"graphic graphic_table graphicRef52025 \" href=\"mobipreview.htm?39/1/39965\">",
"     table 2",
"    </a>",
"    ). For a child who expresses an attitude against smoking and with no significant risk factors, the anti-smoking messages can simply be reinforced at each annual health maintenance visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11571116\">",
"    <span class=\"h1\">",
"     SMOKING PREVENTION IN OTHER SETTINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11571124\">",
"    <span class=\"h2\">",
"     School-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most smoking prevention strategies have been delivered in a school-based setting, and some but not all have shown some efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/48\">",
"     48",
"    </a>",
"    ]. A systematic review focused on the 23 most valid randomized trials of a smoking prevention program in a school setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/70\">",
"     70",
"    </a>",
"    ]. The interventions included provision of information, teaching of social competence, modifying social influences (correcting misperceptions about the frequency of smoking among peers, teaching awareness of media and peer influences, and resisting social influences, as described above), or multimodal programs. Nine of 13 studies targeting social influences found some effect on smoking prevention and four others failed to detect an intervention effect. A meta-analysis of a school-based incentive program (primarily the Smokefree Class Competition, widely used in Europe) did not demonstrate a significant effect on limiting smoking initiation in youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/71\">",
"     71",
"    </a>",
"    ]. While studies vary in conclusions, it appears that the more effective school-based programs are comprehensive, interactive, start early, and address more distal, social, and community influences as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/72\">",
"     72",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11571131\">",
"    <span class=\"h2\">",
"     Family-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some counseling interventions focus on helping family members strengthen non-smoking attitudes and promote non-smoking among targeted children and adolescents; techniques include smoking cessation among parents and siblings, enhanced family communication, and household smoking bans. A systematic review of these family based interventions found that four of nine were effective in reducing smoking initiation, four had no effect, and one had negative effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/41,73\">",
"     41,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5188977\">",
"    <span class=\"h1\">",
"     SMOKELESS TOBACCO AND ALTERNATIVE NICOTINE SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to smoking cigarettes, many teens use smokeless tobacco, including chewing tobacco (dip) and snuff, as well as alternative forms of inhaled tobacco, such as bidis, kreteks, snus, hookahs, and electronic cigarettes (e-cigarettes) (",
"    <a class=\"graphic graphic_table graphicRef50718 \" href=\"mobipreview.htm?2/25/2461\">",
"     table 1",
"    </a>",
"    ). Among high school students in the United States, 13 percent of males and 2 percent of females use smokeless tobacco; the use is greatest in rural areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/74\">",
"     74",
"    </a>",
"    ]. It is important to ask specifically about all forms of tobacco use, because teens may fail to mention smokeless tobacco when asked about smoking. Health concerns about e-cigarettes and other nicotine sources are discussed in more detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link&amp;anchor=H279603278#H279603278\">",
"     \"Patterns of tobacco use\", section on 'Nicotine sources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many adolescents are poorly informed about the dangers of smokeless tobacco, and some believe that it is a safe substitute for smoking cigarettes. The health effects of smokeless tobacco include oral, pharyngeal, and esophageal cancer, oral leukoplakia (a premalignant lesion) and periodontal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Use of smokeless tobacco produces levels of nicotine that are similar to those produced by smoking, and are also addictive. Smokeless tobacco use is associated with higher levels of cigarette smoking and lower rates of smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies similar to those described above for smoking prevention can also be used for prevention and cessation of smokeless tobacco use. Providers should emphasize the specific health risks of smokeless tobacco use, as well as the cosmetic consequences of stained teeth and bad teeth (gum disease and tooth loss). Oral health professionals and medical providers have important opportunities for intervention, in addition to educational efforts in the community and school, although few intervention trials have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124877\">",
"    <span class=\"h1\">",
"     ADVERTISING AND MEDIA INFLUENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, tobacco advertising that targets people younger than 18 years of age has been prohibited since 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/79\">",
"     79",
"    </a>",
"    ]. Despite this legislation, advertising spending on youth cigarette brands and advertising spending in youth magazines did not significantly change from 1995 to 2000. Adolescents are also exposed to tobacco advertising through point-of-sale advertising, promotional products, and demonstration of tobacco use in films and on television, and a substantial portion of tobacco company expenditures are focused on marketing efforts that reduce the prices of some tobacco products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,80\">",
"     6,80",
"    </a>",
"    ]. There is good evidence that these promotional activities effectively promote smoking among youth.",
"    <br/>",
"    <br/>",
"    Depiction of smoking in movies also has an important influence on the initiation of smoking among youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,81,82\">",
"     6,81,82",
"    </a>",
"    ]. Although the film industry participates in a voluntary ban of paid product placement, endorsements by actors have increased from 1 to 11 percent during the 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/83\">",
"     83",
"    </a>",
"    ]. Depiction of tobacco use in popular youth-rated movies decreased substantially from an average of 20 incidents per movie in 2005 to seven per movie in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/84\">",
"     84",
"    </a>",
"    ]. Most of the improvements were seen in movies produced by the three companies with specific anti-tobacco policies.",
"   </p>",
"   <p>",
"    To counteract these influences, anti-smoking advertising campaigns have been launched, and these appear to be effective in fostering smoking resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. Studies indicate that a child's exposure to \"truth\" (anti-smoking) advertisements was associated with positive changes in attitudes, beliefs, and intentions to avoid smoking. Conversely, exposure to advertisements created by the tobacco industry that purport to discourage smoking among youth (eg, Phillip Morris' \"Think. Don't Smoke\" campaign) was associated with more favorable beliefs and attitudes toward the tobacco industry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6,85\">",
"     6,85",
"    </a>",
"    ]. The findings suggest that well executed anti-smoking campaigns can positively and consistently change youths' beliefs and attitudes, whereas a tobacco industry-sponsored campaign can have a counterproductive influence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124884\">",
"    <span class=\"h1\">",
"     YOUTH ACCESS TO TOBACCO PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents and providers may be better able to limit youth access to tobacco by understanding how youths are able to purchase these products.",
"   </p>",
"   <p>",
"    Despite numerous laws in the United States that restrict access to cigarettes for individuals under 18 years of age, most youths report that they can obtain cigarettes through one or more of the following means:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Having an older friend purchase cigarettes for them, or by using false identification.",
"     </li>",
"     <li>",
"      Purchasing cigarettes themselves, if the merchant fails to enforce the age limit. Merchant compliance with tobacco purchasing laws is inconsistent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Purchasing cigarettes over the internet, using credit cards or money orders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher costs of cigarettes also reduces adolescents' tobacco use because cigarette smoking in this age group is particularly sensitive to price. Studies in the United States have estimated that a 10 percent increase in the price of cigarettes would reduce the number of teenagers who smoke by 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/88\">",
"     88",
"    </a>",
"    ]. Taxation is one approach to increasing cigarette prices. However, because of inflation, the relative burden of cigarette taxes has decreased over time; when adjusted for inflation, the 24 cents per pack Federal cigarette tax used in 1997 is only half the tax of the original eight cents per pack tax imposed in 1951 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/88\">",
"     88",
"    </a>",
"    ]. Because smoking among young age groups is sensitive to price, tobacco companies have specifically sought ways to reduce the price of tobacco products as part of their marketing strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37081/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15124877\">",
"     'Advertising and media influence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15124898\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of individuals who start smoking during adolescence will continue to smoke in adulthood, the pediatric population is a critical target for public health efforts to reduce smoking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 20 percent of high school students in the United States smoke; the rate has gradually declined since the late 1990s but has now plateaued (",
"      <a class=\"graphic graphic_figure graphicRef79503 \" href=\"mobipreview.htm?18/63/19454\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15124721\">",
"       'Prevalence and trends'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nicotine dependence can appear within days to weeks of the onset of occasional cigarette use and often before the onset of daily smoking. As a result, experimentation or a light smoking habit can rapidly escalate into daily or heavy smoking, and many adolescent smokers have difficulty quitting although they are often motivated to do so. (See",
"      <a class=\"local\" href=\"#H15124750\">",
"       'Nicotine dependence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pediatric health care provider should include smoking prevention measures in all primary care visits. The recommended steps can be summarized as a mnemonic with five A's: Ask, Advise, Assess, Assist, and Arrange follow-up (",
"      <a class=\"graphic graphic_table graphicRef52025 \" href=\"mobipreview.htm?39/1/39965\">",
"       table 2",
"      </a>",
"      ). The focus of each step will vary with the child's age and the smoking status of parents and child. (See",
"      <a class=\"local\" href=\"#H15124835\">",
"       'Smoking prevention in the primary care office'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key elements of smoking prevention measures in the pediatric office include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asking all parents of all patients whether they smoke. For parents who smoke, firmly advise smoking cessation and offer assistance or referral. (See",
"      <a class=\"local\" href=\"#H5194262\">",
"       'Guidance for parents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asking all patients five years and older",
"      <strong>",
"      </strong>",
"      what they think about smoking, whether they have tried smoking, or whether they smoke. (See",
"      <a class=\"local\" href=\"#H11571243\">",
"       'Ask about smoking habits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Educating all patients and families about the health risks of smoking, tailored to the age of the child and the parents' smoking status (",
"      <a class=\"graphic graphic_table graphicRef73345 \" href=\"mobipreview.htm?12/2/12333\">",
"       table 3",
"      </a>",
"      ), and specifically advising children to avoid smoking initiation. (See",
"      <a class=\"local\" href=\"#H33466776\">",
"       'Advise about the health risks of smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recognizing risk factors for smoking initiation in individual patients (",
"      <a class=\"graphic graphic_table graphicRef72938 \" href=\"mobipreview.htm?11/33/11803\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33467654\">",
"       'Assess risk factors for smoking initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Promoting smoking resistance skills among children and teens, by increasing awareness of social and media influences. (see",
"      <a class=\"local\" href=\"#H11572038\">",
"       'Fostering smoking resistance'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Counseling all parents about techniques to prevent smoking initiation in their children. (See",
"      <a class=\"local\" href=\"#H5194262\">",
"       'Guidance for parents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking prevention counseling can be integrated into routine health maintenance visit because it can usually be performed in three to five minutes; such counseling is welcomed by the majority of parents including those who smoke. (See",
"      <a class=\"local\" href=\"#H15124835\">",
"       'Smoking prevention in the primary care office'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pediatric health care provider should also inquire about the use of smokeless tobacco and educate patients about its health effects (",
"      <a class=\"graphic graphic_table graphicRef50718 \" href=\"mobipreview.htm?2/25/2461\">",
"       table 1",
"      </a>",
"      ). Many adolescents are poorly informed about the dangers of smokeless tobacco and falsely believe that it is a safe substitute for smoking cigarettes. (See",
"      <a class=\"local\" href=\"#H5188977\">",
"       'Smokeless tobacco and alternative nicotine sources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/1\">",
"      Best D, Moss DA, Winickoff JP, et al. Ambulatory Pediatric Association policy on tobacco. Ambul Pediatr 2006; 6:332.",
"     </a>",
"    </li>",
"    <li>",
"     American Medical Association. Promoting Healthy Lifestyles: Smoking and Tobacco Control www.ama-assn.org/ama/pub/physician-resources/public-health/promoting-healthy-lifestyles/smoking-tobacco-control.shtml (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     World Health Organization report on the global tobacco epidemic 2008 - the MPOWER package. World Health Organization, Geneva file://www.who.int/tobacco/mpower/2008/en/index.html (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/4\">",
"      Committee on Environmental HealthHealth, Committee on Substance Abuse, Committee on Adolescence, Committee on Native American Child. From the American Academy of Pediatrics: Policy statement--Tobacco use: a pediatric disease. Pediatrics 2009; 124:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/5\">",
"      Executive summary of the surgeon general's report: preventing tobacco use among young people. Oncology (Williston Park) 1994; 8:16, 19, 46 passim.",
"     </a>",
"    </li>",
"    <li>",
"     2012 US Surgeon General's Report: Preventing Tobacco Use Among Youth and Young Adults. Available at: file://www.surgeongeneral.gov/library/reports/preventing-youth-tobacco-use/ (Accessed on August 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Cigarette use among high school students--United States, 1991-2005. MMWR Morb Mortal Wkly Rep 2006; 55:724.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: Detailed Tables. file://oas.samhsa.gov/ (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     Healthy People 2010 data and Healthy People 2020 objectives, available at: file://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=41 (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Current tobacco use among middle and high school students--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:581.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Trends in current cigarette smoking among high school students and adults, United States, 1965-2007 www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking (Accessed on May 26, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. The tobacco atlas www.who.int/tobacco/statistics/tobacco/en/atlas7.pdf (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/13\">",
"      Grimshaw GM, Stanton A. Tobacco cessation interventions for young people. Cochrane Database Syst Rev 2006; :CD003289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Cigarette use among high school students - United States, 1991-2009. MMWR Morb Mortal Wkly Rep 2010; 59:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/15\">",
"      Cokkinides V, Bandi P, McMahon C, et al. Tobacco control in the United States--recent progress and opportunities. CA Cancer J Clin 2009; 59:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/16\">",
"      Harrell JS, Bangdiwala SI, Deng S, et al. Smoking initiation in youth: the roles of gender, race, socioeconomics, and developmental status. J Adolesc Health 1998; 23:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/17\">",
"      Costello DM, Dierker LC, Jones BL, Rose JS. Trajectories of smoking from adolescence to early adulthood and their psychosocial risk factors. Health Psychol 2008; 27:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/18\">",
"      Pierce JP, Choi WS, Gilpin EA, et al. Validation of susceptibility as a predictor of which adolescents take up smoking in the United States. Health Psychol 1996; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/19\">",
"      Kaufman NJ, Castrucci BC, Mowery PD, et al. Predictors of change on the smoking uptake continuum among adolescents. Arch Pediatr Adolesc Med 2002; 156:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/20\">",
"      Unger JB, Chen X. The role of social networks and media receptivity in predicting age of smoking initiation: a proportional hazards model of risk and protective factors. Addict Behav 1999; 24:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/21\">",
"      Meier KS. Tobacco truths: the impact of role models on children's attitudes toward smoking. Health Educ Q 1991; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/22\">",
"      Gilman SE, Rende R, Boergers J, et al. Parental smoking and adolescent smoking initiation: an intergenerational perspective on tobacco control. Pediatrics 2009; 123:e274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/23\">",
"      Stone SL, Kristeller JL. Attitudes of adolescents toward smoking cessation. Am J Prev Med 1992; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/24\">",
"      Sussman S, Dent CW, Mestel-Rauch J, et al. Adolescent nonsmokers, triers, and regular smokers' estimates of cigarette smoking prevalence: when do overestimations occur and by whom? J App Soc Psy 1988; 18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/25\">",
"      Hollis JF, Polen MR, Lichtenstein E, Whitlock EP. Tobacco use patterns and attitudes among teens being seen for routine primary care. Am J Health Promot 2003; 17:231.",
"     </a>",
"    </li>",
"    <li>",
"     LeMaistre C. Tobacco by the numbers. In: Texas Medicine, 1995. p.42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/27\">",
"      O'Loughlin J, DiFranza J, Tyndale RF, et al. Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med 2003; 25:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/28\">",
"      Doubeni CA, Reed G, Difranza JR. Early course of nicotine dependence in adolescent smokers. Pediatrics 2010; 125:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/29\">",
"      DiFranza JR, Richmond JB. Let the children be heard: lessons from studies of the early onset of tobacco addiction. Pediatrics 2008; 121:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/30\">",
"      DiFranza JR, Rigotti NA, McNeill AD, et al. Initial symptoms of nicotine dependence in adolescents. Tob Control 2000; 9:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/31\">",
"      Choi WS, Pierce JP, Gilpin EA, et al. Which adolescent experimenters progress to established smoking in the United States. Am J Prev Med 1997; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/32\">",
"      Escobedo LG, Reddy M, Giovino GA. The relationship between depressive symptoms and cigarette smoking in US adolescents. Addiction 1998; 93:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/33\">",
"      Goodman E, Capitman J. Depressive symptoms and cigarette smoking among teens. Pediatrics 2000; 106:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/34\">",
"      Acierno R, Kilpatrick DG, Resnick H, et al. Assault, PTSD, family substance use, and depression as risk factors for cigarette use in youth: findings from the National Survey of Adolescents. J Trauma Stress 2000; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/35\">",
"      Young TL, Rogers KD. School performance characteristics preceding onset of smoking in high school students. Am J Dis Child 1986; 140:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/36\">",
"      Bryant AL, Schulenberg JE, O'Malley PM, et al. How academic achievement, attitudes, and behaviors relate to the course of substance use during adolescence: A 6-year multiwave national longitudinal study. J Res Adol 2003; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/37\">",
"      Siqueira L, Diab M, Bodian C, Rolnitzky L. Adolescents becoming smokers: the roles of stress and coping methods. J Adolesc Health 2000; 27:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/38\">",
"      Myers MG, Brown SA. Smoking and health in substance-abusing adolescents: a two-year follow-up. Pediatrics 1994; 93:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/39\">",
"      Torabi MR, Bailey WJ, Majd-Jabbari M. Cigarette smoking as a predictor of alcohol and other drug use by children and adolescents: evidence of the \"gateway drug effect\". J Sch Health 1993; 63:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/40\">",
"      Lai S, Lai H, Page JB, McCoy CB. The association between cigarette smoking and drug abuse in the United States. J Addict Dis 2000; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     2012 US Surgeon General's report: Preventing tobacco use among youth and young adults. US Department of Health and Human Services, Rockville MD, 2012. p. 727. Available at: file://www.surgeongeneral.gov/library/preventing-youth-tobacco-use/full-report.pdf (Accessed on April 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/42\">",
"      Pbert L, Flint AJ, Fletcher KE, et al. Effect of a pediatric practice-based smoking prevention and cessation intervention for adolescents: a randomized, controlled trial. Pediatrics 2008; 121:e738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/43\">",
"      Pbert L, Fletcher KE, Flint AJ, et al. Smoking prevention and cessation intervention delivery by pediatric providers, as assessed with patient exit interviews. Pediatrics 2006; 118:e810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/44\">",
"      Patnode CD, O'Connor E, Whitlock EP, et al. Primary care-relevant interventions for tobacco use prevention and cessation in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:253.",
"     </a>",
"    </li>",
"    <li>",
"     Middle childhood, Adolescence. In: Bright Futures: Guidelines for health supervision of infants, children, and adolescents, 3, Hagan JF, Shaw JS, Duncan PM.  (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2008. p.512, 563.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/46\">",
"      Klein JD, Camenga DR. Tobacco prevention and cessation in pediatric patients. Pediatr Rev 2004; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/47\">",
"      Epps RP, Manley MW. Prevention of tobacco use during childhood and adolescence. Five steps to prevent the onset of smoking. Cancer 1993; 72:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/48\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/49\">",
"      Benuck I, Gidding SS, Binns HJ. Identification of adolescent tobacco users in a pediatric practice. Arch Pediatr Adolesc Med 2001; 155:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/50\">",
"      Kaplan CP, P&eacute;rez-Stable EJ, Fuentes-Afflick E, et al. Smoking cessation counseling with young patients: the practices of family physicians and pediatricians. Arch Pediatr Adolesc Med 2004; 158:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/51\">",
"      Males M. The influence of parental smoking on youth smoking: is the recent downplaying justified? J Sch Health 1995; 65:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/52\">",
"      Winickoff JP, Berkowitz AB, Brooks K, et al. State-of-the-art interventions for office-based parental tobacco control. Pediatrics 2005; 115:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/53\">",
"      Tyc VL, Throckmorton-Belzer L. Smoking rates and the state of smoking interventions for children and adolescents with chronic illness. Pediatrics 2006; 118:e471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/54\">",
"      Precht DH, Keiding L, Madsen M. Smoking patterns among adolescents with asthma attending upper secondary schools: a community-based study. Pediatrics 2003; 111:e562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/55\">",
"      Bender BG. Depression symptoms and substance abuse in adolescents with asthma. Ann Allergy Asthma Immunol 2007; 99:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/56\">",
"      Hublet A, De Bacquer D, Boyce W, et al. Smoking in young people with asthma. J Public Health (Oxf) 2007; 29:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/57\">",
"      Verma A, Clough D, McKenna D, et al. Smoking and cystic fibrosis. J R Soc Med 2001; 94 Suppl 40:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/58\">",
"      den Exter Blokland EA, Engels RC, Hale WW 3rd, et al. Lifetime parental smoking history and cessation and early adolescent smoking behavior. Prev Med 2004; 38:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/59\">",
"      Sims TH, Committee on Substance Abuse. From the American Academy of Pediatrics: Technical report--Tobacco as a substance of abuse. Pediatrics 2009; 124:e1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/60\">",
"      Rosen LJ, Noach MB, Winickoff JP, Hovell MF. Parental smoking cessation to protect young children: a systematic review and meta-analysis. Pediatrics 2012; 129:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/61\">",
"      Frankowski BL, Weaver SO, Secker-Walker RH. Advising parents to stop smoking: pediatricians' and parents' attitudes. Pediatrics 1993; 91:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/62\">",
"      Winickoff JP, Tanski SE, McMillen RC, et al. A national survey of the acceptability of quitlines to help parents quit smoking. Pediatrics 2006; 117:e695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/63\">",
"      Winickoff JP, Park ER, Hipple BJ, et al. Clinical effort against secondhand smoke exposure: development of framework and intervention. Pediatrics 2008; 122:e363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/64\">",
"      Mills AL, Messer K, Gilpin EA, Pierce JP. The effect of smoke-free homes on adult smoking behavior: a review. Nicotine Tob Res 2009; 11:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/65\">",
"      Wakefield MA, Chaloupka FJ, Kaufman NJ, et al. Effect of restrictions on smoking at home, at school, and in public places on teenage smoking: cross sectional study. BMJ 2000; 321:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/66\">",
"      Sargent JD, Dalton M. Does parental disapproval of smoking prevent adolescents from becoming established smokers? Pediatrics 2001; 108:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/67\">",
"      Jackson C, Dickinson D. Enabling parents who smoke to prevent their children from initiating smoking: results from a 3-year intervention evaluation. Arch Pediatr Adolesc Med 2006; 160:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/68\">",
"      Jackson C, Dickinson D. Can parents who smoke socialise their children against smoking? Results from the Smoke-free Kids intervention trial. Tob Control 2003; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/69\">",
"      Hecht ML, Graham JW, Elek E. The drug resistance strategies intervention: program effects on substance use. Health Commun 2006; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/70\">",
"      Thomas R, Perera R. School-based programmes for preventing smoking. Cochrane Database Syst Rev 2006; :CD001293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/71\">",
"      Johnston V, Liberato S, Thomas D. Incentives for preventing smoking in children and adolescents. Cochrane Database Syst Rev 2012; 10:CD008645.",
"     </a>",
"    </li>",
"    <li>",
"     2012 US Surgeon General's Report: Preventing tobacco use among youth and young adults. US Department of Health and Human Services, Rockville MD, 2012. p. 792. Available at: file://www.surgeongeneral.gov/library/preventing-youth-tobacco-use/full-report.pdf (Accessed on April 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/73\">",
"      Thomas RE, Baker P, Lorenzetti D. Family-based programmes for preventing smoking by children and adolescents. Cochrane Database Syst Rev 2007; :CD004493.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Smoking &amp; Tobacco Use: Smokeless tobacco facts file://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/smokeless_facts/index.htm#use (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     National Cancer Institute. Fact Sheet: Smokeless Tobacco and Cancer www.cancer.gov/cancertopics/factsheet/tobacco/smokeless/ (Accessed on July 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/76\">",
"      Tomar SL, Winn DM, Swango PA, et al. Oral mucosal smokeless tobacco lesions among adolescents in the United States. J Dent Res 1997; 76:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/77\">",
"      Dent CW, Sussman S, Johnson CA, et al. Adolescent smokeless tobacco incidence: relations with other drugs and psychosocial variables. Prev Med 1987; 16:422.",
"     </a>",
"    </li>",
"    <li>",
"     2012 US Surgeon General's Report: Preventing tobacco use among youth and young adults. US Department of Health and Human Services, Rockville MD, 2012. p. 802. Available at: file://www.surgeongeneral.gov/library/preventing-youth-tobacco-use/full-report.pdf (Accessed on April 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/79\">",
"      King C 3rd, Siegel M. The Master Settlement Agreement with the tobacco industry and cigarette advertising in magazines. N Engl J Med 2001; 345:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/80\">",
"      Henriksen L, Schleicher NC, Feighery EC, Fortmann SP. A longitudinal study of exposure to retail cigarette advertising and smoking initiation. Pediatrics 2010; 126:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/81\">",
"      Primack BA, Longacre MR, Beach ML, et al. Association of established smoking among adolescents with timing of exposure to smoking depicted in movies. J Natl Cancer Inst 2012; 104:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/82\">",
"      Sargent JD, Tanski S, Stoolmiller M. Influence of motion picture rating on adolescent response to movie smoking. Pediatrics 2012; 130:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/83\">",
"      Sargent JD, Tickle JJ, Beach ML, et al. Brand appearances in contemporary cinema films and contribution to global marketing of cigarettes. Lancet 2001; 357:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/84\">",
"      Centers for Disease Control and Prevention (CDC). Smoking in top-grossing movies --- United States, 1991-2009. MMWR Morb Mortal Wkly Rep 2010; 59:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/85\">",
"      Farrelly MC, Davis KC, Duke J, Messeri P. Sustaining 'truth': changes in youth tobacco attitudes and smoking intentions after 3 years of a national antismoking campaign. Health Educ Res 2009; 24:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/86\">",
"      Levinson AH, Hendershott S, Byers TE. The ID effect on youth access to cigarettes. Tob Control 2002; 11:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/87\">",
"      Ribisl KM, Williams RS, Kim AE. Internet sales of cigarettes to minors. JAMA 2003; 290:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37081/abstract/88\">",
"      Grossman M, Chaloupka FJ. Cigarette taxes. The straw to break the camel's back. Public Health Rep 1997; 112:290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14583 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37081=[""].join("\n");
var outline_f36_13_37081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15124898\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124707\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124714\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15124721\">",
"      Prevalence and trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15124728\">",
"      Persistence of smoking into adulthood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124735\">",
"      FACTORS CONTRIBUTING TO SMOKING INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15124743\">",
"      Attitudes and beliefs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15124750\">",
"      Nicotine dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10239848\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124835\">",
"      SMOKING PREVENTION IN THE PRIMARY CARE OFFICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11571243\">",
"      Ask about smoking habits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33466776\">",
"      Advise about the health risks of smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33467654\">",
"      Assess risk factors for smoking initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10240060\">",
"      Assist with parenting skills and smoking resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5194262\">",
"      - Guidance for parents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11572038\">",
"      - Fostering smoking resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11575502\">",
"      Arrange follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11571116\">",
"      SMOKING PREVENTION IN OTHER SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11571124\">",
"      School-based interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11571131\">",
"      Family-based interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5188977\">",
"      SMOKELESS TOBACCO AND ALTERNATIVE NICOTINE SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124877\">",
"      ADVERTISING AND MEDIA INFLUENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124884\">",
"      YOUTH ACCESS TO TOBACCO PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15124898\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14583|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/63/19454\" title=\"figure 1\">",
"      Trends in smoking rates among US youth and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/25/2461\" title=\"table 1\">",
"      Alternate forms of tobacco",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/1/39965\" title=\"table 2\">",
"      5As of smoking prevention counseling children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/2/12333\" title=\"table 3\">",
"      Age-specific counseling to prevent smoking initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/6/31852\" title=\"table 4\">",
"      Smoking consequences among adolescents with chronic illnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/33/11803\" title=\"table 5\">",
"      Risk factors for smoking initiation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41497?source=related_link\">",
"      Management of smoking cessation in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_13_37082="Patient survival and maintenance dialysis";
var content_f36_13_37082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient survival and maintenance dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/13/37082/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/13/37082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although maintenance dialysis prevents death from uremia, patient survival remains an important issue. Once renal replacement therapy is initiated, the range of the expected remaining life span in the United States Renal Data System report was approximately 8 years (varies with race) for dialysis patients aged 40 to 44, and approximately 4.5 years for those 60 to 64 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"     1",
"    </a>",
"    ]. These values in older patients are only slightly better than those in patients with lung cancer and are much worse than the general population (which is 30 to 40 years for those aged 40 to 44, and 17 to 22 years for individuals aged 60 to 64). Despite this, some evidence suggests that mortality rates among incident dialysis patients have decreased over the last few years, suggesting that improvements in therapy may provide beneficial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is well established that inadequate dialysis is a contributor to lower overall survival. This has important implications since more intensive dialysis, particularly above a certain threshold value, may improve survival, as possibly with nocturnal hemodialysis.",
"   </p>",
"   <p>",
"    Additional factors associated with the dialysis procedure may also correlate with decreased survival. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis vintage is associated with an enhanced risk of death, with each year of dialysis treatment increasing the risk of death by approximately 6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Potassium levels less than 4.0 or greater than 5.6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      are associated with increased mortality in hemodialysis patients, compared with serum levels between 4.6 and 5.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States, some, but not all, studies have reported that mortality may be lower among dialysis patients being treated in not-for-profit facilities compared to those undergoing dialysis in for-profit facilities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/4-8\">",
"       4-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of those factors associated with mortality among dialysis patients, with an emphasis upon those characteristics related to dialysis itself, will be presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing the different factors underlying mortality in dialysis patients, it is helpful to briefly review the major causes of death in this patient population: cardiovascular disease, infection, and withdrawal from dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,9-11\">",
"     1,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular disease accounts for approximately 50 percent of deaths. While a decline in cardiovascular deaths has occurred in the general population, a similar trend has not been observed in dialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"       1",
"      </a>",
"      ]. This discrepancy is in part due to the demographics of patients about to be started on dialysis: about 40 percent are diabetic; the average age is now approximately 60 years and about 20 percent are over 75 years; and many patients have underlying cardiac disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors not related to dialysis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11288?source=see_link\">",
"       \"Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections, which are the second most common cause of death, are usually due to common organisms (such as Staphylococcus aureus) and are frequently related to the hemodialysis vascular access [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link\">",
"       \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37849?source=see_link\">",
"       \"Non-access related infections in chronic dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Withdrawal from dialysis accounts for approximately 15 to 25 percent of patient deaths. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=see_link\">",
"       \"Withdrawal from and withholding of dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS NOT RELATED TO DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of risk factors for decreased survival that are unrelated to the dialysis procedure have been identified, making prognostic evaluation of a single patient more accurate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of comorbid disease is an increasingly common problem, being much more prevalent in new patients started on dialysis today than previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,11,13-19\">",
"     1,11,13-19",
"    </a>",
"    ]. As noted in the 2007 United States Renal Data System Annual Report, diabetes mellitus was the leading cause of end-stage renal disease in those initiating hemodialysis (44 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"     1",
"    </a>",
"    ]. Extended survival at ten years appears to be less likely for diabetic as compared to nondiabetic patients (4 versus 11 to 14 percent).",
"   </p>",
"   <p>",
"    Heart disease is also very common in the dialysis population. Approximately 80 percent of all patients enrolled in the HEMO study were noted to have some form of heart disease, with nearly 40 percent having ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/20\">",
"     20",
"    </a>",
"    ]. It has also been estimated that only 27 percent of patients about to enter a dialysis regimen have a normal echocardiogram, while 19 percent already have severe left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition, as many as 75 percent of the total end-stage renal disease population have at least a 50 percent narrowing of at least one coronary artery. Even patients with mild to moderate chronic renal failure are at markedly increased cardiovascular risk, with chronic renal disease alone currently considered a coronary heart disease risk equivalent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to antecedent coronary artery disease, additional factors common in dialysis patients may promote the development of coronary disease and enhanced cardiovascular mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension, which is present in approximately 80 percent of patients at the onset of dialysis and, with effective fluid control, about 25 to 30 percent at the end of the first year. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20202?source=see_link\">",
"       \"Hypertension in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic abnormalities, particularly hyperphosphatemia, an elevated calcium phosphorous product, and increased parathyroid hormone levels. These extremely common abnormalities are increasingly recognized as possibly important unique risk factors for dialysis patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"       \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"       \"Vascular calcification in chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H22\">",
"       'Disorders of mineral metabolism'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy, due in part to hypertension, chronic anemia, and perhaps decreased renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=see_link\">",
"       \"Myocardial dysfunction in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperlipidemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"       \"Chronic kidney disease and coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetes mellitus, which is a major risk factor for coronary artery disease (in patients with and without renal failure) and is common among patients requiring dialysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"       \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The concurrent presence of other life-threatening conditions will also affect overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/17,19,23-25\">",
"     17,19,23-25",
"    </a>",
"    ]. In an extensive analysis of DOPPS data, 17 comorbid conditions accounted for nearly all of the total variance that predicted survival among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Underlying renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five year survival among dialysis patients is best with chronic glomerular diseases and polycystic kidney disease, intermediate with hypertension-induced renal disease, and worst with diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]; five year survival of the patient with diabetic nephropathy is only 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival declines with increasing age, with patients under age 45 doing best [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,13,26,27\">",
"     1,13,26,27",
"    </a>",
"    ]. Elderly patients with renal vascular disease appear to have the worst prognosis, with such patients having 5 and 10 year survival rates of only approximately 15 and 5 percent, respectively. In one prospective study from Canada, these elderly patients were frequently not offered dialysis as possible therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Country",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival among dialysis patients has been substantially lower in the United States than in Europe and Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/13,17,27,30,31\">",
"     13,17,27,30,31",
"    </a>",
"    ]. Some evidence suggests that this is due in part to general differences in mortality (particularly that due to cardiovascular disease) among the general population in various countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In one European study that adjusted for age, gender, and diabetes, for example, approximately 25 percent of the difference in mortality among dialysis patients between the Northern and Southern areas of Europe could be attributed to differences in mortality in the general population of these areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in mortality in various countries and geographic regions therefore cannot be entirely explained by differences among patients that are unrelated to dialysis itself. These include variations among comorbid conditions (with increased incidence of diabetes, psychiatric diseases, and cardiovascular disease [heart failure and peripheral vascular disease] in the United States), patient age (which tends to be higher in the United States), racial or genetic differences, other demographic factors, or differences in transplantation rate (low rate in Japan) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/17,31\">",
"     17,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that may contribute to the differences in survival include variations in underlying renal disease (such as increased incidence of IgA nephropathy in Japan) and differences in thresholds for accepting patients for dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/31\">",
"     31",
"    </a>",
"    ]. A decline in the relative mortality rates in the United States may reflect the consistent widespread improvement in the overall quality of the national dialysis prescription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Improved survival with more intensive dialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, African-Americans and Asian-Americans have a lower mortality rate than whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1,34-36\">",
"     1,34-36",
"    </a>",
"    ]. In one study, the survival rates of black, white, and other races at five years were 35, 25, and 32 percent, respectively. Similar relative results were observed in a single center study, which reported 47 and 36 percent survival rates at five years for black and white patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/37\">",
"     37",
"    </a>",
"    ]. In initial studies, this survival advantage appeared to persist after adjustment for patient characteristics, comorbidities, and laboratory abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/34,38\">",
"     34,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However in subsequent studies, the survival advantage was markedly attenuated or lost in multivariate analyses that adjusted for other patient variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, in an analysis of outcomes of 1,330,007 patients identified in the United States Renal Data System, although the survival of black patients as a group was better compared to white patients, this advantage was modified by age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/40\">",
"     40",
"    </a>",
"    ]. Whereas a survival advantage persisted for black patients over 50, black patients younger than 50 had higher mortality compared to white counterparts, particularly when transplantation was factored in as a competing risk.",
"   </p>",
"   <p>",
"    The underlying reasons for increased survival among older blacks are unclear. One possibility is that mortality among blacks with predialysis chronic kidney disease (CKD) is much higher than among whites with predialysis kidney disease, resulting in the selection of relatively \"healthier\" patients who eventually require dialysis. This, in turn, would result in an apparent survival advantage among blacks with ESRD. Support for this hypothesis was provided by a study of participants of the Third National Health and Nutrition Examination Survey in which a higher risk for death in early stages of CKD was observed among blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/41\">",
"     41",
"    </a>",
"    ]. Another possibility is that black dialysis patients may have a relatively greater use of activated vitamin D therapy, a modality indirectly linked with improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial factors also appear to significantly affect mortality, independent of the presence of other comorbid conditions. Increased levels of social support, enhanced behavioral compliance, and positive perceptions of the effects of illness are all associated with a decreased risk of dying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/43\">",
"     43",
"    </a>",
"    ]. Their effect on mortality appears to be equivalent to those of medical risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/3/11322?source=see_link\">",
"     \"Psychiatric illness in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Location of residence may alter survival. Residence in areas with higher median household income has been associated with improved survival, and among blacks, residence in highly segregated areas with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is greater medical risk and increased mortality in undernourished patients, particularly those with hypoalbuminemia. Although these observations have primarily been made in patients on maintenance hemodialysis and are related to the dialysis dose (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Malnutrition'",
"    </a>",
"    below), the presence of malnutrition prior to the initiation of dialysis is strongly predictive of increased mortality with the onset of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617445752\">",
"    <span class=\"h2\">",
"     Salt intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;A post-hoc analysis of the HEMO study including 1770 hemodialysis patients has suggested that higher reported dietary sodium intake and the ratio of sodium to calorie or potassium intake are associated with increased all-cause mortality and a slightly increased ultrafiltration requirement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/46\">",
"     46",
"    </a>",
"    ]. Reported sodium intake was not associated with pre-dialysis systolic blood pressure. Prescribed sodium restriction was not associated with mortality, systolic blood pressure or ultrafiltration requirement in this study. This study is somewhat limited by the use of dietary recall, which may have underestimated both sodium and calorie intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/47\">",
"     47",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect on mortality of a number of additional patient characteristics has been assessed, primarily in observational cohort studies; to what extent there is a direct cause and effect relationship between these characteristics and mortality amongst ESRD patients is largely unknown.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation &mdash; Dialysis patients with evidence of an ongoing inflammatory state have an enhanced mortality. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum cardiac enzymes &mdash; Elevations of cardiac troponin T among asymptomatic chronic dialysis patients are associated with decreased survival. The exact source of cTnT in this setting and the reasons for the correlation between elevated levels and a poor prognosis are unknown. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"       \"Serum cardiac enzymes in patients with renal failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep disorder &mdash; The presence of a sleep disorder enhances the risk of death in patients without renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .) A paucity of data exists concerning their effect upon survival in patients undergoing maintenance dialysis. Limited observational evidence suggests that the presence of periodic limb movements in sleep, the total number of arousals, and a decline in sleep quality during the first year on dialysis may strongly and independently correlate with near-term mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Predialysis care &mdash; An increasing number of studies, although all observational and retrospective, suggest that patients referred late to a nephrologist for predialysis medical care, compared with those referred early in the disease course, have an enhanced mortality risk once dialysis is initiated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25640?source=see_link\">",
"       \"Late referral to nephrologists of patients with chronic kidney disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is marked variability in the quality of predialysis care based upon the medical center and geographic area. In the United States, there also appears to be geographic clustering of centers with increased mortality and less than adequate predialysis care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemoglobin levels &mdash; A discussion of the role of low hemoglobin levels in association with mortality among patients with renal disease is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"       \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is also some evidence that variability in hemoglobin levels increases mortality in ESRD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/51-53\">",
"       51-53",
"      </a>",
"      ]. This was shown in a retrospective cohort study of 34,963 hemodialysis patients in which survival analysis found that each 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase in hemoglobin variability (defined by the residual standard deviation) was associated with a 33 percent increase in the death rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fractures &mdash; Patients with ESRD who fall and have hip fractures have an increased risk of death, which is higher than that observed in those without fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. This was shown in a study from the United States Renal Systems Database in which dialysis patients with a hip fracture had a two-fold higher risk of death than those matched controls with a fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/55\">",
"       55",
"      </a>",
"      ]. Risk factors for falling include older age, diabetes, high number of prescribed oral drugs, antidepressant use, and inability to walk without significant help [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frailty &mdash; Frailty is defined by the presence of three or more of the following: weight loss, muscle weakness, fatigue or exhaustion, low physical activity, and slow gait. Independent of age, increased mortality is noted among frail dialysis patients. As an example, based upon data from 2275 adults from the dialysis Wave 2 study, a higher risk of death was noted among those defined as frail (adjusted hazard ratio 2.24, 95% CI 1.60-3.15) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Noncompliance &mdash; Noncompliance, which can be defined in part by regularly skipping hemodialysis sessions and poor adherence to dietary restrictions, is associated with increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/57\">",
"       57",
"      </a>",
"      ]. In a study of 739 patients of whom 67 were classified as skippers (absent &gt;3 percent of treatments), increased mortality was associated with skipping (hazard ratio 1.69, 95% CI 1.23-2.3) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical activity &mdash; Habitual physical activity has been associated with decreased mortality among patients undergoing maintenance hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/58-61\">",
"       58-61",
"      </a>",
"      ]. As an example, among 202 hemodialysis outpatients, at a median follow-up of 45 months, mortality risk decreased with increased physical activity, as quantitated by an accelerometer (hazard ratio per 10",
"      <span class=\"nowrap\">",
"       min/day",
"      </span>",
"      increase in physical activity 0.78 [95% CI 0.66-0.92]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/60\">",
"       60",
"      </a>",
"      ]. A similar observation was made in the Comprehensive Dialysis Study, in which, among 1554 ambulatory dialysis patients, lower physical activity estimated using the 94-item Human Activity Profile (HAP) was associated with increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional features &mdash; A large number of additional patient characteristics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      agents are reportedly associated with mortality. These include periodontal disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and high blood lead levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/62-65\">",
"       62-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remainder of this topic review will focus upon those factors largely unique to the dialysis procedure that affect patient mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADEQUACY OF DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The higher mortality rate in the United States was thought to be related at least in part to",
"    <strong>",
"     inadequate dialysis",
"    </strong>",
"    . The weekly dialysis times declined progressively in the United States from 25 to 40 hours in the 1960s to 12 to 15 hours in the 1970s and 1980s to as low as seven to eight hours in the 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in both Germany and the United States have documented the relationship between shorter dialysis time and poorer outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Patients dialyzed fewer than 3.5 hours three times per week have approximately twice the mortality risk compared to patients dialyzed four or more hours three times per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The group from Tassin, France has reported one of the best dialysis survival estimates of any program or registry, with a 15-year survival rate of 65 percent in 445 patients followed from 1970 through 1990 (",
"    <a class=\"graphic graphic_figure graphicRef53811 \" href=\"mobipreview.htm?42/40/43661\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/27\">",
"     27",
"    </a>",
"    ]. These patients, who were dialyzed very intensively",
"    <span class=\"nowrap\">",
"     (Kt/V",
"    </span>",
"    of 1.67), also had a high incidence of full rehabilitation and almost all patients were rendered normotensive on no antihypertensive medications.",
"   </p>",
"   <p>",
"    Similar benefits with longer times on dialysis have been observed among patients undergoing nocturnal hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Historic overview of survival and Kt/V",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utilization of urea kinetic modeling and the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    index was in part responsible for the decreasing hemodialysis time and concomitant increase in mortality in the United States. Urea kinetic modeling became widely applied after the results of the National Cooperative Dialysis Study (NCDS) were published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The NCDS found that a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    urea above 0.9 with thrice weekly treatment provided an \"adequate\" dialysis prescription in that the patient failure rate of 13 percent was substantially below that in patients with a lower",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the NCDS included no diabetic patients or those with other important comorbid conditions, a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.0 was widely accepted as representing adequate dialysis. Shorter dialysis times were permitted as long as the goal",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was attained. However, this goal was quite arbitrary, since no attempt was made in the NCDS to determine whether a higher",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    might be associated with further clinical, biochemical, or rehabilitative improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Improved survival with more intensive dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent observational data suggested that a higher",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    was beneficial. Excellent survival rates have been reported in Tassin, France",
"    <span class=\"nowrap\">",
"     (Kt/V",
"    </span>",
"    &gt;1.6) and Minnesota, United States",
"    <span class=\"nowrap\">",
"     (Kt/V",
"    </span>",
"    &gt;1.3) where patients, even those in high-risk groups, were more intensively dialyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/27,73\">",
"     27,73",
"    </a>",
"    ]. Urea kinetic modeling was utilized, but attention was paid to all the details involved in delivering a more optimal dialysis prescription. This improvement in survival occurred despite a striking increase in comorbidity, which itself would have decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were reported in a retrospective analysis of 13,473 patients in which patient outcome was compared to dialysis intensity. Patient survival was significantly reduced at urea reduction ratios below 60 percent",
"    <span class=\"nowrap\">",
"     (Kt/V",
"    </span>",
"    below 1.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/74\">",
"     74",
"    </a>",
"    ]. A definition of the urea reduction ratio can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of observational studies were compatible with the hypothesis that more intensive dialysis leads to improved survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, increasing the mean",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      from 0.82 (pre-1988) to 1.33 led to a reduction in the gross mortality rate from 22.8 down to 9.1 percent per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/75\">",
"       75",
"      </a>",
"      ]. This was associated with increases in protein catabolic rate from 0.83 to 1.0 (an index of protein intake (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/277?source=see_link\">",
"       \"Protein catabolic rate in maintenance dialysis\"",
"      </a>",
"      )) and in plasma albumin concentration from 3.5 to 3.9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (35 to 39",
"      <span class=\"nowrap\">",
"       g/L).",
"      </span>",
"      Thus, enhanced nutrition probably contributed to the improvement in survival (see below). However, increasing the degree of dialysis was associated with the use of biocompatible hemodialysis membranes; it is therefore possible that the observed benefits were due at least in part to avoidance of bioincompatible membranes (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Hemodialysis membranes'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In another report, increasing the mean",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      from 1.18 (pre-1989) to 1.46 (and the urea reduction ratio from 61 to 70 percent) led to a reduction in the gross mortality rate from 22.5 down to 18.1 percent per year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/76\">",
"       76",
"      </a>",
"      ]. This improvement was achieved with standard cellulosic bioincompatible membranes.",
"     </li>",
"     <li>",
"      A national sample in the United States suggested a 7 percent reduction in mortality for each 0.1 unit increase in",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef77222 \" href=\"mobipreview.htm?6/43/6846\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/77\">",
"       77",
"      </a>",
"      ]. Although no statistically significant benefit was noted above a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.3, a projected trend favoring an increased benefit with increasing dialysis was observed above this dialysis level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A difficulty concerning the optimal dialysis dose was that some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/80\">",
"     80",
"    </a>",
"    ], studies observed an increased relative risk of death among patients with extremely high values for",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    (greater than 1.6) or the urea reduction ratio (URR between 75 and 79 percent). Since these values reflect increased urea clearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an extremely low body volume (which may represent poor nutrition), the increased death rate may have been due to the effects of marked malnutrition.",
"   </p>",
"   <p>",
"    Support for this hypothesis comes from a study that evaluated the correlation between mortality, dialysis dose, and body volume in over 3000 dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/79\">",
"     79",
"    </a>",
"    ]. Consistent with previous reports, patients with a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR value in the highest (or fifth) quintile had an increased relative risk of death (19 percent greater than those in the third quintile). However, a higher Kt alone was not associated with an increased relative risk of death, as there was a 2 percent decrease in mortality risk per liter increase in clearance.",
"   </p>",
"   <p>",
"    These observations, in combination with the finding that patients in the fifth quintile suffered from more severe protein-calorie malnutrition, suggest that the increased mortality associated with very high",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or URR values may reflect poor nutrition. Such findings support the use of alternative measures of dialysis adequacy, such as the Kt alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observational studies, the optimal level of hemodialysis and the best measure of hemodialysis adequacy were",
"    <strong>",
"     therefore undefined",
"    </strong>",
"    . Statistical analysis of the previous studies as well as others by Gotch et al suggested that faulty methodology may have supported the conclusion that increasing dialysis equals increasing survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/81\">",
"     81",
"    </a>",
"    ]. The above studies were also retrospective in design and ignored the wide variation in dialysis delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     HEMO study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to overcome these difficulties concerning survival and dialysis dose (as well as survival and low and high flux dialysis membranes), a large prospective clinical trial, called the Hemodialysis (",
"    <strong>",
"     HEMO",
"    </strong>",
"    ) Study, was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/82\">",
"     82",
"    </a>",
"    ]. In this study, 1846 patients were randomly assigned to a standard or high dose of dialysis",
"    <strong>",
"     and",
"    </strong>",
"    a low- or high-flux dialyzer. The standard dose goal was an equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.05, which is equivalent to a urea reduction ratio of 65 percent or a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.25. The high dose goal was an equilibrated",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.45, which is the same as a ratio of 75 percent or a single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.65. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access), and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of greater than 15 percent of the serum albumin from baseline value or death.",
"   </p>",
"   <p>",
"    The following results concerning dialysis dose were reported at a mean follow-up of 4.5 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impressive separation was obtained. The standard dose group received an equilibrated",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.16, a single-pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of 1.32, and a urea reduction ratio of 66.3 percent, while the high dose group had values of 1.53, 1.71, and 75.2 percent, respectively.",
"     </li>",
"     <li>",
"      The risk of death from any cause, the primary outcome, was the",
"      <strong>",
"       same",
"      </strong>",
"      in the high and standard dose groups (RR of 0.96 for high versus standard dose, CI of 0.84-1.10).",
"     </li>",
"     <li>",
"      The risk of the main secondary outcomes (as previously delineated) was also the",
"      <strong>",
"       same",
"      </strong>",
"      for both dialysis doses.",
"     </li>",
"     <li>",
"      Subgroup analysis revealed a significant survival benefit for",
"      <strong>",
"       women",
"      </strong>",
"      receiving a high dialysis dose (19 percent lower risk of death than women in the standard dose group). However, men receiving high dose dialysis had a 16 percent higher risk of death than those receiving standard dose dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent analysis found that differences in dialysis dose also had no effect upon the incidence of infection-related deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, hemodialysis patients",
"    <strong>",
"     do not",
"    </strong>",
"    appear to derive a major benefit from a higher than standard dialysis dose, as recommended by the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some data suggest that mortality among patients in dialysis centers with the highest percentage of patients who exceed current",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines (urea reduction ratios of greater than 65 percent) is lower than those with fewer patients who achieve these ratios. As an example, based upon data from 2858 United States dialysis facilities from 1999 to 2002, those centers in the lowest quintile for the percentage of patients with higher than recommended urea reduction ratios had 22 percent higher mortality rates than those in the highest quintile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated with PD, a similar correlation between the degree of solute clearance (measured weekly either by",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or the creatinine clearance) and survival was also postulated to exist. This hypothesis was supported by the results of a prospective, cohort, multicenter study in Canada and the United States (CANUSA) which evaluated the relationship of the adequacy of dialysis and nutritional status to mortality, morbidity, and technique failure.",
"   </p>",
"   <p>",
"    However, survival in this study was related to residual renal function (which changed over time) and",
"    <strong>",
"     not",
"    </strong>",
"    to peritoneal clearance alone (which did not change). Confirmation that an increase in peritoneal clearance alone (beyond a minimum threshold value) is not a principle factor underlying survival was provided by the ADEMEX trial. Instead, subsequent analysis of this trial found that measures of health-related quality of life significantly predicted patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival, dialysis adequacy, and the biocompatibility of hemodialysis membrane may all be closely interrelated. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences in survival may also be due to variations in the ability of hemodialysis membranes to remove molecules larger than urea, the so-called middle molecules. High flux membranes are better able to remove such substances compared to that observed with low flux membranes. Whether survival differs upon exposure to high and low flux membranes was also evaluated in the HEMO Study, in which nearly 2000 patients were randomly assigned to a standard or high dose of dialysis",
"    <strong>",
"     and",
"    </strong>",
"    a low- or high-flux dialyzer (based on clearance of beta-2-microglobulin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/82\">",
"     82",
"    </a>",
"    ]. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access), and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of greater than 15 percent of the serum albumin from baseline value or death. The results and discussion relating to survival and dialysis dose can be found elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'HEMO study'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With respect to dialysis membranes, the following results were reported at a mean follow-up of 4.5 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impressive separation was obtained as the low and high flux groups had clearances of beta-2-microglobulin of 3 and 34",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The risk of death from any cause, the primary outcome, was the",
"      <strong>",
"       same",
"      </strong>",
"      in the high and low flux groups (RR of 0.92).",
"     </li>",
"     <li>",
"      The risk of the main secondary outcomes (as previously delineated) was also the",
"      <strong>",
"       same",
"      </strong>",
"      for both flux groups. In the high flux group, there were significant reductions, compared with the low flux group, in the risk of death from cardiac causes and the combined outcome of first hospitalizations or death from a cardiac cause [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/20\">",
"       20",
"      </a>",
"      ]. However, as previously mentioned, total mortality was the same in both flux groups.",
"     </li>",
"     <li>",
"      Subgroup analysis revealed a significant survival benefit for patients with more than 3.7 years of dialysis receiving high flux dialysis (32 percent lower risk than the low flux group). However, men receiving high dose dialysis had a 16 percent higher risk of death than those receiving standard dose dialysis, and the strength of the interaction between flux and years of dialysis was weakened when years of dialysis was treated as a continuous variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent analysis found that differences in dialysis membrane also had no effect upon the incidence of infection-related deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, as noted in the HEMO study, survival was the",
"    <strong>",
"     same",
"    </strong>",
"    in patients chronically dialyzed with either high or low flux dialysis membranes. This was also found in the Membrane Permeability Outcome (MPO) study, in which 738 incident hemodialysis patients, separated by serum albumin levels &le;4 and &gt;4",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    were randomly assigned to high or low flux dialysis membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/86\">",
"     86",
"    </a>",
"    ]. Overall, there was no difference in survival with either membrane, although there was a nonsignificant trend for increased survival with high flux (RR 0.76, 95% 0.56-1.04). Among the subgroup of patients with serum albumin &le;4",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    survival was significantly higher in the high flux group (HR 0.63, 95% CI 0.45-0.90). This is less likely to be a spurious finding given that this was a prespecified subgroup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/87\">",
"     87",
"    </a>",
"    ]; nevertheless, this result was not observed in the HEMO trial and should be confirmed by additional studies.",
"   </p>",
"   <p>",
"    Although not directly applicable to the chronic setting, the relative risk for mortality (and recovery of renal function) also appears to be the same with both high and low flux membranes among those with acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS SESSION LENGTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of hemodialysis session length on mortality independent of conventional markers of dialysis adequacy is unclear among patients undergoing standard three times per week dialysis therapy. Some observational studies of large databases suggest that increased session length improves survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon data from the Dialysis Outcomes and Practice Patterns Study of 22,000 hemodialysis patients, treatment time that was greater than 240 minutes per session was significantly associated with decreased risk of mortality (RR of 0.81) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/90\">",
"       90",
"      </a>",
"      ]. In addition, a seven percent lower relative risk of death was observed with each additional one-half hour time on dialysis.",
"     </li>",
"     <li>",
"      In a study of 6593 patients in the",
"      <span class=\"nowrap\">",
"       Australian/New",
"      </span>",
"      Zealand registry, the lowest mortality risk was observed in patients with hemodialysis session lengths of 4.5 to 4.9 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies did not control for body size which is usually a determinant of session length. However, support for a role of session length independent of body size was provided by an analysis of data from a large outpatient dialysis organization that showed that treatment time less than 240 minutes per session was associated with increased mortality independent of body size (HR of 1.26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the effect of prolonged dialysis session length on outcomes, including survival, with nocturnal hemodialysis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CONTROL OF FLUID BALANCE AND HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate fluid removal depends upon the technical ability to remove excess fluid, the patient's tolerance to the fluid removal rate, and the patient's adherence to fluid-intake restrictions. Shorter dialysis necessitates more rapid fluid removal, which is more likely to induce episodes of hypotension that are treated with fluid administration. The net effect is that \"dry weight\" is never achieved, leading to persistent volume expansion, hypertension, and possible deterioration in left ventricular function. These complications may contribute to the high cardiac mortality in dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dry weight has been defined as not merely the absence of edema, but the minimal body sodium content and volume of body water that can be tolerated without inducing hypotension. Gradual fluid removal with longer dialysis permits a greater degree of total fluid loss and more likely attainment of dry weight. As an example, slow dialysis, such as with nocturnal hemodialysis, commonly results in normotensive patients who do not require the use of antihypertensive medications. The ability to discontinue drug therapy may be an important component of this regimen, since it further minimizes the risk of hypotension as the excess fluid is removed.",
"   </p>",
"   <p>",
"    The ability to remove adequate fluid also depends upon the ability of the patient to adhere to fluid-intake restrictions. Some data suggest that psychologic interventions may improve the ability to adhere to such restrictions, although the quality of the medical literature is generally poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate total body fluid removal may increase the overall risk of death. In one study of over 3,000 hemodialysis patients, the relative risk of death was correlated with ultrafiltration status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/94\">",
"     94",
"    </a>",
"    ]. In this study, soft tissue hydration was determined via bioelectric impedance analysis and impedance vector length; a shorter vector length, which was associated with inadequate ultrafiltration, was associated with a increased relative risk of death. A similar correlation between survival and ultrafiltration was observed in a study from the Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Better volume management via intradialytic blood volume monitoring may improve outcomes, including mortality. This was evaluated in a six month study in which 443 patients were randomly assigned to an intradialytic blood volume monitoring device and conventional monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/96\">",
"     96",
"    </a>",
"    ]. Mortality and non-access related hospitalizations were significantly higher with the device; this result may have been due in part to the atypically low hospitalization and mortality rates for the conventionally monitored group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520250775\">",
"    <span class=\"h1\">",
"     INTERDIALYTIC INTERVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long interdialytic intervals that occur over a weekend among patients who are dialyzed on a three times weekly schedule likely contribute to mortality and morbidity. This was suggested by a retrospective analysis of 32,065 hemodialysis patients who participated in the End Stage Renal Disease Clinical Performance Measures Project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/97\">",
"     97",
"    </a>",
"    ]. This analysis demonstrated an increase in all-cause mortality on the day following the long interval compared to other days (22.1 versus 18.0 deaths per 100 person-years). After the long interval there was also an increase in the following (per 100 patient-years):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality from cardiac causes (10 versus 7.5)",
"     </li>",
"     <li>",
"      Mortality from infection (2.5 versus 2.1)",
"     </li>",
"     <li>",
"      Mortality from cardiac arrest (1.3 versus 1.0)",
"     </li>",
"     <li>",
"      Mortality from myocardial infarction (6.3 versus 4.4)",
"     </li>",
"     <li>",
"      Admissions for myocardial infarction (6.3 versus 3.9)",
"     </li>",
"     <li>",
"      Congestive heart failure (29.9 versus 16.9)",
"     </li>",
"     <li>",
"      Stroke (4.7 versus 3.1)",
"     </li>",
"     <li>",
"      Dysrhythmia (20.9 versus 11.0)",
"     </li>",
"     <li>",
"      Any cardiovascular event (44.2 versus 19.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors were unable to determine whether adverse events occurred before, during or after the first weekly dialysis sessions.",
"   </p>",
"   <p>",
"    These data suggest that the two-day interval is a time of increased risk for cardiovascular and noncardiovascular mortality and morbidity for patients who are on a three times weekly dialysis schedule. Potential reasons for the increased risk were not addressed in this study but fluid accumulation, hemodynamic changes, and electrolyte abnormalities or changes may contribute at least to the cardiovascular events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MALNUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have demonstrated greater medical risk and increased mortality in undernourished and small dialysis patients (as noted by a low body mass index) with hypoalbuminemia and lower plasma levels of urea nitrogen and creatinine than expected from the intensity of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/74,98-100\">",
"     74,98-100",
"    </a>",
"    ]. As an example, a plasma albumin concentration below 4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    is the single laboratory finding most closely associated with an increased probability of death. The increase in risk is dose-dependent, rising modestly at a plasma albumin concentration of 3.5 to 3.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (35 to 39",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    but being much greater at values below 3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef70749 \" href=\"mobipreview.htm?19/37/20061\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/74,98,99\">",
"     74,98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have primarily been made in patients on maintenance hemodialysis and may overestimate the effect of hypoalbuminemia, since some measurements taken in the weeks to months before death were included. However, a similar relationship between hypoalbuminemia and increased mortality has been demonstrated with peritoneal dialysis and, although less pronounced than in Figure 1, with plasma albumin concentrations measured within six weeks of starting dialysis (",
"    <a class=\"graphic graphic_figure graphicRef60944 \" href=\"mobipreview.htm?19/49/20253\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14519?source=see_link\">",
"     \"Nutritional status and protein intake in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of malnutrition prior to the initiation of dialysis is also strongly predictive of increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/45\">",
"     45",
"    </a>",
"    ]. Despite this, the presence of associated conditions, particularly comorbid conditions, significantly contributes to mortality, independent of nutritional status. In one study, for example, the outcomes of a total of 153 consecutive peritoneal dialysis patients were analyzed based upon the presence or absence of malnutrition, with or without comorbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/102\">",
"     102",
"    </a>",
"    ]. The combined presence of malnutrition plus a comorbid condition was associated with a high mortality, while there is a trend with malnutrition alone for an increase in mortality.",
"   </p>",
"   <p>",
"    Conversely, measures of good nutritional status, such as high body mass index (BMI) in combination with normal or high muscle mass, are associated with increased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. As an example, in a study of incident peritoneal dialysis patients, the best survival was observed in those with high BMI and normal or high muscle mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with hypoalbuminemia, a similar incidence of undernutrition has been noted with the use of creatinine production to assess lean body mass in stable patients on maintenance dialysis. In one study, estimated lean body mass was below normal in 47 and 66 percent of hemodialysis and peritoneal dialysis patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/105\">",
"     105",
"    </a>",
"    ]. There was a significant correlation between lean body mass and the plasma albumin concentration in the group as a whole; however, there was substantial variability in individual patients.",
"   </p>",
"   <p>",
"    Another marker of malnutrition, a low ratio of body weight for height, also predicts mortality in hemodialysis patients. In an analysis of data from nearly 13,000 patients, there was a highly significant inverse relationship between mortality rates and the ratio of body weight for height among those with ratios below the 50th percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between markers of malnutrition and reduced patient survival does not prove a cause-and-effect relationship. Nevertheless, it constitutes the rationale for attempting to improve nutrition via diet and more intensive dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The meaning of a low plasma albumin concentration may also differ among hemodialysis and peritoneal dialysis patients, due in part to variations in volume status. The serum albumin among hemodialysis patients is often measured predialysis, a time when volume expansion is maximum; by comparison, the concentration of albumin in the peritoneal dialysis population should not vary acutely. Differences in mortality among these two modalities that appear to correlate with albumin levels may therefore instead be due to variations in intravascular volume.",
"   </p>",
"   <p>",
"    Although poor nutrition is a common cause of hypoalbuminemia in dialysis patients, a number of chronic inflammatory conditions can also reduce the serum albumin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/107\">",
"     107",
"    </a>",
"    ]. This effect appears to be mediated by cytokines, such as interleukin-1 and tumor necrosis factor-alpha, which suppress hepatic albumin synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/108\">",
"     108",
"    </a>",
"    ]. Thus, the presence of an untreated underlying inflammatory process may contribute to the decreased survival observed among chronic hemodialysis patients with hypoalbuminemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike the general population, some, but not all, studies have shown that being overweight (perhaps a surrogate for \"overnutrition\") may enhance survival among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/104,109-115\">",
"     104,109-115",
"    </a>",
"    ]. In one study of over 1300 hemodialysis patients, every one unit increase in the body mass index (BMI) was associated with a reduction of 30 percent in the relative risk of dying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/109\">",
"     109",
"    </a>",
"    ]. This result may be confounded in part by race and gender, since African-American females have the highest BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apparent survival benefit conferred by higher body weight may be limited to older adults (&gt;65 years). This was suggested by a prospective analysis of 1749 patients who were stratified by age and BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/117\">",
"     117",
"    </a>",
"    ]. Among 984 patients younger than 65 years, the age-standardized mortality rate was 1.7 times higher for obese patients compared with those with a normal BMI. By contrast, among 765 patients older than 65 years, there was no difference in mortality between obese individuals and those with normal BMI.",
"    <br/>",
"    <br/>",
"    However this study included both peritoneal and hemodialysis patients, and a larger percentage of patients younger than 65 years were on peritoneal dialysis (50 versus 22 percent in patients older than 65 years). Obesity has been associated with worse survival outcomes among peritoneal dialysis patients in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/112,118\">",
"     112,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CHRONIC HEMODIALYSIS ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous fistulas have advantages over arteriovenous grafts and central venous catheters, with some evidence suggesting a survival benefit with fistulas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISORDERS OF MINERAL METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have delineated an increased risk of all-cause and cardiovascular mortality in patients with disorders of mineral metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. Although not found in all studies, the association with decreased survival primarily involves increased phosphate, calcium, calcium x phosphate product,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parathyroid hormone levels. These in turn may be associated with accelerated atherosclerosis, arterial calcification, and an increased risk of adverse cardiovascular outcomes and death.",
"   </p>",
"   <p>",
"    This was shown in a retrospective analysis of a database of over 40,000 hemodialysis patients in which the relative risks of death were determined for multiple categories of serum phosphate, calcium, calcium x phosphate product, and parathyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/119\">",
"     119",
"    </a>",
"    ]. After multivariate adjustments, the lowest relative risks of death were observed among patients with serum phosphate concentrations between 3 to 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.97 to 1.61",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    serum calcium concentrations less than 8.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a calcium x phosphate product of less than 45 to 50",
"    <span class=\"nowrap\">",
"     mg2/dL2,",
"    </span>",
"    and intact parathyroid hormone levels less than 600",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (600",
"    <span class=\"nowrap\">",
"     ng/L).",
"    </span>",
"   </p>",
"   <p>",
"    Concentrations of these substances that were above each of these levels were significantly associated with decreased survival. Compared to serum phosphate concentrations between 4.0 to 5.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.29 to 1.61",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    for example, an increased relative risk of death was noted for serum phosphate levels greater than 5.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.61",
"    <span class=\"nowrap\">",
"     mmol/L):",
"    </span>",
"    the relative risk increased gradually from 1.07 to 2.02 at serum phosphate levels of 5.0 to 6.0 and &ge;9.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Given that the calcium result may have been confounded by the tendency of calcium levels to increase or decrease with reciprocal changes in serum phosphate, the risk of death was also determined for calcium levels measured within serum phosphate categories of 4 to 5, 5 to 6, 6 to 7, and 7 to 8",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Within each phosphate category, higher calcium levels were associated with significant increases in mortality risk.",
"   </p>",
"   <p>",
"    Analyses of similar large databases have also found that increased levels of calcium, phosphate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PTH had significant adverse effects upon survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/120-124\">",
"     120-124",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 25,588 patients participating in the Dialysis Outcomes and Practice Patterns Study, the highest mortality was noted for those with calcium levels above 10.0",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      phosphorus levels greater than 7.0",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and PTH levels above 600",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1,629 incident hemodialysis and peritoneal dialysis patients from the Netherlands, phosphate and calcium X phosphate levels above",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guideline levels were associated with increased mortality risks in both patient groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other studies have noted that low PTH and calcium levels are associated with an increase or no effect on mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/125-128\">",
"     125-128",
"    </a>",
"    ]. A possible explanation for these disparate findings include variations in study design, differences in population evaluated, and the use of only single measurements of calcium, phosphate, and PTH.",
"   </p>",
"   <p>",
"    To better assess the association between mortality and changes in calcium, phosphate, and PTH over time, two studies have been performed to assess survival compared with differences over time in changes in bone mineral elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. One prospective study, for example, was performed of 1006 incident hemodialysis and peritoneal dialysis patients, in whom longitudinal changes in bone mineral parameters were assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/129\">",
"     129",
"    </a>",
"    ]. PTH levels decreased over the course of one year, while calcium and phosphate levels, and the calcium x phosphate product increased over the first six months and then remained stable. After adjustment for comorbidity and other confounding variables, an increased risk of death was observed with the highest quartile for phosphate levels using both baseline and time-dependent values (hazard ratio of 1.57, 95% CI 1.07-2.30). By comparison, an increased mortality risk with the highest quartile for calcium, calcium x phosphate product, and PTH levels was only observed with the time-dependent values.",
"   </p>",
"   <p>",
"    In addition to phosphate, calcium, calcium x phosphate product, and parathyroid hormone levels, additional serum laboratory values related to bone disease are associated with survival among dialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibroblast growth factor 23 (FGF-23) is an osteoblastic hormone involved in the regulation of phosphate and vitamin D. With increasing phosphate levels in those with increasing kidney dysfunction, elevations in FGF-23 levels stimulate the renal excretion of phosphate and inhibit the synthesis of 1,25-dihydroxyvitamin D. As with increased phosphate levels, elevated FGF-23 levels are associated with increased mortality among patients with end-stage renal disease. This was shown in a nested case-control study of 200 patients who died and 200 patients who survived the first year of hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/131\">",
"       131",
"      </a>",
"      ]. Based upon multivariable analysis, increasing FGF-23 levels were associated with an increasing risk of death when analyzed via either a continuous scale or quartiles. As an example, the risk of death was significantly higher in patients with the highest FGF-23 levels (quartile 4) compared with the group with the lowest FGF-23 levels (quartile 1) (odds ratio of 5.7 95% CI 2.6-12.6).",
"      <br/>",
"      <br/>",
"      FGF-23 has also been associated with cardiovascular events and mortality in pre-dialysis CKD patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/132,133\">",
"       132,133",
"      </a>",
"      ], renal transplant patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/134\">",
"       134",
"      </a>",
"      ] and in non-CKD patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/135\">",
"       135",
"      </a>",
"      ]. Further studies are needed to define the role of FGF-23.",
"     </li>",
"     <li>",
"      Increased mortality is described in dialysis patients with elevated serum alkaline phosphate levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/136,137\">",
"       136,137",
"      </a>",
"      ]. In one study, levels of alkaline phosphatase greater than or equal to 120",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      were associated with an increased risk of death (hazard ratio 1.25, 95% CI 1.21-1.29) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observational studies suggest that the many interventions currently utilized to maintain target calcium, phosphate, and PTH levels must be adequately assessed in rigorous trials to help determine their effect upon survival in patients with end-stage renal disease. These interventions include low phosphate diets, calcium and non-calcium based phosphate binders, vitamin D analogs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcimimetics.",
"   </p>",
"   <p>",
"    Some of these issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ACHIEVING MULTIPLE CLINICAL PERFORMANCE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meeting specific goals for some clinical parameters has a beneficial impact upon survival in dialysis patients. Prominent examples include attaining and maintaining target levels for either hemodialysis dose or hemoglobin concentration. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adequacy of dialysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Practically all studies that have examined the effect upon survival of achieving clinical performance goals have evaluated benefits due to a single measure of clinical care. There is evidence that achieving multiple clinical targets may be associated with superior survival outcomes versus that observed with attaining fewer clinical targets or only one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/138-143\">",
"     138-143",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among nearly 200,000 patients, the risk of death during the first year of hemodialysis correlated with having met zero, one, two, or three of the following guideline goals at initiation of hemodialysis: use of an arteriovenous fistula or graft at initiation, hemoglobin level &ge;11",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and goal albumin level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/143\">",
"       143",
"      </a>",
"      ]. Compared with those who met no goal, the risk of death was significantly lower among those who met one (0.81, 0.80 to 0.83), two (0.53, 0.41 to 0.56), or three goals (0.34, 0.30 to 0.39). A lower mortality rate was also observed in those who met each individual goal.",
"     </li>",
"     <li>",
"      During a 12 month follow-up period in a retrospective study of 15,287 hemodialysis patients, death or hospitalization were compared with achieving target levels for hemoglobin (&ge;11",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      serum albumin levels (3.7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      by bromocresol purple laboratory method), use of a fistula for vascular access, and a single pool",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      urea of &ge;1.2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/138\">",
"       138",
"      </a>",
"      ]. Seven, 24, 39, 24, and 6 percent of patients met 4, 3, 2, 1 and zero targets, respectively. There was a significantly increased risk of death and hospitalization among those in whom targets were not met, which increased with each specific target that was not achieved. Compared with meeting all four targets:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adjusted hazard ratios for death were 1.9 (95% CI 1.4-2.6), 2.6 (95% CI 1.9-3.5), 3.5 (95% CI 2.6-4.7), and 4.6 (95% CI 3.3-6.4) for those who met 3, 2, 1, and zero targets, respectively.",
"     </li>",
"     <li>",
"      Adjusted hazard ratios for hospitalization were 1.1 (95% CI 0.98-1.3), 1.3 (95% CI 1.1-1.5), 1.5 (95% CI 1.3-1.7), and 1.6 (95% CI 1.4-1.9), respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 13,792 incident hemodialysis patients evaluated the correlation between survival and achieving",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      clinical practice guidelines for single-pool",
"      <span class=\"nowrap\">",
"       Kt/V,",
"      </span>",
"      hematocrit, serum albumin, calcium, phosphate, and PTH level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/140\">",
"       140",
"      </a>",
"      ]. Compared with not achieving any one target, the adjusted hazard ratios for mortality were 0.11 (95% CI 0.06-0.19), 0.19 (95% CI 0.15-0.25), 0.30 (95% CI 0.24-0.37), 0.39 (95% CI 0.31-0.49), 0.52 (95% CI 0.42-0.65), and 0.74 (95% CI 0.49-0.93) for those who met 6, 5, 4, 3, 2, and 1 target, respectively. By comparison, an increased mortality was associated with achieving the blood pressure goal",
"      <span class=\"nowrap\">",
"       (predialysis&lt;140/90",
"      </span>",
"      mmHg) (1.90, 95% CI 1.73-2.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies are limited in part because of their design, underreporting of comorbid conditions, and unknown incidence of disease severity. However, these results are generally consistent with other, primarily observational, studies showing increased risk of death and hospitalization with decreased dialysis dose or hemoglobin levels, low serum albumin concentration, abnormal mineral metabolism, and hemodialysis with a vascular access other than an arteriovenous fistula. This suggests that quality improvement measures should be implemented to increase the number of those who meet multiple performance measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS VERSUS PERITONEAL DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data described above were almost entirely from patients treated with maintenance hemodialysis. Survival of hemodialysis versus peritoneal dialysis patients is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With peritoneal dialysis, there is increasing evidence that increased survival is associated with centers that are relatively more experienced with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. In one observational study of outcomes in large dialysis organizations, an increased mortality risk was observed in patients being treated in organizations with the lowest rates of peritoneal dialysis use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HOME HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home hemodialysis is generally associated with good survival rates. Improved survival had been thought to be due to selection bias since fewer older and sicker patients are treated with home hemodialysis. However, adjustments for age, diagnosis, comorbidity, and gender in large dialysis databases did not alter the decreased risk of death among home hemodialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ALTERNATIVE FORMS OF HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although currently undergoing intense study, no significant conclusions can be drawn concerning the effect on survival of nocturnal hemodialysis or short daily hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    as a measure of urea kinetic modeling quantifies the delivery of dialysis and verifies the dialysis prescription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/13/37082/abstract/74-77,82,147,148\">",
"     74-77,82,147,148",
"    </a>",
"    ]. Current recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) Increasing dialysis time is the most certain way to increase the dialysis prescription, but a modest benefit can be obtained with more efficient membranes and higher blood flow rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to appreciate, however, that there may be a significant difference between the dialysis prescription and the amount of dialysis actually delivered to the patient. In particular, problems with cardiovascular and access recirculation can substantially reduce dialysis delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1144?source=see_link\">",
"     \"Prescribed versus delivered dialysis: Importance of dialysis time\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are similar issues among patients undergoing peritoneal dialysis. Minimal weekly total target clearance values in terms of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and creatinine clearance have been published over the last several years by United States and International Societies. There is a general consensus that some previously recommended target weekly dialysis doses are inconsistent and probably unattainable for many patients, particularly low-average and low transporters. The net effect is an unnecessary increase in the number of patients transferred to hemodialysis because of perceived inadequate dialysis with PD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An optimal dialysis prescription, whether for hemodialysis or peritoneal dialysis, also must take into account other factors, such as the patient's symptoms, mineral metabolism status, nutritional status (as estimated in part from the plasma albumin concentration and protein catabolic rate), and degree of rehabilitation toward a fully active life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .) Another important goal is a normotensive patient (without antihypertensive medications) who is maintained at estimated dry weight to minimize any dialysis-induced cardiovascular risk factors.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/1\">",
"      United States Renal Data System. Excerpts from USRDS 2009 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/2\">",
"      Chertow GM, Johansen KL, Lew N, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/3\">",
"      Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/4\">",
"      Szczech LA, Klassen PS, Chua B, et al. Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int 2006; 69:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/5\">",
"      Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 1999; 341:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/6\">",
"      Levinsky NG. Quality and equity in dialysis and renal transplantation. N Engl J Med 1999; 341:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/7\">",
"      Irvin RA. Quality of care differences by ownership in United States renal dialysis facilities. ASAIO J 2000; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/8\">",
"      Devereaux PJ, Sch&uuml;nemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA 2002; 288:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/9\">",
"      Bloembergen WE, Port FK, Mauger EA, Wolfe RA. Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol 1994; 5:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/10\">",
"      Cohen LM, McCue JD, Germain M, Kjellstrand CM. Dialysis discontinuation. A 'good' death? Arch Intern Med 1995; 155:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/11\">",
"      Wallen MD, Radhakrishnan J, Appel G, et al. An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York State. Clin Nephrol 2001; 55:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/12\">",
"      O'Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int 2005; 25:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/13\">",
"      Introduction and summary. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, Tx, September 15 to 17, 1989. Am J Kidney Dis 1990; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/14\">",
"      Collins AJ, Hanson G, Umen A, et al. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long-term mortality. Am J Kidney Dis 1990; 15:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/15\">",
"      Mailloux LU, Napolitano B, Bellucci AG, et al. The impact of co-morbid risk factors at the start of dialysis upon the survival of ESRD patients. ASAIO J 1996; 42:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/16\">",
"      Merkus MP, Jager KJ, Dekker FW, et al. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000; 35:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/17\">",
"      Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/18\">",
"      2005 Annual Report: ESRD clinical performance measures project. Am J Kidney Dis 2006; 48(Suppl 2):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/19\">",
"      Miskulin D, Bragg-Gresham J, Gillespie BW, et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/20\">",
"      Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/21\">",
"      Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/22\">",
"      Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/23\">",
"      Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/24\">",
"      Beddhu S, Zeidel ML, Saul M, et al. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med 2002; 112:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/25\">",
"      Miskulin DC, Meyer KB, Martin AA, et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 2003; 41:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/26\">",
"      Mailloux LU, Bellucci AG, Napolitano B, et al. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol 1994; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/27\">",
"      Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/28\">",
"      Hirsch DJ, West ML, Cohen AD, Jindal KK. Experience with not offering dialysis to patients with a poor prognosis. Am J Kidney Dis 1994; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/29\">",
"      Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/30\">",
"      van Dijk PC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/31\">",
"      Goodkin DA, Young EW, Kurokawa K, et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004; 44:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/32\">",
"      Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17:3510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/33\">",
"      van Dijk PC, Zwinderman AH, Dekker FW, et al. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 2007; 71:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/34\">",
"      Wong JS, Port FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int 1999; 55:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/35\">",
"      Tanna MM, Vonesh EF, Korbet SM. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis 2000; 36:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/36\">",
"      Eisenstein EL, Sun JL, Anstrom KJ, et al. Do income level and race influence survival in patients receiving hemodialysis? Am J Med 2009; 122:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/37\">",
"      Bleyer AJ, Tell GS, Evans GW, et al. Survival of patients undergoing renal replacement therapy in one center with special emphasis on racial differences. Am J Kidney Dis 1996; 28:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/38\">",
"      Mesler DE, McCarthy EP, Byrne-Logan S, et al. Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Am J Med 1999; 106:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/39\">",
"      Robinson BM, Joffe MM, Pisoni RL, et al. Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2006; 17:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/40\">",
"      Kucirka LM, Grams ME, Lessler J, et al. Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 306:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/41\">",
"      Mehrotra R, Kermah D, Fried L, et al. Racial differences in mortality among those with CKD. J Am Soc Nephrol 2008; 19:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/42\">",
"      Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/43\">",
"      Kimmel PL, Peterson RA, Weihs KL, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 1998; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/44\">",
"      Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. J Am Soc Nephrol 2013; 24:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/45\">",
"      Chung SH, Lindholm B, Lee HB. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/46\">",
"      Mc Causland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 2012; 82:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/47\">",
"      Rambod M, Tolouian R. Dietary sodium and clinical outcome in hemodialysis: where do we stand and what is next? Kidney Int 2012; 82:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/48\">",
"      Benz RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/49\">",
"      Unruh ML, Buysse DJ, Dew MA, et al. Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 2006; 1:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/50\">",
"      McClellan WM, Wasse H, McClellan AC, et al. Treatment center and geographic variability in pre-ESRD care associate with increased mortality. J Am Soc Nephrol 2009; 20:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/51\">",
"      Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18:3164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/52\">",
"      Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/53\">",
"      Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/54\">",
"      Desmet C, Beguin C, Swine C, et al. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis 2005; 45:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/55\">",
"      Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/56\">",
"      Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007; 18:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/57\">",
"      Unruh ML, Evans IV, Fink NE, et al. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. Am J Kidney Dis 2005; 46:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/58\">",
"      O'Hare AM, Tawney K, Bacchetti P, Johansen KL. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003; 41:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/59\">",
"      Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/60\">",
"      Matsuzawa R, Matsunaga A, Wang G, et al. Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/61\">",
"      Johansen KL, Kaysen GA, Dalrymple LS, et al. Association of physical activity with survival among ambulatory patients on dialysis: the comprehensive dialysis study. Clin J Am Soc Nephrol 2013; 8:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/62\">",
"      Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/63\">",
"      Kshirsagar AV, Craig RG, Moss KL, et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int 2009; 75:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/64\">",
"      Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/65\">",
"      Lin JL, Lin-Tan DT, Hsu CW, et al. Association of blood lead levels with mortality in patients on maintenance hemodialysis. Am J Med 2011; 124:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/66\">",
"      United States Renal Data System. Excerpts from USRDS 2004 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2005; 45(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/67\">",
"      Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/68\">",
"      Held PJ, Levin NW, Bovbjerg RR, et al. Mortality and duration of hemodialysis treatment. JAMA 1991; 265:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/69\">",
"      Woods JD, Port FK, Stannard D, et al. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int 1996; 49:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/70\">",
"      Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/71\">",
"      Laird NM, Berkey CS, Lowrie EG. Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study. Kidney Int Suppl 1983; :S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/72\">",
"      Parker TF, Laird NM, Lowrie EG. Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal. Kidney Int Suppl 1983; :S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/73\">",
"      Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/74\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/75\">",
"      Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/76\">",
"      Parker TF 3rd, Husni L, Huang W, et al. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/77\">",
"      Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/78\">",
"      McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998; 9:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/79\">",
"      Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/80\">",
"      Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/81\">",
"      Gotch FA, Levin NW, Port FK, et al. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/82\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/83\">",
"      Allon M, Depner TA, Radeva M, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/84\">",
"      Wolfe RA, Hulbert-Shearon TE, Ashby VB, et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 2005; 45:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/85\">",
"      Paniagua R, Amato D, Vonesh E, et al. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int 2005; 67:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/86\">",
"      Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/87\">",
"      Cheung AK, Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/88\">",
"      Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2005; :CD005283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/89\">",
"      Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/90\">",
"      Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/91\">",
"      Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27:4180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/92\">",
"      Flythe JE, Curhan GC, Brunelli SM. Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013; 83:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/93\">",
"      Sharp J, Wild MR, Gumley AI. A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis. Am J Kidney Dis 2005; 45:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/94\">",
"      Pillon L, Piccoli A, Lowrie EG, et al. Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney Int 2004; 66:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/95\">",
"      Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/96\">",
"      Reddan DN, Szczech LA, Hasselblad V, et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J Am Soc Nephrol 2005; 16:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/97\">",
"      Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/98\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/99\">",
"      Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993; 3:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/100\">",
"      Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005; 68:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/101\">",
"      Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/102\">",
"      Chung SH, Lindholm B, Lee HB. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients? Nephrol Dial Transplant 2003; 18:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/103\">",
"      Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/104\">",
"      Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/105\">",
"      Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/106\">",
"      Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/107\">",
"      Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/108\">",
"      Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/109\">",
"      Fleischmann E, Teal N, Dudley J, et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/110\">",
"      Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/111\">",
"      Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/112\">",
"      Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among \"large\" ESRD patients in the United States. Kidney Int 2004; 65:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/113\">",
"      Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/114\">",
"      Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/115\">",
"      de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/116\">",
"      Hakim RM, Lowrie E. Obesity and mortality in ESRD: is it good to be fat? Kidney Int 1999; 55:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/117\">",
"      Hoogeveen EK, Halbesma N, Rothman KJ, et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/118\">",
"      McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003; 14:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/119\">",
"      Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/120\">",
"      Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/121\">",
"      Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/122\">",
"      Noordzij M, Korevaar JC, Boeschoten EW, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/123\">",
"      Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/124\">",
"      Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/125\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/126\">",
"      Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/127\">",
"      Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/128\">",
"      Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/129\">",
"      Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/130\">",
"      Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/131\">",
"      Guti&eacute;rrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/132\">",
"      Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/133\">",
"      McDiarmid SV, Hall TR, Grant EG, et al. Failure of duplex sonography to diagnose hepatic artery thrombosis in a high-risk group of pediatric liver transplant recipients. J Pediatr Surg 1991; 26:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/134\">",
"      Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/135\">",
"      Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/136\">",
"      Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/137\">",
"      Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/138\">",
"      Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med 2006; 145:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/139\">",
"      Plantinga LC, Fink NE, Jaar BG, et al. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Serv Res 2007; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/140\">",
"      Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/141\">",
"      Wingard RL, Pupim LB, Krishnan M, et al. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol 2007; 2:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/142\">",
"      Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/143\">",
"      Slinin Y, Guo H, Gilbertson DT, et al. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin J Am Soc Nephrol 2010; 5:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/144\">",
"      Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant 2002; 17:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/145\">",
"      Schaubel DE, Blake PG, Fenton SS. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001; 60:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/146\">",
"      Mehrotra R, Khawar O, Duong U, et al. Ownership patterns of dialysis units and peritoneal dialysis in the United States: utilization and outcomes. Am J Kidney Dis 2009; 54:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/147\">",
"      Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/13/37082/abstract/148\">",
"      Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50:557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1847 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37082=[""].join("\n");
var outline_f36_13_37082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS NOT RELATED TO DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Country",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H617445752\">",
"      Salt intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADEQUACY OF DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Historic overview of survival and Kt/V",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Improved survival with more intensive dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMO study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HEMODIALYSIS MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEMODIALYSIS SESSION LENGTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CONTROL OF FLUID BALANCE AND HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H520250775\">",
"      INTERDIALYTIC INTERVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MALNUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CHRONIC HEMODIALYSIS ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISORDERS OF MINERAL METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACHIEVING MULTIPLE CLINICAL PERFORMANCE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HEMODIALYSIS VERSUS PERITONEAL DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HOME HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ALTERNATIVE FORMS OF HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1847|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/40/43661\" title=\"figure 1\">",
"      HD survival by site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/43/6846\" title=\"figure 2\">",
"      KtV URR and dialysis survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/37/20061\" title=\"figure 3\">",
"      Risk of mortality among hemodial pts according to serum albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/49/20253\" title=\"figure 4\">",
"      Risk of mortality among dial pts according to baseline albumin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34312?source=related_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11288?source=related_link\">",
"      Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25640?source=related_link\">",
"      Late referral to nephrologists of patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37849?source=related_link\">",
"      Non-access related infections in chronic dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=related_link\">",
"      Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14519?source=related_link\">",
"      Nutritional status and protein intake in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1144?source=related_link\">",
"      Prescribed versus delivered dialysis: Importance of dialysis time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/3/11322?source=related_link\">",
"      Psychiatric illness in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_13_37083="Prevalence of disease";
var content_f36_13_37083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of infectious diseases, Texas Department of Criminal Justice, 1999-2000",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of disease per 100,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latent tuberculosis infection",
"       </td>",
"       <td>",
"        16,511-24,600*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"       <td>",
"        8377",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV/AIDS",
"       </td>",
"       <td>",
"        1458",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphillis",
"       </td>",
"       <td>",
"        655",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRSA",
"       </td>",
"       <td>",
"        328",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster",
"       </td>",
"       <td>",
"        206",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active tuberculosis",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonorrhea",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitis",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Estimate of latent tuberculosis infection from six different correctional institutions in US, 1990-1991.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Baillargeon, J, Black, SA, Leach, CT, et al. The infectious disease profile of Texas prison inmates. Prev Med 2004; 38:607 and Centers for Disease Control and Prevention. Tuberculosis prevention in drug-treatment centers and correctional facilities--selected US sites, 1990-1991. MMWR Morb Mortal Wkly Rep 1993; 42:210.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37083=[""].join("\n");
var outline_f36_13_37083=null;
var title_f36_13_37084="Test results bleeding disorders";
var content_f36_13_37084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected results of tests for hemostatic function in representative bleeding disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        BT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plt",
"       </td>",
"       <td class=\"subtitle1\">",
"        PT",
"       </td>",
"       <td class=\"subtitle1\">",
"        aPTT",
"       </td>",
"       <td class=\"subtitle1\">",
"        TT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculopathies, connective tissue diseases, or collagen disorders affecting skin",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal or increased*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Qualitative platelet abnormalities",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Normal or low",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophilia A (factor VIII deficiency)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        von Willebrand disease",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Normal",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Long",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BT: bleeding time; Plt: platelet count; PT: prothrombin time; aPTT: activated partial thromboplastin time; TT: thrombin time; Fib: fibrinogen.",
"     <br>",
"      * Fibrinogen may be elevated as an acute phase reactant in disorders of inflammation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The platelet count in myeloproliferative disorders is usually high (eg, essential thrombocythemia) and platelets may also be qualitatively abnormal, predisposing to hemorrhagic and thrombotic diatheses.",
"       <br>",
"        &Delta; The platelet count may be low in some patients with type 2B von Willebrand disease.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         The aPTT may be normal in those with Factor VIII activity &gt;40 percent.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37084=[""].join("\n");
var outline_f36_13_37084=null;
var title_f36_13_37085="Expected lifetime based on renal replacement therapy";
var content_f36_13_37085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Expected lifetime based on renal replacement therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: 2005 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD. Available at:",
"     <a href=\"file://optn.transplant.hrsa.gov/data/annualreport.asp\" target=\"_blank\">",
"      file://optn.transplant.hrsa.gov/data/annualreport.asp",
"     </a>",
"     (Accessed 6/23/2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37085=[""].join("\n");
var outline_f36_13_37085=null;
var title_f36_13_37086="Protocol ants on patient";
var content_f36_13_37086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Suggested protocol if fire ants are found on a patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If ants are detected on a patient, they should be removed and the patient carefully assessed. The patient should be transferred from bed and all orifices inspected. Medical personnel should use gloves to prevent stings.",
"    <div class=\"footnotes\">",
"     * Ants are best removed by compression with a damp towel and wiping dead ants off with a damp cloth.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goddard J, Jarrat J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37086=[""].join("\n");
var outline_f36_13_37086=null;
var title_f36_13_37087="Proper sitting posture";
var content_f36_13_37087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proper sitting posture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_13_37087=[""].join("\n");
var outline_f36_13_37087=null;
